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ABSTRACT 
 
ADENOVIRUS STRATEGIES FOR ALTERING THE CELLULAR ENVIRONMENT IN 
FAVOR OF INFECTION 
Christin Herrmann 
Matthew D. Weitzman, Ph.D. 
 
Viruses, as obligate intracellular pathogens, rely on their host cell for successful replication. 
Viruses have evolved different strategies to hijack and redirect cellular processes to benefit 
infection and overcome host immune responses. Understanding the mechanisms by which 
viruses exploit their host cells will reveal new targets for antiviral therapies. In addition, these 
studies can provide insights into the regulation of fundamental cellular processes. While much 
progress has been made in this area, many unexpected nuances of virus-host interaction are still 
being discovered. Here, we employed several strategies to uncover new aspects of viral 
manipulation of the host environment by adenovirus, a nuclear-replicating DNA virus that 
commonly infects humans.  
The first project focused on how viral histone-like proteins impact cellular chromatin. 
Adenovirus encodes the small, basic protein VII that coats and condenses viral genomes. The 
effect of this viral DNA-binding protein on host chromatin structure and function had remained 
unexplored. Here we demonstrated that protein VII interacts with host nucleosomes and is 
sufficient to alter nuclear morphology. We also identified post-translational modifications of 
protein VII that regulate chromatin association. Through a proteomics analysis of chromatin 
composition, we revealed that protein VII causes nuclear retention of HMGB1, a host alarmin, 
and reduces downstream inflammation.   
The second project examined roles of viral-mediated ubiquitination during infection. 
Ubiquitination of host proteins, mediated by adenovirus proteins E1B55K and E4orf6, is important 
for viral RNA processing. However, previously identified substrates of viral-mediated 
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ubiquitination do not explain this phenotype. Here we used a proteomics approach to define new 
substrates of the E1B55K/E4orf6 complex. We uncovered viral-mediated ubiquitination of RNA-
binding proteins (RBPs) which, unlike ubiquitination of other substrates, does not result in 
proteasomal degradation. We furthermore demonstrated that ubiquitination of RBPs RALY and 
hnRNP-C decreases their binding to viral RNA and relieves a restriction these host proteins exert 
on adenovirus RNA processing. 
Our study of adenovirus proteins revealed new strategies employed by viruses to alter host 
functions: manipulating host chromatin through viral histone-like proteins to dampen immune 
responses and regulating RNA processing by non-degradative ubiquitination of cellular RBPs. 
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CHAPTER 1: INTRODUCTION 
 
A portion of this chapter has been adapted from:  
Dybas JM, Herrmann C, Weitzman MD. Ubiquitination at the interface of tumor viruses and DNA 
damage responses. Curr Opin Virol 32, 40-47 (2018). PMID: 30261451.1 
AND 
Charman M, Herrmann C, Weitzman MD. Viral and Cellular Interactions During Adenovirus DNA 
Replication. 2019. FEBS Letters. Submitted. 
 
1.1 Virus vs. Host 
Viruses are obligate intracellular pathogens that rely on host cell components for successful 
infection and have evolved sophisticated mechanisms to alter the cellular environment to their 
advantage (Figure 1.1). This takeover can disrupt host processes with detrimental outcomes for 
the infected cell and the organism as a whole. Accordingly, host cells have developed different 
layers of defense against viral infection that can interfere with each step of the viral life cycle, 
from entry to virus release. Cells can sense molecules that contain foreign patterns introduced by 
viruses, such as aberrant RNA or DNA structures. The recognition of these pathogen-associated 
molecular patterns (PAMPs) activates a multifaceted antiviral response, including the interferon 
pathway that can stimulate an antiviral state in an autocrine and paracrine fashion to directly 
antagonize viral processes and prevent a spread of the infection2-4. Viruses in turn use diverse 
strategies to overcome these host barriers, leading to an arms race of evolution between viruses 
and their hosts5. This coevolution makes viruses an excellent model system to understand 
regulation of cellular processes as these pathogens have evolved to exploit host cells for their 
own replication using as minimal machinery as possible5,6. Understanding virus-host interaction 
will also allow for development of better antiviral drugs as well as treatment of unrelated human 
diseases, as viruses can be used as a platform for oncolytic cancer treatment, gene therapy, and 
vaccine development. While viruses have evolved numerous different strategies to manipulate 
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the host cell environment, there are commonalities to be found as many viruses target the same 
cellular pathways. For example, many DNA and RNA viruses interact with host chromatin 
components to regulate their own replication and transcription7,8. Another common target for viral 
manipulation is the host ubiquitin machinery. The main focus in studying this virus-host interaction 
has been traditionally proteasomal degradation of host factors restrictive to viral infection1,9,10. 
This thesis will examine new aspects of virus-host interaction on the level of chromatin and viral-
mediated ubiquitination. 
 
1.2 Adenovirus 
Adenovirus (Ad) was originally isolated from pediatric adenoid tissue in 195311. It comprises a 
family of small, non-enveloped double-stranded DNA (dsDNA) viruses that replicate in the 
nucleus of host cells12. There are at least 56 human Ad serotypes, all with similar genome 
structure and encoding homologous proteins13. These serotypes can be classified into 7 
subgroups, A through G. Depending on the serotype, Ad causes mild respiratory disease, 
conjunctivitis, or infantile gastroenteritis, but can be life-threatening in immunocompromised 
individuals. Ad is also of particular interest for the healthcare research community as it provides 
an attractive delivery method, both in vitro and in vivo, for genetic information. Its ~36 kb genome 
is relatively easy to manipulate, which allows for inactivation viral gene expression and insertion 
of other genes of interest. These features make Ad an excellent platform for gene therapy, 
vaccines, and oncolytic viruses used in cancer therapy14-17. Most studies have used either Ad2 or 
Ad5, two closely related serotypes in subgroup C that commonly infect the human respiratory 
tract. The work described in this thesis was carried out using Ad5 unless otherwise noted. 
1.2.1 Adenovirus virion structure 
Ad virions are non-enveloped, with an outer capsid and an inner core comprised exclusively of 
viral proteins and nucleic acid (Figure 1.2)18-20. The icosahedral capsid contains the major capsid 
proteins hexon, penton, and fiber21,22. Minor capsid proteins IIIa, VIII, and IX further stabilize the 
structure18,19. The core contains many additional viral proteins. The small, basic core proteins V, 
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VII, and μ interact with the dsDNA genome ranging in size from 25 to 45 kb and likely contribute 
to condensation of the DNA23-26. One copy of the terminal protein, which serves as a primer 
during viral genome replication, is covalently attached to the 5’ end of each DNA strand27,28. In 
addition, the core also contains the viral protease that is involved in maturation of viral particles 
as well as virion entry into the cell29,30, and protein IVa2 that is implicated in packaging31.  
1.2.2 The adenovirus life cycle 
There are two phases of the Ad life cycle: an early and a late phase that are separated by the 
onset of viral DNA replication (Figure 1.3)12. The virus is taken up into host cells through receptor 
mediated endocytosis. First, virions make a low-affinity interaction with integrins on the cell 
surface32,33, followed by a high-affinity interaction of fiber with the viral receptor34. Receptor usage 
differs between the subgroups: A, C, D, E, and F bind to the tight junction protein CAR 
(Coxsackie B, Adenovirus Receptor)35 while subgroup B viruses bind to CD4636. The interaction 
with their respective receptors induces clathrin-mediated endocytosis of the virions37,38. In the 
endosomes, acidification activates the viral protease that cleaves protein VI30. Cleaved protein VI 
then facilitates release of the virions into the cytoplasm. Transport of the virions to the nucleus 
occurs on microtubules through the interaction of hexon with dynein motor proteins39,40. 
Uncoating of the virions begins with the loss of fiber at the cell surface with further uncoating in 
the endosome, thought to be triggered by acidification38. At the nuclear pore, final disassembly is 
triggered and the genome is imported coated only with protein VII and covalently attached to two 
copies of the terminal protein41.  
The Ad genome is divided into early and late transcription units (Figure 1.4). The early 
proteins expressed before the onset of DNA replication mainly fulfill three functions: 1) facilitating 
entry of the infected cell into S-phase to ensure all the necessary resources for virion assembly 
are present, 2) protection from the immune response triggered by infection, and 3) initiation of 
viral genome replication12.  
The first viral protein expressed is E1A, due to the strong promoter of this gene42,43. The E1A 
transcript produces two different major isoforms, called small and large E1A. Large E1A functions 
4 
 
as a transactivator for the E1A gene and other viral early transcription units through recruitment of 
cellular transcription factors to the viral genome44,45. In addition, both small and large E1A are 
capable of inducing cellular entry into S-phase to ultimately support viral DNA replication, which 
occurs through interaction with the Rb family of proteins. E1A binding removes Rb from the E2F 
family of transcription factors, which is required for entry into S-phase46. Both E1A isoforms also 
alter the transcriptional landscape, upregulating proviral and downregulating antiviral genes to 
further support viral replication47. For example, E1A inhibits the induction of interferon stimulated 
genes (ISGs) by preventing activating histone marks at these specific loci48-51. The E1B region 
encodes two major proteins, E1B19K and E1B55K. E1B19K is an anti-apoptotic homolog of the 
BCL2-family member MCL-1 and blocks cell death induced as a consequence of E1A functions52. 
E1B55K can also block apoptosis and alter the cellular environment to support viral infection - 
discussed in detail in Chapter 1.4.353.  
The E2 region encodes the three viral proteins necessary for genome replication28,54: the pre-
terminal protein that serves as primer for DNA replication27, the Ad DNA polymerase, and the 
single-strand DNA-binding protein DBP that stabilizes single-stranded DNA (ssDNA) and 
promotes strand separation during DNA replication55,56. The E3 region encodes several proteins 
that are important for inhibiting innate and adaptive immune responses towards the virus57. The 
E4 region encodes 6 distinct proteins: orf1, orf2, orf3, orf4, orf6, and orf6/7. These early proteins 
are involved in regulating several cellular processes including transcription, mRNA splicing, 
translation, apoptosis, protein turnover, and the host DNA damage repair (DDR) towards the Ad 
genomes58,59. The most important gene products are E4orf3 and E4orf6, as deletion of both 
together severely reduces virus replication60,61. E4orf3 interacts with PML nuclear bodies, a 
nuclear structure involved in antiviral immune responses, transcription, apoptosis, and the DDR62. 
The association with E4orf3 rearranges PML nuclear bodies into tracks63,64. E4orf3 then recruits 
cellular proteins into these tracks, including several proteins involved in the DDR. This 
suppresses recognition of the viral DNA by these DNA repair factors that would otherwise induce 
degradation or concatemerization of the genomes63-67. E4orf6 associates with E1B55K and 
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several host proteins to form a viral ubiquitin ligase, the function of which is discussed in detail in 
Chapter 1.4.3 below. 
The replication of the Ad genome occurs in viral replication centers that can be visualized by 
staining for DBP68. Several host proteins, in addition to the viral gene products of the E2 region, 
are involved in replicating the viral DNA28,69. This process occurs in two rounds. First, one DNA 
strand is replicated while the second strand is displaced as the nascent DNA strand is elongated.  
Second, the displaced strand circularizes by self-annealing of the complementary ends, forming a 
panhandle structure. This DNA structure allows for replication of the second strand via a similar 
mechanism as the first round (Figure 1.5)12,28. 
The late genes are only expressed upon onset of genome replication70. Most late transcripts 
are expressed through the major late promoter (MLP). The MLP is heavily alternatively spliced to 
5 distinct transcription units with separate poly(A) sites that encode at least 14 distinct late mRNA 
species (Figure 1.4)71. These gene products include structural components of viral particles, 
proteins involved in DNA condensation, and proteins that facilitate virion formation. Assembly of 
new particles occurs in the nucleus where virions accumulate until release through lysis of the 
host cell20,72,73. Overall, one infected cell produces tens of thousands new virus particles and a 
large excess of structural proteins12. 
1.2.3 Adenovirus as a model system to study virus-host interaction 
Ad is commonly used in research in part because of its easy propagation in cell culture and 
ability to synchronously infect many different cell types. In addition, the Ad genome can be easily 
manipulated to create different mutant viruses. This makes Ad an excellent model system to not 
only study virus-host interaction but also investigate the regulation of fundamental cellular 
processes6. Ad was instrumental in the discovery of RNA splicing. This fundamental cellular 
process was discovered while trying to map the regions of the Ad genome encoding the hexon 
protein to the corresponding late mRNA74,75. In addition, work with Ad has enabled a better 
understanding of the processes involved in cellular transformation and cancer development. Ad 
was the first human virus shown to induce tumor formation, even though these experiments were 
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carried out in rodents76. This is one reason Ad is sometimes classified as a tumor virus although 
there is no evidence to link Ad to cancer in humans. Several Ad proteins by themselves are 
sufficient to facilitate entry into the cell cycle and transform human cells in culture77. For example, 
HEK293 cells were generated through integration of part of the Ad DNA containing the E1 region 
into the cellular genome, resulting in immortalization of these cells77,78. The E1A protein induces 
entry of these cells into the cell cycle and reprograms transcription46,47. E1B19K as a homolog of 
anti-apoptotic protein MCL-1 prevents cell death52. E1B55K also counteracts apoptosis through 
inactivation of the tumor suppressor p5379-81. In addition, E1B55K was actually the second viral 
protein, after SV40 large T antigen, to be shown to interact with p5382. The DDR is another area 
of research that benefitted greatly from studying Ad. As mentioned earlier, Ad has several 
mechanisms to overcome the host DDR that would otherwise recognize and antagonize viral 
genomes. The virus causes ubiquitin-dependent degradation or mislocalization of the MRN 
complex, which consists of MRE11, RAD50, and NBS1, and is important in recognition and 
processing of dsDNA breaks67. These findings not only enabled the study of these host proteins 
in context of the DDR towards viral genomes but also studies to define their role in DNA repair in 
general83-86. 
These examples highlight the value of Ad as a model system to examine cellular processes 
at the interface of virus-host interaction. The work in this thesis focuses on defining additional 
ways Ad employs viral proteins to alter the host cell environment in favor of infection. Project 1, 
described in Chapter 2, investigates the manipulation of host chromatin by an Ad histone-like 
protein. Project 2, which forms the basis for Chapter 3, examines how hijacking the host ubiquitin 
machinery contributes to viral RNA processing. 
 
1.3 Viruses, histones, and chromatin 
Cellular histones not only serve to condense DNA but also modulate global genome structure 
and accessibility to regulate DNA replication, DNA repair, and gene expression87-90. This 
contributes to processes such as cell differentiation and immune responses91-95. Viruses have 
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evolved many different ways to use host chromatin components to regulate their own genomic 
material and alter the host transcriptome7,8. At the same time viruses have to overcome ways the 
host uses chromatin components to block viral genome replication and to suppress viral 
transcription7,8,83-86. This section will highlight the regulation of host chromatin, different strategies 
viruses have developed to exploit cellular histones, and discuss how viral proteins with similar 
functions to histones may in turn impact host DNA. 
1.3.1 Histones and cellular chromatin 
In human cells, 2 meters of DNA are condensed into a nucleus with an average of 6 μm 
diameter while the organization necessary for proper gene expression, DNA replication, and 
repair is maintained. The basic structure that makes this possible is the nucleosome: 147 bp of 
DNA wrapped around an octamer of core histones, containing two copies each of histones H2A, 
H2B, H3, and H496-98. The tight wrapping of DNA in nucleosomes is possible through the 
interaction of the small, highly basic histones with the positively charged phosphate backbone of 
DNA. The linker histone H1 associates with the core nucleosome and linker DNA to stabilize 
higher-order chromatin structure such as fibers (Figure 1.6)99,100. Nucleosomes compact the 
genome but also regulate access to the DNA, serve as platforms for epigenetic signaling, and 
regulate the formation of higher order structures. There are two basic types of chromatin, 
heterochromatin and euchromatin. In transcriptionally silent heterochromatin nucleosomes form 
more compact structures, limiting access of transcription factors. Euchromatin, on the other hand, 
is more accessible and transcriptionally active. Chromatin is dynamically regulated through DNA 
modifications, histone modifications, and chromatin remodeling complexes. DNA can be 
methylated at CpG motifs throughout the genome, especially at CpG islands, resulting in 
silencing of associated chromatin101. While the C-terminal globular domains of histones form the 
central core of nucleosome, the N-terminal tails of histones are unstructured, extend from the 
core, and can be modified with more than 200 different histone marks including acetylation, 
methylation, ubiquitination, and phosphorylation102. This forms the basis for the histone code, 
which is the principle that different histone marks and their combination determine the protein 
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occupancy and transcriptional state of the associated DNA sequence87-90. More than 150 different 
cellular histone-modifying enzymes have been identified so far103. Modifications of histones can 
alter the local chromatin compaction, impact nucleosome dynamics, and serve as binding 
platforms for chromatin-associated proteins. Several histone marks have been associated with 
more open and active chromatin such as acetylation (e.g. acetylation of histone H3 at lysine 9, 
abbreviated H3K9Ac) and methylation (e.g. H3K4me1 or H3K4me3). Methylation of other lysine 
residues within histones, such as H3K27me3 or H3K9me3, are associated with more tightly-
packed and thus silent chromatin87-89. Some histone modifications can also play a role in other 
processes, such as phosphorylation of histone H2A variant H2A.X (γH2A.X) which is important 
for DDR signaling104,105. Histone marks can be read out by chromatin remodeling complexes. 
More than 100 proteins have been identified as components of these complexes, which use ATP 
to mobilize nucleosomes and change chromatin structure89,106.  
1.3.2 Viral manipulation of histones 
Viruses have evolved different strategies to exploit histones and chromatin regulatory 
mechanisms to facilitate successful infection7,8. Viruses need to regulate the chromatin 
components such as chromatin remodelers, transcription factors, and histone chaperones 
associated with their genomes to their advantage while avoiding detrimental effects such as viral 
genome silencing or activation of an aberrant DDR7,8,83-86. Cellular histones can fulfill different 
roles during virus infection. This includes functions such as condensing viral genomes to 
regulating viral gene expression and ensuring propagation of viral genomes to the two daughter 
cells during cell division (Figure 1.7). This section highlights some examples of viral strategies 
employed to harness cellular histones and host chromatin. 
Viruses have to condense their genetic information for packaging into viral particles and have 
evolved different strategies to achieve this. Papillomaviruses such as HPV and polyomaviruses 
including SV40 package their circular dsDNA genomes into virions as ‘minichromosomes’ using 
the four core histones as well as linker histone H1 from host cells (Figure 1.7a)107,108. This allows 
for condensation of the viral genetic material and eliminates the need to remove histones during 
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packaging. For SV40 it has been demonstrated that the packaged histones contain different post-
translational modifications (PTMs) to optimize compaction and transcription upon infection109-112. 
Herpesviruses (e.g. HSV, KSHV, and EBV) and many other DNA viruses are devoid of 
histones in viral particles. However, viral genomes become rapidly chromatinized upon entry into 
the nucleus (Figure 1.7b). Initially, repressive chromatin marks are deposited to silence the viral 
genomes. This is followed by viral-mediated remodeling of histone marks and activation of viral 
transcription113-115. Herpesviruses can undergo both lytic and latent infection, and the chromatin 
state associated with viral genomes differ under these conditions116. For HSV, lytic or productive 
infection occurs in epithelial cells with active transcription of lytic genes and more euchromatin-
like histone modifications113-115. In neurons, HSV is predominantly latent and there is a 
progressive association of heterochromatin marks with the viral genome as latency is 
established117. In addition, different regions of the Herpesvirus DNA are associated with distinct 
types of histones marks under these conditions. Latency genes are actively transcribed and 
associated with more active chromatin marks. Lytic genes, on the other hand, are silenced. 
Immediate early genes are in a poised chromatin state with both active and repressive histone 
modifications, or active chromatin marks but repression of transcription elongation. Late genes 
are associated with facultative heterochromatin that is silent but poised for reactivation118,119.  
Viruses that integrate into the host genome, including HIV, are also associated with cellular 
histones. For these viruses, the integration site and surrounding host chromatin in part regulate 
the activity of integrated proviruses120. Latently infected cells with silenced proviruses represent a 
major reservoir for HIV and are a barrier for curing infection121. Some latent proviruses can be 
reactivated by altering the repressive chromatin marks associated with viral genomes. A 
proposed strategy to cure HIV is to use drugs to reactivate the proviruses that make up the viral 
reservoir, resulting in recognition and clearance of infected cells by the immune system122. For 
example, histone deacetylase (HDAC) inhibitors that increase histone acetylation can reactivate a 
subset of latent proviruses123,124. However, not all proviruses are reactivated through this 
treatment and additional strategies will be needed for a successful cure125. 
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Certain viruses that undergo viral latency, including HPV, KSHV, and EBV, have evolved 
mechanisms to tether their genomes to host chromatin to facilitate partitioning of viral genomes to 
daughter cells during cell division (Figure 1.7c). HPV protein E2 directly links viral genomes to 
active regions of host chromatin throughout the cell cycle. In addition to facilitating genome 
distribution during mitosis, this also allows access to transcription factors and prevents silencing 
of the viral DNA by the host126,127. 
While RNA viruses do not package their genomes using nucleosomes, studies suggest that 
nuclear-replicating RNA viruses can interact with cellular histones and host chromatin. 
Replication of influenza virus has been proposed to occur in DNase-insensitive nuclear fractions 
at the nuclear matrix, and influenza proteins M1 and NP have been shown to associate with 
nucleosomes128-130. In addition, one serotype of influenza has been shown to alter cellular 
transcription by mimicking cellular histones. The NS1 protein of influenza serotype H3N2 contains 
a short histone-like sequence at its C-terminus that recruits the PAF1 transcription elongation 
complex. This association blocks the function of the host complex and reduces antiviral gene 
expression131.  
1.3.3 Ad protein VII as a viral histone-like protein 
Although some viruses use cellular histones for condensing their genomes inside 
virions107,108, many viruses use alternative strategies. HSV, for example, has little or no protein 
associated with the DNA in virus particles. Instead it uses the highly basic polyamine spermine to 
condense its genomic information132. Other viruses encode their own small basic proteins that are 
thought to function similarly to histones133-137.  
Ad encodes a small, basic protein named protein VII that condenses viral DNA inside 
virions133-135. Protein VII is an Ad late protein expressed from the L2 region of the viral genome 
(Figure 1.4) and its functions have been extensively studied in the context of association with 
viral genomes. Like many other Ad proteins, protein VII is produced as a precursor and then 
cleaved by the viral protease during virion maturation138. Protein VII contributes to many stages of 
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the Ad life cycle such as transcription139-143, evasion of the DDR144, and, of course, condensation 
of the viral DNA in virions133,134. These functions of protein VII are summarized below.  
There are conflicting reports about the role of protein VII in viral transcription. Condensation 
of the genome is essential for packaging, but impedes transcription once imported into the 
nucleus140,142. It is thought that displacement of protein VII is necessary for transcription to occur. 
Indeed, over time the levels of protein VII on viral genomes decrease while the amount of cellular 
histones on the viral DNA increases139,145-148. Initially, the histone variant H3.3 is loaded onto the 
Ad genome in a replication-independent manner by the histone chaperone HIRA149,150. This 
results in nucleosome spacing on viral genomes comparable to that found on cellular chromatin 
by 6 hours post infection (hpi)149. Later during infection, when viral DNA replication has been 
initiated, the association with histone H3 decreases and the nucleosome pattern is less 
structured150. There is evidence that remodeling of protein VII regulates the timing of 
transcription. At 6 hpi, protein VII is still largely associated with the transcriptionally silent MLP 
region of the genome, and association with the highly transcribed E1A region is decreased139. 
While these observations suggest that protein VII functions as a transcriptional repressor, there 
are reports that association of protein VII with DNA can facilitate transcription and that this viral 
core protein can recruit the E1A transactivator to the genome to support gene expression139,143.  
Protein VII also interacts with the cellular protein SET (also known as TAF-I - template-
activating factor-I)139-142. SET promotes dissociation of protein VII from viral DNA to support early 
gene expression and genome replication139-142. It was recently shown that SET also contributes to 
the protein VII-mediated protection of the incoming genome from the host DDR144,151.  
Protein VII is the major core component of viral particles with about 800 copies per virion and 
is thought to contribute to condensation of viral DNA in capsids22,152. Interestingly, protein VII is 
dispensable for the actual packaging process153. Viral particles containing genomes are still made 
in the absence of protein VII, suggesting that other viral proteins can condense the viral DNA. 
However, virions lacking protein VII do not properly uncoat upon infection of the next cell and do 
not escape the endosome153. Viral DNA isolated from virions is coated with protein VII and 
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exhibits a beads-on-a-string pattern reminiscent of host DNA wrapped around cellular 
histones134,154. This observation further highlights the similarity between Ad protein VII and 
histones. Protein VII is expressed in large excess during infection, which is thought to contribute 
to assembly of new virions. Yet, what are the consequences of producing large amounts of 
excess protein VII, a viral protein designed to bind to and change the structure of DNA? 
While many studies have examined the effect of cellular histones on viral genomes7,8, little is 
known about the association of viral histone-like proteins, like Ad protein VII, with cellular 
chromatin. What we do know is that large structural changes of the host nucleus and chromatin 
occur upon infection by numerous viruses155-158. During Ad infection, for example, the nucleus of 
host cells increases in size over time and chromatin structure, visualized by DAPI, changes from 
a pan-nuclear staining to a more speckled pattern with large areas of less dense DNA (Figure 
1.8)158. While this phenomenon has been observed for different viruses, whether viral histone-like 
proteins, such as Ad protein VII, contribute to these drastic changes in nuclear architecture and 
how this impacts infection has not been examined. We hypothesized that protein VII, in addition 
to its functions on Ad genomes mentioned above41,133,134,139-144, interacts with and manipulates 
cellular chromatin (Figure 1.9). In Chapter 2 of this thesis, we first examined whether protein VII, 
as a viral histone-like protein, could interact with components of host chromatin. We found that 
protein VII tightly associates with host chromatin and nucleosomes, and that expression of this 
viral protein alone is sufficient to alter nuclear morphology. We also discovered that protein VII, 
similar to cellular histones, can be modified by different PTMs and these modifications regulate 
the association of protein VII with host chromatin. Next, we used a proteomics approach to 
characterize protein VII-mediated changes in protein composition of cellular chromatin. This 
revealed that protein VII sequesters a family of cellular alarmins in the nucleus, resulting in a 
blunted immune response. As such, our work examines a novel aspect of virus-host interaction 
and serves as a proof-of-principle study regarding the association of viral histone-like proteins 
with host DNA and the contribution of this interaction to virus infection by assisting immune 
evasion. 
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1.4 Viruses and the ubiquitin system 
Viruses have evolved many different strategies to shape the host cell environment to their 
advantage. One way is to use PTMs such as ubiquitination to manipulate host cell processes1,9,10. 
It is becoming increasingly apparent that ubiquitination can fulfill many functions in addition to 
induction of protein turnover, including altering protein localization, protein-protein interactions, 
and complex stability159-161. This diversity in function makes hijacking the host ubiquitin machinery 
an attractive means for viruses to manipulate host cells. 
1.4.1 The host ubiquitin system 
Ubiquitin is a 76 amino acid protein that can be covalently attached to primary amines through 
its C-terminus. The new isopeptide bond is typically formed with lysine residues in the substrate, 
although ubiquitination of other amino acids and the substrate N-terminus have been reported162. 
This is accomplished by a three-enzyme cascade involving E1 ubiquitin-activating enzymes, E2 
conjugating enzymes, and E3 ubiquitin ligases (Figure 1.10a). The protein family of E3 ubiquitin 
ligases is subdivided into the HECT (homologous to the E6AP carboxyl terminus) and RING 
(really interesting new gene) type ligases. The HECT type ligases form an intermediary bond with 
the ubiquitin protein before passing it on to the substrate. The RING type ligases mediate a direct 
transfer of ubiquitin from the E2 to the substrate without forming a catalytic intermediate with the 
ubiquitin protein. The substrate specificity is provided by the E3 ubiquitin ligases. An estimated 
500-1000 different E3 enzymes are encoded in the human genome, while only 2 E1 enzymes and 
35 E2 enzymes have been identified. 
In addition to simple mono- and multi-mono ubiquitination of substrates, ubiquitin itself can be 
ubiquitinated at any of the 7 lysine residues within its sequence (K6, K11, K27, K29, K33, K48, 
and K63) as well as at the N-terminus (linear or M1-linked ubiquitin) (Figure 1.10b)159-161. This 
can lead to the formation of ubiquitin chains with distinct topologies that can be recognized by 
proteins with ubiquitin-binding domains163. These domains are able to distinguish between 
different forms of ubiquitination and can provide the readout and function for different forms of 
ubiquitination. The most well-studied linkages are K48 and K63, which are also the linkages most 
14 
 
commonly found in cells159. We are just starting to understand the diverse functions of the less 
abundant linkages164. Below are examples for proposed functions for each of the different 
ubiquitin-linkages. The proteasome contains several subunits that specifically bind to K48-linked 
chains containing at least four ubiquitin proteins165. This induces subsequent proteasomal 
degradation of the substrate to small peptides while the ubiquitin molecules are recycled166. As 
such, K48-linked ubiquitin plays a major role in protein recycling and turn over167. Ubiquitin chains 
containing K11 have also been associated with substrate degradation168-170. Other ubiquitin-
linkages, such as K63 and M1, are important for signaling cascades by forming platforms for 
complex assembly. Both of these chain types are important for NFκB signaling171-173. K63-linked 
ubiquitin chains are also involved in DNA repair174,175, protein sorting176,177, and oxidative 
stress178,179. K6 is thought to contribute to the DDR180 and the removal of damaged mitochondria 
from cells181,182, while K27 regulates DNA repair183 and is involved in host immune responses184. 
K29 is linked to Wnt/β-catenin signaling185, and K33 regulates trafficking through the trans-Golgi 
network186. Mono and multi-mono ubiquitination can alter protein-protein interactions and are 
involved in membrane trafficking, endocytosis and the DDR177,187,188. Furthermore, ubiquitination 
can occur in functional domains of proteins, such as a nuclear localization sequence (NLS)189, 
and thereby impact protein function and localization. In addition to ubiquitin chains composed of a 
single linkage type, there also exist chains with mixed linkages or even branched chains. 
Furthermore, ubiquitin chains can also contain other ubiquitin-like proteins such as SUMO, 
NEDD8, and ISG15160. Ubiquitination is highly dynamic and can be reversed by deubiquitinating 
enzymes (DUBs)190. These enzymes can be specific for processing one or multiple different 
ubiquitin chain types. This section highlights just how complex ubiquitination is and that we are 
only just beginning to understand the functions mediated by this system160. 
1.4.2 Viral manipulation of the host ubiquitin system 
Many different viruses exploit the host ubiquitin system to alter the host environment in favor 
of viral infection. Commonly targeted pathways include the immune response such as NFκB 
signaling or antigen presentation by MHC molecules, apoptosis, transcription, and the DDR. 
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There are many different viral strategies to alter ubiquitination (for more examples of the different 
strategies see Figure 1.11)1,9,10.  
Some viruses encode their own E3 ubiquitin ligases that facilitate ubiquitination of substrates 
(Figure 1.11 Type I). HSV, for example, encodes the RING-type ubiquitin ligase ICP0 that 
induces the degradation of host E3 ligases RNF8 and RNF168. These host proteins are involved 
in the DDR and without degradation they could facilitate recruitment of the host DNA repair 
machinery to viral genomes191,192. Other substrates of ICP0 include PML and SP100193,194. 
Degradation of these host proteins results in disruption of PML nuclear bodies that could 
otherwise repress viral infection195.    
 Other viruses encode viral proteins that hijack host Cullin complexes (Figure 1.11 Type II). 
Cullin ubiquitin ligase complexes are the largest family of cellular E3 ubiquitin ligases and have 
been extensively studied in context of protein turnover mediated through K48-linked ubiquitin 
chains196. They belong to the RING type family of E3 ligases and recruit an E2 for ubiquitination 
of the substrates. Multiple viruses encode proteins that assume the substrate adapter function of 
the Cullin ubiquitin ligase complexes, recruiting host proteins for ubiquitination. For example, the 
HIV protein Vif associates with a Cullin complex composed of Cullin5, Elongin B, Elongin C, and 
RBX2. By hijacking this cellular E3 ubiquitin ligase, Vif induces the degradation of APOBEC3G, a 
cellular cytidine deaminase that can restrict HIV infection by editing the RNA/DNA intermediate 
during reverse transcription of the viral RNA197-201. In addition to hijacking of the Cullin complexes, 
some viral proteins can indirectly mediate ubiquitination through interaction with host E3 ubiquitin 
ligases (Figure 1.11 Type III). For instance, the HPV E6 oncoprotein interacts with the host E3 
ligase E6AP (E6 associated protein) to mediate ubiquitination and subsequent degradation of the 
tumor suppressor p53202-204. 
Furthermore, viruses can alter deubiquitination by either encoding their own DUBs or 
interacting with cellular DUBs that then alter the removal of ubiquitin from substrates (Figure 1.11 
Type IV). The EBNA1 protein of EBV, for example, competes with p53/MDM2 for binding to the 
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host DUB USP7, resulting in p53 destabilization and reduction of DNA-damage associated 
apoptosis205,206. 
The best-characterized function of ubiquitination is facilitating degradation of substrates by the 
proteasome and this is also the most well-studied in the context of virus-host interaction. The use 
of non-degradative ubiquitination is clearly widespread within cells and thus is likely exploited by 
viruses. However, there are only few known examples of viral-mediated non-degradative 
ubiquitination207,208. For instance, while KSHV proteins K3 and K5 have been shown to facilitate 
ubiquitination of MHC class I with K63-linked chains this still results in degradation of the 
substrate, in this case by the lysosome instead of the proteasome209. Use of non-degradative 
ubiquitination could vastly increase the ways viruses can alter the host cell environment through 
altering protein localization, protein-protein interactions, and protein functions independent of 
changes in protein abundance. One possible explanation for the shortage in studies on viral-
mediated ubiquitination without subsequent degradation is the limited availability of experimental 
techniques that allow for detection of non-degradative ubiquitination events. Advances in 
proteomics such as di-glycine remnant profiling now allow for global detection of ubiquitinated 
proteins210,211. Combining these techniques with a whole cell proteome analysis enables the 
identification of both degraded and non-degraded substrates of viral-mediated ubiquitination. One 
example of how this approach can be used to define new substrates of a viral ubiquitin ligase can 
be found in Chapter 3 of this thesis. 
1.4.3 Adenovirus E1B55K/E4orf6 and the ubiquitin system 
Ad also exploits the host ubiquitin machinery to support successful viral infection. The two 
early proteins E1B55K and E4orf6 recruit cellular proteins to form a viral E3 ubiquitin ligase 
complex (Figure 1.4)212-215. E1B55K is thought to function as the substrate recognition 
component and recruits cellular proteins for ubiquitination213. E4orf6, on the other hand, hijacks a 
cellular E3 ubiquitin ligase complex of the Cullin family that consists of Cullin5, Elongin B, Elongin 
C, and RBX1 (Figure 1.12, see Chapter 1.4.2 for details on Cullin ligases)212,213. This is facilitated 
through two BC box motifs in the E4orf6 sequence which directly interact with the Elongin 
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proteins216-218. E1B55K contains several highly disordered regions within its structure that are 
important for substrate binding, and interaction with different substrates requires distinct residues 
within the viral protein219. E1B55K expressed by itself remains cytoplasmic and the interaction 
with E4orf6 is required for the nuclear localization of the complex220. It has been demonstrated 
that this viral ubiquitin ligase marks host proteins for proteasomal degradation, and K48-linked 
ubiquitin chains have been shown for one substrate67,212,213,221-223.  
Several substrates of the Ad ubiquitin ligase have been identified. One such substrate is the 
tumor suppressor p53 that is degraded to prevent the cell cycle arrest and apoptosis, induced as 
a consequence of forced entry into the cell cycle by E1A212,213,224,225. Interestingly, both E1B55K 
and E4orf6 can interact with and suppress p53-mediated transcription independently of their 
function in the ubiquitin ligase complex. E4orf6 can also interact with and repress the function of 
p73, a homolog of p53226,227. E1B55K suppresses p53 by binding to the N-terminal transcriptional 
activation domain79-81 while E4orf6 binds to the C-terminus226,228, resulting in inhibition of different 
subsets of p53 target genes227. Several substrates of E1B55K/E4orf6 are components of the host 
DDR, including the MRN complex67, Bloom Helicase (BLM)221, and Ligase IV (LIG4)222. The MRN 
complex recognizes dsDNA breaks and is important for initial processing of breaks prior to repair 
by homologous recombination or non-homologous end joining229. BLM is important for unwinding 
DNA during repair, while LIG4 functions at the ligation step in the repair of dsDNA breaks during 
non-homologous end joining230,231. As described in Chapter 1.2.2, the DDR is also antagonized 
by E4orf3, highlighting the importance of preventing the interaction of the host repair machinery 
with viral dsDNA for Ad infection. Failure to antagonize these host proteins results in partial digest 
of viral DNA, concatemerization of the genome, problems in DNA replication, and defects in 
packaging of Ad DNA into virions65,67,232-237. Another substrate of the Ad ubiquitin ligase is integrin 
α3223,238. This surface protein is important for interactions between cells and its degradation may 
promote release and spread of Ad. E1B55K/E4orf6 substrates have mostly been identified using 
Ad5 and it has been demonstrated that substrate specificity of the E1B55K/E4orf6 complex differs 
between different serotypes239,240.  
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While multiple substrates of the Ad ubiquitin ligase have been identified, there are several 
unexplained phenotypes that have been observed upon inhibition of the Ad ubiquitin ligase 
function. E1B55K-deleted viruses (ΔE1B) have been developed for oncolytic therapy as it was 
thought that their replication would rely on the inactivation of p53 that commonly occurs in cancer 
cells. While ΔE1B viruses indeed replicate efficiently in certain cancer cells as opposed to 
untransformed cells, the phenotype displayed is inconsistent with induction of apoptosis and has 
been shown to be independent of the p53 status of the cells78,241,242. Instead, deletion of E1B55K 
decreases late protein expression and progeny production with only mild impact on early gene 
expression and DNA replication. This defect has been mapped to a step in nuclear RNA 
processing of specifically viral late RNA transcripts, with little difference observed in RNA 
transcription or decay rates243,244. The original study by Babiss et al. from 1985 concluded that 
deletion of E1B55K results in a failure to export viral late RNA243. Furthermore, during the late 
stage of Ad wild-type (WT) infection, the export of cellular as well as viral early RNA is inhibited to 
enable exclusive export of viral late RNA species243,245,246. This switch does not occur upon 
deletion of E1B55K. The decrease in viral late mRNA results in reduced expression of viral late 
proteins. This is further potentiated by low levels of L4-100K, an Ad late protein, that normally 
inhibits cap dependent translation247,248 and enhances cap independent translation of the late 
RNA species through ribosome shunting facilitated by the tripartite leader present in all late 
transcripts249,250. Deletion of E4orf6, mutation of the BC box motifs in E4orf6 to prevent ubiquitin 
ligase assembly, expression of a dominant negative Cullin5, or inhibition of the ubiquitin ligase 
complex all show a similar phenotype60,216,242,246,251,252. This highlights that it is E1B55K/E4orf6-
mediated ubiquitination, and not an E1B55K function independent of the ubiquitin ligase complex, 
that contributes to viral late RNA processing.  
The currently known substrates for the E1B55K/E4orf6 complex are involved in apoptosis 
(p53) and the host DDR (MRN complex, Lig4, and BLM)67,212,213,221,222,224,225. Activation of these 
cellular pathways do not explain the RNA processing defects observed for E1B55K- or E4orf6 
mutant viruses, as it has been demonstrated that defects in Ad late RNAs still occur in cells that 
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are p53-deficient or do not possess a functional DDR241,242. This suggests that additional 
unidentified substrates of the Ad ubiquitin ligase exist, and that ubiquitination of these host 
proteins is important for viral RNA processing. Several different strategies have been previously 
employed to identify new substrates and interaction partners of the Ad ubiquitin ligase complex 
that may contribute to viral RNA processing. These experiments included immunoprecipitation of 
the viral proteins followed by mass spectrometry (IP-MS)212,213,253, 2D-gel electrophoresis followed 
by MS238, and whole cell proteomics coupled with a transcriptome analysis comparing WT and 
ΔE1B viruses254,255. However, none of these approaches have identified substrates of 
E1B55K/E4orf6 that explain the RNA processing defect. One possible explanation is that these 
experiments were only designed to identify degraded substrates of the Ad ubiquitin ligase, 
potentially missing any substrates that are not degraded by the proteasome upon ubiquitination. 
Furthermore, it has been revealed that while IP-MS studies can identify regulators of ubiquitin 
ligases, the interaction with substrates is often too transient to be reliably detected with this 
method256,257. This indicates that different approaches are necessary for identification of 
additional substrates of the E1B55K/E4orf6 complex that are responsible for proper processing of 
viral late RNA.  
In Chapter 3 of this thesis we employed an alternative strategy to identify substrates of the Ad 
ubiquitin ligase. We used a combined proteomics approach to identify proteins ubiquitinated upon 
expression of the E1B55K/E4orf6 complex and assessed resulting changes in protein abundance 
by whole cell proteome profiling (Figure 1.13). We furthermore demonstrated that two of the 
newly identified substrates of E1B55K/E4orf6 are indeed involved in processing of viral late RNA. 
Interestingly, we showed that these host proteins were not degraded upon Ad-mediated 
ubiquitination, but that instead their binding to viral RNA was altered. These findings revealed an 
unexpected function of non-degradative ubiquitination during virus infection. 
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1.5 Figures 
 
 
 
 
Figure 1.1 | Virus vs. host. Viruses rely on manipulating the environment of their host cell for 
their own replication. In addition, viruses have to overcome antiviral responses developed by the 
host to counteract infections. 
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Figure 1.2 | Schematic of the Ad virion structure. Viral particles consist of an outer capsid and 
inner core. 
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Figure 1.3 | Schematic of the Ad life cycle highlighting the different stages of virus 
replication. During the early phase of infection, early proteins rewire host processes towards 
late protein production. In the late phase the viral genome is replicated, and the structural late 
proteins are produced and assembled into virions. 
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Figure 1.4 | Schematic of the Ad genome structure. There are four early (E1-E4) transcription 
units that encode the proteins expressed during the early phase of infection. The five late 
transcription units (L1-L5) are expressed from one common major late promoter (MLP) and 
encode mainly structural proteins and those involved in virion assembly. Schematic courtesy of 
AM Price. 
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Figure 1.5 | Schematic of the replication of the Ad genome. Three viral proteins (pre-terminal 
protein - TP, Ad DNA polymerase - Pol, single-strand DNA binding protein - DBP) are essential 
for the replication of the Ad genome. Replication is initiated through a protein priming mechanism, 
in which TP is covalently linked to the first nucleotide of the new strand and serves for a primer 
for Pol. DBP binds to the displaced single-stranded DNA that circularizes through the inverted 
terminal repeats. This panhandle structure has the same structure and sequence as the original 
replication origin, enabling replication by the same mechanism as the first strand. The pre-
terminal protein is processed into its mature form by the viral protease during virion maturation. 
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Figure 1.6 | The basic structure of cellular chromatin. Double-stranded DNA is wrapped 
around an octamer of histones to form nucleosomes as the basic component of chromatin. 
Nucleosomes then form higher order structures such as fibers that are intertwined in the nucleus 
and can be further condensed to distinct chromosomes during cell division. 
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Figure 1.7 | Different viral strategies to exploit cellular histones and chromatin. a, Viruses 
such Papillomavirus and Polyomavirus use cellular histones to condense the viral genomes 
inside virions. b, Other DNA viruses are not packaged with cellular histones but associate with 
histones within the host cell. The structure of viral chromatin and associated histone marks differs 
between actively replicating and latent infection and is exploited to regulate viral gene expression. 
c, Tethering to host chromatin enables even distribution of viral genomes to the daughter cells 
during division of the host cell. 
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Figure 1.8 | Change in nuclear architecture during Ad infection. Changes in nuclear 
architecture and size upon infection of primary-like HBE3C-KT with Ad WT (multiplicity of 
infection/MOI = 20) over a time course visualized by immunofluorescence staining of DNA with 
DAPI (grey). Figure courtesy of M Charman. 
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Figure 1.9 | Rationale for project 1. The Ad histone-like protein VII that condenses the viral 
genome inside virions is produced in large quantities during infection for packaging of new virus 
particles. Considering the ability of protein VII to bind DNA and that it is produced in large excess 
to what is needed for production of new virions, we hypothesized that this viral protein can 
interact with and manipulate the cellular chromatin, contributing to the distortion of the host cell 
nucleus observed during infection, forming the basis for Chapter 2 of this thesis. 
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Figure 1.10 | The host ubiquitin system. a, Ubiquitination is a three-step cascade facilitated by 
the E1, E2, and E3 enzymes. Substrate specificity is conferred by the E3 enzymes that can be 
divided into HECT and RING type ligases. Ubiquitination can be reversed by deubiquitinating 
enzymes (DUBs). b, There are different forms of ubiquitination such as mono and multi-mono 
ubiquitination in addition to ubiquitin chains that can contain one specific linkage, multiple 
linkages or even be branched. 
a 
b 
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Figure 1.11 | Different viral strategies to hijack the cellular ubiquitin system. Type I, viruses 
encode proteins with E3 ubiquitin activity that directly ubiquitinate cellular substrates. Type II, 
viral proteins integrate into cellular Cullin E3 ubiquitin ligase complexes and assume the substrate 
adaptor function to dictate cellular substrates that are ubiquitinated. Type III, viral proteins 
interact with cellular E3 ligases to direct ubiquitination of cellular substrates or alter cellular E3 
ligase activity. Type IV, viruses can impart the opposite function of E3 ligases by directing 
deubiquitination of cellular substrates either by encoding viral proteins with DUB activity or by 
interacting with cellular DUBs. 
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Figure 1.12 | Schematic of the E1B55K/E4orf6 ubiquitin ligase complex. E1B55K recruits 
cellular proteins for ubiquitination facilitated by the Cullin5 complex hijacked by E4orf6. All 
currently identified substrates of the Ad ubiquitin ligase are subsequently degraded by the 
proteasome while alternative outcomes of ubiquitination by E1B55K/E4orf6 have remained 
unexplored. 
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Figure 1.13 | Rationale for project 2. It has long been known that Ad-mediated ubiquitination is 
important for proper processing of Ad late RNA. This phenotype is unexplained by the currently 
known substrates for the Ad ubiquitin ligase complex. We therefore hypothesize that 
ubiquitination of one or several undiscovered E1B55K/E4orf6 substrates is critical for processing 
of viral late RNA, forming the basis of Chapter 3 of this thesis. 
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CHAPTER 2: A CORE VIRAL PROTEIN BINDS HOST NUCLEOSOMES TO 
SEQUESTER IMMUNE DANGER SIGNALS 
 
This chapter has been published as: 
Avgousti DC, Herrmann C, Kulej K, Pancholi NJ, Sekulic N, Petrescu J, Molden RC, Blumenthal 
D, Paris AJ, Reyes ED, Ostapchuk P, Hearing P, Seeholzer SH, Worthen GS, Black BE, Garcia 
BA, Weitzman MD. A core viral protein binds host nucleosomes to sequester immune danger 
signals. Nature 535, 173-177 (2016). PMID: 27362237.258 
 
2.1 Abstract 
Viral proteins mimic host protein structure and function to redirect cellular processes and 
subvert innate defenses259. Small basic proteins compact and regulate both viral and cellular 
DNA genomes. Nucleosomes are the repeating units of cellular chromatin and play an important 
part in innate immune responses92. Viral-encoded core basic proteins compact viral genomes, but 
their impact on host chromatin structure and function remains unexplored. Adenoviruses encode 
a highly basic protein called protein VII that resembles cellular histones133. Although protein VII 
binds viral DNA and is incorporated with viral genomes into virus particles23,24, it is unknown 
whether protein VII affects cellular chromatin. Here we show that protein VII alters cellular 
chromatin, leading us to hypothesize that this has an impact on antiviral responses during 
adenovirus infection in human cells. We find that protein VII forms complexes with nucleosomes 
and limits DNA accessibility. We identified post-translational modifications on protein VII that are 
responsible for chromatin localization. Furthermore, proteomic analysis demonstrated that protein 
VII is sufficient to alter the protein composition of host chromatin. We found that protein VII is 
necessary and sufficient for retention in the chromatin of members of the high-mobility-group 
protein B family (HMGB1, HMGB2 and HMGB3). HMGB1 is actively released in response to 
inflammatory stimuli and functions as a danger signal to activate immune responses260,261. We 
showed that protein VII can directly bind HMGB1 in vitro and further demonstrated that protein VII 
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expression in mouse lungs is sufficient to decrease inflammation-induced HMGB1 content and 
neutrophil recruitment in the bronchoalveolar lavage fluid. Together, our in vitro and in vivo results 
show that protein VII sequesters HMGB1 and can prevent its release. This study uncovers a viral 
strategy in which nucleosome binding is exploited to control extracellular immune signaling. 
 
2.2 Introduction 
As viruses commandeer cellular functions to promote viral production, they induce numerous 
cellular changes. Manipulation of host chromatin is important for viral takeover of cellular 
functions7,131,259,262,263. Although there are known examples of viral control by manipulating gene 
expression47,92,131, an alternative strategy for immune evasion could exploit cellular chromatin to 
affect extracellular signaling. Genomes of DNA viruses are compacted and packaged into virus 
particles with small basic proteins encoded by the host or virus. Adenoviruses encode protein VII, 
a small basic protein packaged with viral genomes23,24,133. We hypothesized that protein VII 
contributes to host chromatin manipulation.  
 
2.3 Results 
We investigated protein VII localization during infection, and found it present in both viral 
replication centers stained for viral DNA-binding protein (DBP; Figure 2.1a and Figure 2.S1a), 
and in cellular chromatin stained for histone H1 and 4′,6-diamidino-2-phenylindole (DAPI; Figure 
2.1b). These observations suggest that protein VII functions on both viral and host genomes. To 
determine the impact of protein VII on cellular chromatin, we generated cell lines with inducible 
expression. In multiple cell types we observed that protein VII accumulation altered nuclear DNA 
into a punctate appearance (Figure 2.1c and Figure 2.S1b, c). We tested whether other basic 
proteins produce similar effects on chromatin. Viral core protein V and the precursor of protein VII 
(preVII) localized to nucleoli and did not affect chromatin appearance (Figure 2.S1d). Human 
protamine PRM1, a basic protein involved in sperm DNA compaction264, also localized to nucleoli 
and did not affect chromatin appearance (Figure 2.S1d). Taken together, our data demonstrate 
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that protein VII is sufficient to alter cellular chromatin and is distinct from other small basic 
proteins. 
To affect cellular chromatin at the nucleosome level during infection, we reasoned that protein 
VII must be abundant and associated with histones. Acid extraction of histones265,266 from 
infected cells revealed viral proteins VII and V isolated with cellular histones (Figure 2.1d), as 
verified by western blot (Figure 2.S2a) and mass spectrometry (MS). Protein VII abundance was 
comparable to cellular histone levels (Figure 2.1d). We further analyzed association of protein VII 
with cellular chromatin by salt fractionation of nuclei267. We found protein VII with cellular histones 
and DNA in high-salt fractions (Figure 2.1e and Figure 2.S2b-d). Ectopically expressed protein 
VII is also found in high-salt fractions, in contrast to other viral proteins that elute at low salt 
(Figure 2.1e and Figure 2.S2b). These data suggest that protein VII is highly abundant and 
tightly associated with cellular chromatin. 
We hypothesized that protein VII interacts with chromatin by forming complexes with DNA, 
histones, or nucleosomes, and examined protein VII interactions in vitro. Purified recombinant 
protein VII binds to DNA24 (Figure 2.S2e, f). We reconstituted nucleosomes in vitro with 
recombinant histone proteins on 195 base pairs (bp) of DNA268. Protein VII changed nucleosome 
mobility upon native gel electrophoresis (Figure 2.1f and Figure 2.S2g). We analyzed native gel 
bands by denaturing SDS-polyacrylamide gel electrophoresis (SDS-PAGE), and confirmed that 
complexes contained core histones with protein VII (Figure 2.1f, bottom). Unlike protamines264, 
protein VII forms complexes with nucleosomes but does not appear to replace histones. Next, we 
examined whether protein VII association with nucleosomes affects DNA wrapping using 
micrococcal nuclease (MNase) digestion followed by DNA fragment analysis268. We found that 
protein VII pauses nucleosomal DNA digestion at ~165 bp, the point at which DNA strands cross 
over the nucleosome dyad (Figure 2.1g and Figure 2.S3a). By contrast, nucleosome digestion 
alone paused with core particles at ~150 bp, suggesting that protein VII encumbers DNA access. 
Unlike linker histone binding that is dependent on DNA length269, protein VII protects against 
MNase digestion on the nucleosome core particle of 147 bp (Figure 2.S3b). Protein VII alone 
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protects DNA from MNase digestion, as would be expected given its role in the viral core. 
Together, these data demonstrate that protein VII binds directly to nucleosomes and limits DNA 
accessibility at the DNA entry/exit site. 
Post-translational modifications (PTMs) on histones are central to regulating chromatin 
structure90,265. Owing to the histone-like nature of protein VII133, we hypothesized that it is subject 
to post-translational modification similar to histones. PreVII was previously proposed to be 
acetylated by N-terminal addition during protein synthesis270. We noted that protein VII contains 
conserved lysine residues within an AKKRS motif271, similar to the commonly modified canonical 
histone motif ARKS90. We therefore purified protein VII from histone extracts over an adenovirus 
infection time course by reverse-phase high-performance liquid chromatography (RP-HPLC; 
Figure 2.2a and Figure 2.S4). Consistent with observations from histone extracts (Figure 2.1d), 
protein VII levels were comparable to endogenous histones. We digested purified protein VII and 
preVII with chymotrypsin to distinguish the two proteins, and analyzed peptides by tandem mass 
spectrometry (MS/MS). We identified several PTMs, with two acetylation sites and three 
phosphorylation sites the most abundant modifications (Figure 2.2b and Figures 2.S5, 2.S6b). 
Interestingly, we identified acetylation sites on ectopically expressed protein VII but not on protein 
VII in virus particles (Figure 2.S6a). We speculate that this provides a possible mechanism for 
distinguishing protein VII bound to cellular chromatin from protein destined for packaged virus. To 
investigate the relevance of the identified PTMs, we mutated modified sites in protein VII. An 
alanine-replacement mutant for all five PTM sites localized to nucleoli instead of cellular 
chromatin (Figure 2.2c). Results with individual point mutations suggest that the K3 residue is 
important for chromatin localization, and employing glutamine as an acetylation mimic (K3Q) 
mirrored the pattern of wild-type protein (Figure 2.2c). Effects induced by protein VII are not due 
to global alteration of histone PTMs since only six PTMs on histones H3 and H4 showed minor 
but significant changes (Figure 2.S6c-e). These data suggest that protein VII modification has 
critical roles during virus infection. 
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To determine whether protein VII manipulation of cellular chromatin is part of a strategy to 
counteract host defenses, we employed MS to examine changes in the protein composition of 
nuclear fractions. We compared the total chromatin proteome in the presence and absence of 
protein VII (Figure 2.3a). We identified 20 proteins that changed significantly across three 
biological replicates (Figure 2.S7). The categories of proteins most significantly changed upon 
protein VII expression were related to immune responses (Figure 2.S7c). The top four proteins 
enriched in chromatin fractions by protein VII were SET (also known as TAF-1), a protein 
previously shown to interact with protein VII141,145, and HMGB1, HMGB2, and HMGB3 (Fig. 3a). 
The HMGB proteins are alarmins with multiple functions as activators of immunity and 
inflammation260,261. HMGB1 is a nuclear protein normally only transiently associated with 
chromatin272,273. Cells also release HMGB1 as an extracellular danger signal that promotes 
immune responses after injury or infection274. We confirmed increased chromatin association of 
HMGB1 and HMGB2 by analysis of fractionated nuclei, upon protein VII expression and during 
adenovirus infection (Figure 2.3b). We verified that these changes are not due to altered HMGB1 
expression levels (Figure 2.S8a, b). We demonstrated direct binding of recombinant protein VII 
to HMGB1 in vitro and confirmed HMGB1 co-immunoprecipitation with protein VII (Figure 2.3c). 
We visually observed reorganization of HMGB1 and HMGB2 distribution upon protein VII 
expression, and at late stages of infection (Figure 2.3d-f and Figure 2.S8c-e). We also showed 
reorganization of HMGB1 distribution by vector transduction to express protein-VII-green 
fluorescent protein (GFP; Figure 2.3g and Figure 2.S8f). The effect of protein VII on HMGB1 is 
also conserved across human adenovirus serotypes (Figure 2.S8g). We further defined the 
effects of protein VII on HMGB1 mobility by fluorescence recovery after photobleaching (FRAP) 
and found decreased HMGB1 diffusion (Figure 2.3h). We next investigated whether protein VII is 
necessary for chromatin retention of HMGB1 during virus infection. We used a replication-
competent adenovirus with loxP sites inserted on either side of the protein VII gene, allowing 
deletion of protein VII during infection of cells expressing Cre recombinase (Figure 2.3i, j and 
Figure 2.S9a, b). We fractionated nuclei from infected cells and found that HMGB1 and HMGB2 
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were no longer retained in chromatin when protein VII was deleted (Figure 2.3k and Figure 
2.S9c). Together, these data indicate that protein VII is necessary and sufficient to promote 
chromatin association and immobilization of HMGB1. 
We hypothesized that protein VII retains HMGB1 in chromatin during natural infection to 
prevent cellular release and abrogate host immune responses. We therefore visualized 
endogenous HMGB1 during adenovirus infection in precision-cut lung slices275 from human 
donors (Figure 2.4a). Consistent with cell culture experiments, we demonstrate that protein VII is 
sufficient to relocalize endogenous HMGB1. We then tested whether protein VII prevents HMGB1 
release in cell culture and in vivo models. We expressed GFP or protein-VII-GFP in macrophage-
like THP-1 cells, and confirmed that protein-VII-GFP was sufficient to alter chromatin and HMGB1 
localization (Figure 2.S9d). Cells were treated to stimulate inflammasomes, and HMGB1 content 
was analyzed in supernatants. Protein VII expression resulted in reduced levels of HMGB1 and 
HMGB2 in supernatants (Figure 2.4b, c). Subsequently, we employed a murine model of 
lipopolysaccharide (LPS)-induced lung injury276 to investigate the impact of protein VII on HMGB1 
release and neutrophil recruitment in vivo (Figure 2.4d). We confirmed that protein VII was 
expressed in transduced mouse lungs (Figure 2.S10a-c) and retained mouse HMGB1 (Figure 
2.S9e, f). We exposed mice to inhaled LPS to induce HMGB1 release and neutrophil recruitment 
to alveoli. Bronchoalveolar lavage fluid obtained 24 h after LPS exposure showed that mice 
transduced to express protein VII had significantly less HMGB1 and fewer neutrophils than mice 
expressing GFP (Figure 2.4d-f). Together, these data suggest that protein VII functions in 
cellular chromatin to retain HMGB1 as a mechanism to blunt immune responses.  
In addition to known roles on packaged viral DNA143,144, we show that protein VII interacts with 
cellular chromatin and binds nucleosomes. We suggest that protein VII PTMs contribute to 
chromatin localization, and that protein VII affects the chromatin association of host proteins. 
Finally, we show that protein VII in cellular chromatin leads to sequestration of HMGB family 
members, contributing to abrogated immune responses (Figure 2.S10d). Our study reveals that 
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chromatin retention of signaling molecules by a viral protein may represent a previously 
unrecognized immune evasion strategy. 
 
 
40 
 
2.4 Figures 
 
 
Figure 2.1 | Protein VII is sufficient to alter chromatin and directly binds nucleosomes. a, 
b, Adenovirus serotype 5 (Ad5)-infected small airway epithelial cells (SAECs) stained for protein 
VII (red) with DBP (a) or histone H1 (b) (green), and DAPI (grey, blue in merge). hpi, hours post-
infection. c, Protein-VII-haemagglutinin (HA)-induced cells over 4 days showing HA (green) and 
DAPI (grey, blue in merge). dox, doxycycline. a-c, Scale bars, 10 μm. d, SDS-PAGE of histone 
extract from Ad5-infected cells showing protein V and protein VII. e, Western blot of chromatin 
fractionation from nuclei of Ad5-infected cells, induced for protein-VII-HA, or untreated. f, Protein 
VII binds to nucleosomes (Nucs). Protein bands from native gel stained with Coomassie (top) 
were subjected to two-dimensional analysis by SDS-PAGE (bottom). g, Protein VII protects 
nucleosome complexes from MNase digestion. Bioanalyzer curves represent nucleosomes alone 
(black) or protein-VII-nucleosome complexes (orange). Panels a-d and f-g by DC Avgousti. 
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Figure 2.S1 | Adenovirus protein VII distorts chromatin. a, Protein VII localizes to cellular 
chromatin and viral replication centers in U2OS cells similarly to SAECs in Figure 2.1a. b, Protein 
VII messenger RNA levels measured by quantitative PCR showing that after 4 days of induction 
in the A549 cell line, the level of protein VII transcripts is approximately 10% of that measured 
during infection at 16 hpi. Despite the low relative level, this amount of protein VII is sufficient to 
cause dramatic changes in the nucleus (graph shows mean ± s.d., n = 3 biological replicates). c, 
Inducible cell lines of U2OS and HeLa expressing protein-VII-HA show chromatin localization and 
distortion, similar to A549 cells in Figure 2.1c. d, Inducible A549 cell lines expressing viral protein 
V, the precursor for protein VII (preVII) or cellular protamine PRM1 with C-terminal HA tags. 
Although all three proteins possess a large number of charged residues, none are sufficient to 
distort cellular chromatin or increase nuclear size as observed with mature protein VII. Scale 
bars, 10 μm. Panels a, c, and d by DC Avgousti, panel b by NJ Pancholi. 
42 
 
 
Figure 2.S2 | Protein VII associates tightly with chromatin and binds DNA and 
nucleosomes in vitro. a, Western blot analysis showing protein VII in histone extracts from 
infected HeLa cells at 24 hpi. b, Chromatin fractionation of lysates from A549 cells that were 
uninfected (mock) or infected for 24 h with Ad5. Viral and cellular proteins were detected by 
western blotting with various antibodies as indicated. c, Agarose gel analysis of DNA extracted 
from nuclear fractionation experiments, indicating that the size of DNA is between 100 and 
200 bp and elutes predominantly in the higher-salt fractions. d, Chromatin fractionation of cells 
induced to express protein VII, indicating that protein VII is present in the highest-salt fraction 
from the first day of induction. e, f, Recombinant protein-VII-His binds DNA. Incubating 
increasing molar amounts of protein VII with 195 bp DNA results in shifts by native gel 
electrophoresis, indicating protein-VII-DNA complex formation. Staining with either ethidium 
bromide (e) or Coomassie (f) are shown to verify the presence of DNA and protein, respectively. 
g, Ethidium bromide staining shows DNA content of nucleosome shifts from gel in Figure 2.1f. 
Panels a and e-g by DC Avgousti. 
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Figure 2.S3 | Bioanalyzer examination of MNase-digested nucleosomes and protein-VII-
nucleosome complexes. a, 195 bp nucleosomes or protein-VII-nucleosome complexes were 
incubated with MNase for the indicated times, the reaction was stopped, DNA was extracted and 
analyzed. As in Figure 2.1g, nucleosomes are shown in black and protein-VII-nucleosome 
complexes in orange. The presence of protein VII pauses digestion at 165 bp, suggesting that 
protein VII is blocking access to the DNA. b, 147 bp nucleosomes or protein-VII-nucleosome 
complexes were incubated with MNase for the indicated times, the reaction was stopped, DNA 
was extracted and analyzed. Graphs show nucleosomes in grey and protein-VII-nucleosome 
complexes in orange. The presence of protein VII completely blocks digestion even after 
nucleosomes alone have been digested well beyond the core particle. In contrast to what would 
be expected for linker histones, protein VII protects the core nucleosome particle from digestion. 
These data indicate that protein VII may be masking the substrate for MNase through complex 
formation. This represents a unique mechanism of nucleosome binding and suggests a model for 
blocking DNA access in cellular chromatin during infection. Panels a and b by DC Avgousti. 
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Figure 2.2 | Post-translational modifications on protein VII contribute to chromatin 
localization. a, RP-HPLC analysis of histone extracts. Viral proteins V, VII and preVII are 
indicated at 24 hpi. b, Primary sequence of protein VII with modified residues identified in 
infected cells. Underlined residues represent moieties that may also be modified in identified 
peptides (see Extended Data Fig. 5). ac, acetylated; P, phosphorylated. c, Immunofluorescence 
showing DAPI (grey, blue in merge) and protein VII (red) as wild type or with alanine substitutions 
at PTM sites (ΔPTM), K3A or K3Q. Scale bar, 10 μm. Panels a-c by DC Avgousti. 
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Figure 2.S4 | Purification of protein VII from infected cells. a, Coomassie-stained SDS-PAGE 
analysis of fractions from RP-HPLC in Figure 2.2a. The bands in fraction 38-41 min correspond 
to histone H1. Protein VII and V, as indicated, were verified by MS analysis (data not shown). 
The slight upward shift of the protein VII bands in the later peak corresponds to the higher 
abundance of protein preVII, as seen by HPLC in Figure 2.2a. b, Western blot analysis of protein 
VII in HPLC fractions from a. c, Time course of infection followed by histone extraction and HPLC 
analysis. MS analysis verified peaks in each sample as indicated. Panels a-c by DC Avgousti and 
K Kulej. 
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Figure 2.S5 | Representative mass spectra. a-f, Annotated MS/MS spectra of identified 
peptides of protein VII containing PTMs (a-c, acetylated peptides; d-f, phosphorylated peptides). 
The images represent the observed fragment ions collected using MS/MS collision-induced 
dissociation (CID). Colored lines represent matches between observed and expected fragment 
ions of the given peptides. Specifically, green lines represent not fragmented precursor mass, 
blue lines represent matches with y-type fragments, red lines with b-type fragments, and yellow 
boxed masses represent fragments containing PTM neutral losses (for example, ions that lost the 
phosphorylation during fragmentation). Panels a-f by DC Avgousti and K Kulej. 
 
47 
 
 
Figure 2.S6 | Acetylated protein VII spectra from virus particles and analysis of total 
histone PTM changes upon protein VII expression. a, Liquid chromatography-mass 
spectrometry (LC-MS) analysis of unmodified and modified chymotryptic peptide 
AKKRSDQHPVRVRGHY. On the left, nano-LC-MS-extracted ion chromatograms of protein VII 
peptides identified in the histone extracts of adenovirus infected cells (Inf) or viral particles (VP). 
The top left represents the modified form, while the bottom left represents the unmodified form. 
Non-modified forms were detected in both conditions for Inf and VP, while the acetylated form 
was unique for the infected sample only (Inf). On the right, full MS spectrum of the modified (top) 
and unmodified (bottom) peptide. Circled mass represents the monoisotopic signal of the 
peptide. b, Summary of post-translational modifications detected on protein VII. Peptides shown 
were identified during infection at various time points with the mature protein VII in the top row 
and preVII in the bottom row. The numbers in brackets for preVII indicate the location of the 
same moiety in mature protein VII. Acetylation sites were detected in approximately 3% of 
peptides for mature protein VII and 2% of peptides in preVII. Phosphorylation was detected in 
approximately 1% of peptides for mature protein VII and preVII. c, d, Quantification of histone H3 
(c) and H4 (d) PTMs in protein-VII-HA-induced (+dox) and -uninduced (−dox) A549 cells from the 
analysis of crude histone mixtures (n = 3 biological replicates). Positions of PTMs are listed along 
the x axis. Modification type is indicated by colour as shown. y Axis represents the cumulative 
extent of PTMs relative to the total histone H3 or H4, respectively. e, Breakdown of the histone 
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were identified during infection at various time points with the mature protein VII in the top row 
and preVII in the bottom row. The numbers in brackets for preVII indicate the location of the 
same moiety in mature protein VII. Acetylation sites were detected in approximately 3% of 
peptides for mature protein VII and 2% of peptides in preVII. Phosphorylation was detected in 
approximately 1% of peptides for mature protein VII and preVII. c, d, Quantification of histone H3 
(c) and H4 (d) PTMs in protein-VII-HA-induced (+dox) and -uninduced (−dox) A549 cells from 
the analysis of crude histone mixtures (n = 3 biological replicates). Positions of PTMs are listed 
along the x axis. Modification type is indicated by color as shown. y Axis represents the 
cumulative extent of PTMs relative to the total histone H3 or H4, respectively. e, Breakdown of 
the histone marks (H3K14ac, H3K27me1, H3K36me3, H4K20me1, H4K20me2 and H4K20me3) 
found to be significantly different (n = 3 biological replicates) in terms of relative abundance 
between the protein-VII-HA-induced and -uninduced states (<5% homoscedastic two-tailed t-
test). Mean ± s.d. Panels a-e by DC Avgousti and K Kulej. 
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Figure 2.3 | Protein VII directly binds HMGB1 and is necessary for retention of the alarmin 
in cellular chromatin. a, Volcano plot for proteomics analysis of one representative biological 
replicate of the high-salt fraction. The y axis represents −log2 statistical P value and the x axis 
represents log2 protein fold-change between uninduced or protein-VII-expressing cells 
(homoscedastic two-tailed t-test, P < 0.05 red dots; n = 3 technical replicates). b, Nuclear 
fractionation shows that HMGB1 and HMGB2 normally elute from nuclei at low salt 
concentrations but are retained in high-salt fractions by protein-VII-HA. d, day; dox, doxycycline. 
c, Protein VII interacts with HMGB1 in pull-down of recombinant HMGB1-glutathione S-
transferase (GST) (left, Coomassie-stained SDS-PAGE) and immunoprecipitation of HMGB1 
(right, western blots). d, e, Protein VII expression alters localization of HMGB1 (d) and HMGB2 
(e). Immunofluorescence shows protein-VII-HA (green) colocalized with HMGB1 (d) and HMGB2 
(e) (red) in cellular chromatin (DAPI, grey, blue in merge). f, Same as d at 18 hpi with Ad5 DBP 
(green). g, Protein-VII-GFP relocalizes HMGB1 (red) to chromatin with DAPI (grey, blue in 
merge). rAd, recombinant adenovirus. d-g, Scale bars, 10 μm. h, FRAP experiment with HMGB1-
monomeric GFP (mGFP). Recovery of FRAP signal in time-course images (left) with 
quantification and diffusion coefficients (right). Scale bar, 5 μm. D, diffusion coefficient; t1/2, 
halftime of recovery. i, Schematic showing loxP strategy for deleting protein VII. j, Western blots 
comparing 293 and 293-Cre cells infected with Ad5-flox-VII virus. k, Salt fractionation in nuclei 
from j. Analysis of panel a by K Kulej, panels c-h by DC Avgousti, and panels i and j by NJ 
Pancholi. 
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Figure 2.S7 | Bioinformatic analysis of proteins enriched in the high-salt fraction upon 
protein VII expression. a, Venn diagram showing overlap between three biological replicates of 
high-salt-fraction proteins significantly enriched compared with uninduced cells. b, Proteins found 
significantly enriched in the protein-VII-HA-induced state compared with uninduced (<5% 
homoscedastic t-test) in all three biological replicates (‘VII-HA induced’ indicates proteins 
identified only in protein-VII-HA-induced condition). c, d, Classification of proteins significantly 
enriched in minimum two out of three biological replicates (protein-VII-HA-induced versus 
uninduced) according to process network enrichment and Gene Ontology biological process 
(GeneGo MetaCore pathways analysis package; false discovery rate (FDR) < 5%); each Gene 
Ontology term was ranked using P-value enrichment. Analysis of panel a-d by K Kulej. 
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Figure 2.S8 | Protein VII retains HMGB1 and HMGB2 in chromatin. a, Western blot of 
adenovirus-infected or doxycycline-treated A549 cells showing the relative levels of protein VII 
expression. HMGB1 levels do not change upon infection or protein VII expression. Tubulin is 
shown as a loading control. b, Quantitative PCR analysis of mRNA transcripts of HMGB1 in 
various cell types as indicated (for A549, n = 3 biological replicates; for THP-1, n = 2 biological 
replicates; mean ± s.d.). The levels of HMGB1 do not significantly change. c, 
Immunofluorescence analysis of a time course of protein-VII-HA (red) induction shown with 
HMGB1 (green) and DAPI (grey, blue in merge) in A549 cells. Expression of protein-VII-HA 
results in a change to the HMGB1 distribution upon expression. d, HMGB1 (green) localization 
changes between 12 and 24 hpi of wild-type adenovirus in A549 cells, and adopts a pattern 
similar to protein VII as in Figure 2.1a. DBP (red) is shown as a marker of infection, DNA is 
stained with DAPI (blue in merge). e, Same as d showing that HMGB2 adopts the same pattern 
as HMGB1 during Ad5 infection at 24 hpi. f, Multiple cells showing the same pattern of HMGB1 
relocalization upon expressing protein-VII-GFP as in Figure 2.3g. g, HMGB1 retention in the 
high-salt fraction is conserved across adenovirus serotypes. Western blot analysis of HMGB1 
from salt-fractionated A549 cells infected with Ad5, Ad9 or Ad12 as shown. Scale bars, 10 μm. 
Panels a and b by NJ Pancholi, panels c-f by DC Avgousti. 
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Figure 2.S9 | Protein VII is necessary and sufficient for chromatin retention of HMGB1 in 
human and mouse cells. a, b, Replication of Ad5-flox-VII virus on 293 or 293-Cre cells. 
Quantitative PCR analysis of viral genomic DNA over a time course of infection (a) shows the 
DBP gene is increasing exponentially in 293 and 293-Cre cells when infected with Ad5-flox-VII 
virus. In contrast, PCR for the protein VII gene (b) demonstrates deletion in 293-Cre cells (n = 2 
biological replicates, mean ± s.d.). c, Salt fractionation of 293-Cre cells infected with wild-type 
Ad5, indicating that the Cre recombinase does not interfere with the ability of protein VII to retain 
HMGB1 in the high-salt chromatin fraction. Protein VII is also necessary for the chromatin 
retention of HMGB2. d, THP-1 cells transduced to express protein-VII-GFP results in chromatin 
distortion and HMGB1 retention in chromatin. Immunofluorescence of transduced PMA-treated 
THP-1 cells showing protein-VII-GFP (green), HMGB1 (red) and DNA (grey, blue in merge). e, 
Transduction to express protein-VII-GFP is sufficient to relocalize mouse HMGB1 in mouse 
embryonic fibroblast (MEF) cells. f, Salt fractionation of mouse embryonic fibroblast cells 
transduced to express protein-VII-GFP. Human Ad5 protein VII is sufficient to retain mouse 
HMGB1 in the high-salt fraction in MEF cells. The control vector expressing GFP alone does not 
have this effect. Panels a and b by NJ Pancholi, panels d and e by DC Avgousti. 
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Figure 2.4 | Protein VII prevents HMGB1 release. a, Precision-cut lung slices infected with Ad5 
or transduced to express protein-VII-GFP. Endogenous HMGB1 (red) is redistributed in cells with 
virus (DBP, top) and protein-VII-GFP (bottom). b, Protein-VII-GFP is sufficient to inhibit HMGB1 
and HMGB2 release in THP-1 cells. Numbers indicate relative intensities of bands quantified with 
ImageJ. c, Enzyme-linked immunosorbent assay (ELISA)-based quantification of HMGB1 in 
supernatants from b. Mean ± standard deviation (s.d.), n = 4 technical replicates, homoscedastic 
one-tailed t-test. d, Schematic for investigating protein VII in a mouse lung injury model. e, 
Expression of protein-VII-GFP decreases HMGB1 in mouse BAL fluid as quantified by ELISA. 
Mean ± s.d., biological replicates: nLPS = 4, nGFP+LPS = 6, nVII-GFP+LPS = 7, homoscedastic 
one-tailed (P = 0.02) or two-tailed (P = 0.003) t-test. f, Neutrophils in bronchoalveolar lavage 
(BAL) fluid are significantly fewer in mice expressing protein-VII-GFP. Mean ± s.d., biological 
replicates: nGFP+LPS = 6, nVII-GFP+LPS = 4, nLPS = 5, nGFP = 3, nVII-GFP = 3, homoscedastic 
two-tailed t-test. Panels a, and d-f by DC Avgousti, panels e and f with help of GS Worthen and 
AJ Paris. 
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Figure 2.S10 | Transduction of mouse lungs demonstrating expression of GFP or protein-
VII-GFP. a, Sections of mouse lungs transduced to express protein-VII-GFP or GFP co-stained 
for HMGB1. GFP signal shows multiple cell types transduced in both cases. Protein-VII-GFP has 
a more distinct nuclear signal than GFP, which also appears cytoplasmic. Two sections for each 
condition are shown to indicate transduction efficiency. b, Same as a but co-stained for 
prosurfactant-C to mark type II pneumocytes. Some cells are positive for both, confirming that 
multiple cell types were transduced. c, Zoomed images of individual epithelial cells from mouse 
lungs showing the characteristic protein-VII-GFP pattern colocalizing with DAPI in the nucleus. 
GFP only is mostly cytoplasmic. d, Schematic summarizing function of protein VII during 
infection. Newly synthesized protein VII late during infection can be post-translationally modified 
and binds to HMGB1, sequestering it on the cellular chromatin and preventing its release. 
Unmodified protein VII is packaged in viral progeny. Panels a-d by DC Avgousti. 
55 
 
2.5 Methods 
2.5.1 Cells 
Primary SAECs, U2OS, HeLa, 293, THP-1 and A549 cells were obtained from the American 
Type Culture Collection (ATCC) and grown according to the provider’s instructions. Cell lines 
were not authenticated or tested for mycoplasma. Acceptor cells for generation of inducible cell 
lines were provided by E. Makeyev and used as previously reported277,278. Protein VII, preVII and 
V were cloned from genomic DNA isolated from HeLa cells infected with adenovirus type 5 and 
inserted into the inducible plasmid cassette with a C-terminal HA tag using restriction enzymes 
BsrGI and AgeI (primer sequences available upon request). Positive clones were selected in 
DH5α cells, sequenced, and transfected into A549, U2OS or HeLa acceptor cells along with 
plasmid expressing the Cre recombinase. Recombined clones were selected by puromycin 
resistance (1 μg/ml) and induced with doxycycline (0.2 μg/ml) to express the desired protein. 
Protein expression was verified by immunofluorescence and western blot. All figures shown are 
after 4 days of induction unless otherwise stated. Protein VII and preVII were also verified by 
HPLC purification and MS analysis. Point mutations were generated by gene synthesis from 
Genewiz. 293-Cre cells were provided by P. Hearing. 
2.5.2 Viruses and infections 
Wild-type Ad5, Ad9, Ad12 and recombinant adenovirus vectors expressing only GFP were 
propagated in 293 cells as previously described278. Recombinant adenovirus vector with protein-
VII-GFP replaced in the E1 region was a gift from D. Curiel279. Infections were carried out as 
described previously221 using a multiplicity of infection of 10 for primary cells and cell lines for Ad5 
infections. Ad9 and Ad12 infections were carried out with a multiplicity of infection of 50 and 20, 
respectively. Ad5-flox-VII was generated by P. Hearing and also prepared using standard 
methods in 293 cells. loxP sites were added flanking protein VII in the Ad5 genome resulting in 
protein VII deletion during infection of 293 cells expressing Cre recombinase. 
2.5.3 Antibodies 
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Primary antibodies were purchased from Covance (HA MMS-101R), Abcam (H1 ab4269, H3 
ab1791, HMGB1 ab18256, HMGB2 ab67282), Millipore (H2A 07-146, prosurfactin-C AB3786), 
and Santa Cruz (Ku86 sc5280, tubulin sc69969). The antibodies to DBP, adenoviral late proteins, 
terminal protein and protein VII were gifts from A. Levine280, J. Wilson278, R. Hay and L. Gerace, 
respectively. Secondary antibodies for immunoblotting were obtained from Jackson 
ImmunoResearch and secondary antibodies for immunofluorescence were obtained from Life 
Technologies. 
2.5.4 Immunofluorescence 
Cells were grown on glass coverslips in 24-well plates and either infected or induced with 
doxycycline (0.2 μg/ml). Cells were harvested for immunofluorescence at the indicated time 
points, washed in PBS, fixed in 4% paraformaldehyde for 15 min and post-fixed with 100% ice-
cold methanol for 5 min. Coverslips were then blocked and stained as previously described36 and 
mounted using ProLong Gold Antifade Reagent (Life Technologies). Immunofluorescence was 
visualized using a Zeiss LSM 710 Confocal microscope (Cell and Developmental Microscopy 
Core at UPenn) and ZEN 2011 software. Images were processed using ImageJ and assembled 
with Adobe CS6. 
2.5.6 Immunoblotting 
Western blot analysis was carried out using standard methods. Briefly, equal amounts of total 
protein lysates were separated by SDS-PAGE and transferred to a nitrocellulose membrane 
(Millipore) for at least 30 min at 30 V. Membranes were stained with ponceau to confirm protein 
loading and blocked in 5% milk in TBST containing 0.1% azide. Membranes were incubated with 
primary antibodies overnight, washed for 30 min in TBST and incubated with secondary 
antibodies conjugated to horseradish peroxidase (Jackson Laboratories) for 1 h. Membranes 
were washed again and proteins were visualized with Pierce ECL Western Blotting Substrate 
(Thermo Scientific) and detected using a Syngene G-Box. 
2.5.7 Mice 
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All mice were housed in specific-pathogen-free (SPF) conditions in an animal facility at the 
Children’s Hospital of Philadelphia. All studies in mice were carried out in accordance with the 
recommendations in the Guide for the Care and Use of Laboratory Animals of the National 
Institutes of Health and approved by the Institutional Animal Care and Use Committee, Children’s 
Hospital of Philadelphia Animal Welfare Assurance Number A3442-01. C57BL/6J male mice 
aged 8-10 weeks were used for experiments. Mice were sedated with ketamine and xylazine. 
Once sedated, mice underwent orotrachial intubation, as previously described281, with a 20G 
angiocatheter from BD. Mice subsequently received 5 × 1010 genome copies (GC) of recombinant 
adenovirus expressing protein-VII-GFP or GFP purified by the Penn Vector Core. Four days after 
infection, mice were exposed to aerosolized LPS, 3 mg/ml for 30 min as previously described282. 
One day after LPS exposure, bronchoalveolar lavage (BAL) and lung tissue were harvested as 
previously detailed283 and examined for HMGB1 content (ELISA, Chondrex 6010) and neutrophil 
count (haematoxylin and eosin stain kit EMD 65044/93). Immunostaining was carried out by the 
CHOP Pathology Core using standard methods. A minimum of four biological replicates were 
used for each condition studied. Mice were assigned a random number and color at the start of 
the experiment and were randomized. Technicians carrying out the experiments were blinded to 
the identity of the samples. Tissue samples were assigned a random study number such that the 
technician performing the analysis was blinded. Unblinding for the purpose of data analysis 
occurred only after all data had been collected. 
2.5.8 Salt fractionation of nuclei 
Salt fractionation of nuclei was adapted from established protocols267,284. Briefly, 2-4 × 107 
cells were collected and resuspended in 2 ml of ice-cold buffer I (0.32 M sucrose, 60 mM KCl, 
15 mM NaCl, 5 mM MgCl2, 0.1 mM EGTA, 15 mM Tris, pH 7.5, 0.5 mM dithiothreitol (DTT), 
0.1 mM PMSF and protease inhibitor cocktail from Roche). To dissolve the plasma membrane, 
2 ml ice-cold buffer I supplemented with 0.1% IGEPAL were added and samples were incubated 
on ice for 10 min. The 4 ml of nuclei was layered on 8 ml of ice-cold buffer II (1.2 M sucrose, 
60 mM KCl, 15 mM NaCl, 5 mM MgCl2, 0.1 mM EGTA, 15 mM Tris, pH 7.5, 0.5 mM DTT, 0.1 mM 
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PMSF and protease inhibitor cocktail from Roche) and centrifuged for 20 min at 10,000 g and 
4 °C. The pelleted nuclei were resuspended in 400 μl buffer III (10 mM Tris pH 7.4, 2 mM MgCl2, 
0.1 mM PMSF) supplemented with 5 mM CaCl2 and the DNA was digested to mononucleosomes 
by addition of 1 unit of MNase (Sigma-Aldrich, N3755). The reaction was incubated at 37 °C for 
30 min and then stopped by addition of 25 μl of 0.1 M EGTA. The samples were centrifuged for 
10 min, 350 g, at 4 °C, and supernatants were set aside for western blot analysis. The pellet was 
resuspended in 400 μl of buffer IV (70 mM NaCl, 10 mM Tris pH 7.4, 2 mM MgCl2, 2 mM EGTA, 
0.1% Triton X-100, 0.1 mM PMSF) with 80 mM salt and rotated for 30 min at 4 °C. The sample 
was centrifuged for 10 min at 350 g, 4 °C, and the supernatant collected for western blot analysis. 
This step was repeated for salt concentrations in buffer IV of 150 mM, 300 mM and 600 mM. The 
final pellet was resuspended in 400 μl H2O and all samples were analyzed together by western 
blot. An aliquot of each supernatant was set aside for DNA purification using a PCR purification 
kit (Qiagen) and analyzed by agarose gel electrophoresis. Alternatively, 4 × 107 cells were 
resuspended in 400 μl hypotonic buffer (10 mM HEPES pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 
1:1,000 PMSF, 0.5 mM DTT) and incubated on ice for 30 min. The cells were transferred to a 1 ml 
dounce tissue grinder and the cell membranes were gently disrupted with 40 strokes of a tight-
fitting pestle. The samples were centrifuged for 5 min at 1,500 g and 4 °C. The pelleted nuclei 
were resuspended in 400 μl buffer III and the fractionation was continued as described earlier. 
2.5.9 Preparation of salt fractions for MS analysis 
All chemicals used for preparation of MS samples were of at least sequencing grade and 
purchased from Sigma-Aldrich, unless otherwise stated. Only the 600 mM salt fraction was used 
for LC-MS/MS analysis. The 0.1% Triton X-100 detergent was removed from samples before MS 
analysis by precipitation using chloroform (CHCl3)-methanol (MeOH) precipitation285. The protein 
pellet from CHCl3-MeOH precipitation was resuspended in 6 M urea and 2 M thiourea in 50 mM 
ammonium bicarbonate. Samples were reduced with 10 mM DTT for 1 h at room temperature and 
then carbamidomethylated with 20 mM iodoacetamide for 30 min at room temperature in the dark. 
Afterwards, alkylated proteins were digested first with endopeptidase Lys-C (Wako, MS grade) for 
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3 h, after which the solution was diluted 10 times with 20 mM ammonium bicarbonate. 
Subsequently, samples were digested with trypsin (Promega) at an enzyme-to-substrate ratio of 
approximately 1:50 for 12 h at room temperature. The samples were acidified with 5% formic acid 
(FA) to pH ≤ 3 and desalted using Poros Oligo R3 RP columns (PerSeptive Biosystems) packed 
in a P200 stage tip with C18 3M plug (3M Bioanalytical Technologies). Purified peptide samples 
were dried by lyophilization and stored at −20 °C until further analysis. This procedure was 
carried out for three biological replicas. 
2.5.10 Nano-LC-MS/MS and analysis of salt fractions 
Samples were loaded onto a 16 cm C18-AQ column (inner diameter 75 μm, 3 μm beads, Dr, 
Maisch GmbH, Germany) using an Easy nano-flow HPLC system (Thermo Fisher Scientific). The 
nano-LC was coupled to an Orbitrap Fusion Tribrid Mass Spectrometer (Thermo Fisher Scientific) 
via a nanoelectrospray ion source (Thermo Fisher Scientific). Peptides were loaded in buffer A 
(0.1% formic acid) and eluted with a 120 min linear gradient from 2-30% buffer B (95% 
acetonitrile, 0.1% formic acid). After the gradient, the column was washed with 90% buffer B. 
Mass spectra were acquired using a data-dependent acquisition method with the TopSpeed set 
with 3-s cycle. Spectra were acquired in the Orbitrap analyzer with mass range of 350-1,200 m/z 
and 120,000 resolution (200 m/z), with a maximum injection time of 50 ms and an AGC target of 
5 × 105. Signals with 2-5 charges were selected for HCD fragmentation using a normalized 
collision energy of 27, a maximum injection time of 120 ms and an AGC target of 10,000. 
Fragments were analyzed in the ion trap. Raw MS files were analysed by MaxQuant (v.1.5.2.8)286 
(http://www.maxquant.org). MS/MS spectra were searched against the UniProt-human database 
(version June 2014, 59,345 entries). All used search parameters were default, with the exception 
of including the match between runs (1 min window) and the intensity-based absolute 
quantification (iBAQ) label-free quantification287. The search included variable modifications of 
methionine oxidation and N-terminal acetylation, and fixed modification of carbamidomethyl 
cysteine. Each iBAQ value was log2 transformed and subsequently normalized by the average 
protein abundance within each run. Biological process association analysis and process network 
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enrichment were performed using the GeneGo MetaCore pathways analysis package with 
FDR < 5%; each Gene Ontology term was ranked using P-value enrichment. 
2.5.11 Purification of recombinant protein-VII-His 
Protein VII was cloned from genomic DNA isolated from adenovirus-infected HeLa cells into a 
pET21a backbone to generate a C-terminal hexahistidine tag. Positive clones were selected in 
DH5α cells, sequenced, and transformed into BL21 (DE3) cells (NEB C2527I). The purification of 
insoluble protein-VII-His was adapted from existing protocols to purify histone proteins from 
Escherichia coli97,288. Briefly, BL21 cells were inoculated from overnight cultures and grown to an 
optical density of 0.5-0.6 OD260 nm, induced with 0.1 mM isopropyl-β-d-thiogalactoside (IPTG; 
Sigma) and harvested after 4 h at 37 °C. Cell pellets were resuspended in a mild buffer (50 mM 
Tris-HCl pH 8.0, 500 mM NaCl, 1 mM PMSF, 5% glycerol, 2.5 μg/ml aprotinin, leupeptin and 
pepstatin) and disrupted by sonication using a Branson 250 sonifier. The lysate was then 
centrifuged at 27,000 g for 20 min at 4 °C. The supernatants were discarded, and pellets were 
resuspended in a denaturing buffer (50 mM Tris-HCl, pH 8.0, 500 mM NaCl, 5% glycerol, 8 M 
urea). The suspension was centrifuged again to eliminate insoluble cell debris and the His-tagged 
protein was isolated using a cobalt resin (ThermoScientific 89964) according to the 
manufacturer’s instructions for denaturing conditions. The purified protein was then dialysed 
against water and lyophilized. Purified protein was verified by western blot and MS. 
2.5.12 In vitro binding assays 
HMGB1-GST (Abnova) or GST (Sigma) were combined with recombinant protein-VII-His at 
equimolar ratios and incubated at 4 °C for 1 h. Complexes were then mixed with a cobalt resin 
(ThermoScientific 89964) to bind protein-VII-His and any associated protein and washed three 
times in the binding buffer (50 mM Tris pH 8, 300 mM NaCl, 0.1% IGEPAL). The beads were then 
boiled in sample buffer, separated on a 4-12% NuPage gel and visualized by Coomassie staining. 
2.5.13 Nucleosome in vitro binding and MNase digestion assays 
Gel shift and MNase digestion assays were carried out as previously described268,289,290. 
Briefly, nucleosomes were reconstituted by incubating purified recombinant histones with ‘601’ 
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DNA of either 195 or 147 bp over a series of dialysis. Recombinant protein-VII-His was then 
combined with nucleosomes at various molar ratios, incubated at room temperature for 15 min, 
and analyzed by native gel electrophoresis. Complexes were also digested with MNase 
(Affymetrix) by addition of 1 unit per μg of DNA for 147 bp nucleosome experiments and 0.1 unit 
per μg of DNA for 195 bp nucleosome experiments, incubated at 22 °C for varying amounts of 
time followed by the addition of EGTA and guanidine thiocyanate to stop the reaction. The DNA 
fragments were then purified using a MinElute PCR purification kit (Qiagen) and analyzed on an 
Agilent 2100 Bioanalyzer as previously described268. 
2.5.14 Release assay of HMGB1 in THP-1 cells 
THP-1 cells were seeded at a density of 2 × 105 cells per well in a 24-well plate, and 
stimulated into macrophage-like cells by addition of 10 ng/ml PMA for 48 h. Cells were washed in 
PBS and transduced with recombinant adenovirus vectors expressing only GFP or protein-VII-
GFP such that >90% of cells were GFP positive. At 48 h after transduction, cells were washed 
and 200 μl of serum-free RPMI was added. To stimulate the inflammasome, LPS (Sigma-Aldrich 
L2880) with a final concentration of 0.5 μg/ml was added to wells and incubated for 2 h, then 
nigericin (Sigma-Aldrich N7143) was added with a final concentration of 10 μM for 1 h. 
Supernatants were collected and proteins precipitated overnight at 4 °C with a final concentration 
of 20% trichloroacetic acid (Sigma), washed with acetone, dried, and resuspended in 1 × LDS 
sample buffer with reducing agent (Invitrogen). For ELISA analysis, supernatants were harvested 
directly and HMGB1 content was detected by the manufacturer’s instructions (Chondrex 6010). 
Cells were also harvested by the addition of 1×LDS sample buffer with reducing agent 
(Invitrogen) and boiled. Supernatants and lysates were analyzed together by western blot. 
2.5.15 Acid extraction and RP-HPLC 
Histones were prepared for MS analysis as detailed previously291. Nuclei were isolated and 
histones from infected cells were extracted by acid as previously described265. The preVII and 
protein VII variants were fractionated using an offline RP-HPLC. Briefly, ~100 μg proteins were 
resuspended in buffer A (0.1% trifluoroacetic acid (TFA) in HPLC-grade water) and loaded onto a 
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C18 5 μm column (4.6 mm internal diameter × 250 mm, Vydac) using a Beckman Coulter (System 
GoldA) HPLC (buffer A: 0.1% TFA; buffer B: 95% acetonitrile, 0.08% TFA). The proteins were 
separated using a gradient from 30 to 45% buffer B in 100 min at a flow rate of 0.2 ml/min. The 
fractions containing the proteins of interest were collected using an automatic fraction collector 
and individual peaks were combined based on their ultraviolet signal. The fractions were 
subsequently dried by vacuum centrifugation and prepared for MS (see later). Protein VII was 
purified from three biological replicates and analyzed as follows for MS. 
2.5.16 MS analysis of protein VII PTMs 
2.5.16.1 Sample preparation/protein VII  
RP-HPLC-purified samples of protein VII variants were reduced in 10 mM DTT in 50 mM 
ammonium bicarbonate for 1 h at 56 °C. After cooling to room temperature, samples were 
alkylated in 20 mM iodoacetamide in 50 mM ammonium bicarbonate for 30 min in the dark. 
Samples were digested with chymotrypsin or Arg-C, at an enzyme-to-substrate ratio of 
approximately 1:20 for 8 h at 37 °C. The samples were acidified to a final concentration of 5% 
formic acid to pH ≤ 3 and desalted using P200 stage tip columns packed with C18 3M plug (3M 
Bioanalytical Technologies). Purified peptide samples were dried by lyophilization and stored at 
−20 °C until further analysis. 
2.5.16.2 Nano-LC-MS/MS analysis of histone PTMs  
The nano-LC-MS/MS analysis was performed as previously described291. 
2.5.16.3 Nano-LC-MS/MS analysis of protein VII peptides  
The nano-LC-MS/MS analysis was performed in triplicate for each sample. Samples were 
loaded onto a 16 cm C18-AQ column (inner diameter 75 μm, 3 μm beads, Dr, Maisch GmbH) 
using an Easy nano-flow HPLC system (Thermo Fisher Scientific). The nano-LC was coupled to 
an Orbitrap Velos Pro Mass Spectrometer (Thermo Fisher Scientific) via a nanoelectrospray ion 
source (Thermo Fisher Scientific). Peptides were loaded in buffer A (0.1% formic acid) and eluted 
with a 45 min linear gradient from 2 to 30% buffer B (95% acetonitrile, 0.1% formic acid). After the 
gradient, the column was washed with 90% buffer B. Mass spectra were acquired using a data-
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dependent acquisition method with the top 15 most intense ions. Spectra were acquired in the 
Orbitrap analyzer with mass range of 350-1,600 m/z and 60,000 resolution (400 m/z), with a 
maximum injection time of 10 ms and an AGC target of 10×106. Signals above 1,000 count 
charges were selected for HCD fragmentation using normalized collision energy of 36, a 
maximum injection time of 100 ms and an AGC target of 50,000. Fragments were analyzed in the 
orbitrap. 
2.5.17 Data processing of protein VII spectra 
Raw mass spectrometer files were analyzed using Proteome Discoverer (v.1.4, Thermo 
Scientific). MS/MS spectra were converted to .mgf files and searched against the UniProt 
adenovirus C serotype 5 database using Mascot (v.2.5, Matrix Science). Database searching was 
performed with the following parameters: precursor mass tolerance 10 p.p.m.; MS/MS mass 
tolerance 0.05 Da; enzyme chymotrypsin (Promega) or Arg-C (Roche), with two missed 
cleavages allowed; fixed modification was cysteine carbamidomethylation; variable modifications 
were methionine oxidation, serine/threonine/tyrosine phosphorylation, lysine acetylation and 
methylation, asparagine and glutamine deamidation. Specifically, phosphorylation, acetylation, 
and methylation were searched separately, not as co-existing modifications. Peptides were 
filtered for <1% FDR, Mascot ion score >20 and peptide rank 1. 
2.5.18 Co-immunoprecipitation of protein-VII-HA 
A549 cells were induced to express protein VII with doxycycline for 4 days as described 
earlier. Approximately 4×107 cells were harvested and pelleted for each immunoprecipitation 
reaction. Cell pellets were resuspended in 500 μl of IC wash buffer with protease inhibitors 
(20 mM HEPES pH 7.9, 110 mM KOAc, 2 mM MgCl2, 150 mM NaCl, 0.1% Tween-20, 0.1% Triton 
X-100) and incubated on ice for 10 min with intermittent vortexing to disrupt cells. Samples were 
then incubated on ice for 1 h with 5 μl of benzonase (Millipore) added to each sample to digest 
DNA to ~150 bp, which was confirmed by DNA isolation and agarose gel analysis. Samples were 
then sonicated in a Diagenode Bioruptre for 30 s on and 30 s off for five rounds at 4 °C and 
centrifuged at 14,000 g for 15 min at 4 °C. Supernatants were then incubated rotating for 1 h at 
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4 °C with 30 μl of HA-conjugated magnetic beads (Thermo Scientific) and washed three times for 
5 min in IC buffer. Isolated proteins were eluted with 100 μl of 2 mg/ml HA peptide (Thermo 
Scientific) for 20 min rotating at 37 °C and separated on an SDS-PAGE gel. For protein 
separation by SDS-PAGE the NuPAGE 1DE System was used (NuPAGE Novex 4-12% Bis-Tris 
1.0 mm gels, Invitrogen). Uninduced cells were used as a negative control. The 
immunoprecipitation was carried out in biological triplicate and pull-down of protein-VII-HA and 
HMGB1 was confirmed by western blotting standard techniques as described earlier. 
2.5.19 Quantitative PCR 
Genomic DNA was isolated using the PureLink Genomic DNA kit (Thermo Scientific). 
Quantitative PCR was performed using primers specific for viral DBP (5′-
GCCATTGCGCCCAAGAAGAA and 5′-CTGTCCACGATTACCTCTGGTGAT), protein VII (5′-
GCGGGTATTGTCACTGTGC and 5′-CACCCAATACACGTTGCCC), and cellular tubulin (5′-
CCAGATGCCAAGTGACAAGAC and 5′-GAGTGAGTGACAAGAGAAGCC). Values for DBP and 
protein VII were normalized internally to tubulin and to the 4 h time point to control for any 
variation in virus input. RNA was isolated using the RNeasy Mini Kit (Qiagen) and reverse 
transcribed using the High Capacity RNA to cDNA Kit (Applied Biosystems). Quantitative PCR 
was performed using primers specific for HMGB1 (5′-TAACTAAACATGGGCAAAGGAG and 5′-
TAGCAGACATGGTCTTCCAC) and β-actin (5′-GCACCACACCTTCTACAATGAG and 5′-
GGTCTCAAACATGATCTGGGTC). Quantitative PCR was performed using the standard protocol 
for Sybr Green (Thermo Scientific) and analyzed using the ViiA 7 Real-Time PCR System 
(Thermo Scientific). 
2.5.20 Precision-cut lung slice immunofluorescence 
Precision-cut lung slices were obtained and prepared as previously described275,292. De-
identified human lung tissue from donors was obtained from the National Disease Research 
Interchange. Analysis of human samples was approved by the University of Pennsylvania Internal 
Review Board. Samples were infected with 108 plaque-forming units (p.f.u.) of Ad5 per slice or 
109 GC of rAd protein-VII-GFP for 24 h. Samples were fixed in 4% PFA at room temperature for 
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15 min and washed three times in PBS. Samples were permeabilized with 0.5% Triton X-100 and 
washed twice more in PBS. Samples were then incubated with 3% BSA and 0.03% Triton X-100 
in PBS for 1 h to block. Primary antibodies (DBP or HMGB1) were incubated in the same buffer 
for 1 h and then samples were washed three times in PBS with 3% BSA, incubated with 
secondary antibodies and DAPI for 1 h, and washed three more times. Whole slices were 
mounted on slides with mounting solution and imaged by confocal microscopy. 
2.5.21 FRAP 
Full-length HMGB1 was cloned from pcDNA3.1 Flag-hHMGB1 (Addgene 31609) into pEGFP-
N1 containing a L221K mutation to prevent dimerization of GFP molecules293. A549 cells were 
induced to express protein VII for 4 days with doxycycline in glass-bottom dishes. Cells were then 
transfected with the construct that constitutively expresses HMGB1 with a monomeric GFP C-
terminal tag. FRAP was carried out using standard methods on a Zeiss LSM 710 confocal 
microscope. Diffusion coefficients were calculated using the ‘simFRAP’ algorithm 
(http://imagej.nih.gov.proxy.library.upenn.edu/ij/plugins/sim-frap/index.html), a simulation based 
approach to FRAP analysis294. 
2.5.22 Statistical analyses 
Statistical details are reported in each figure legend. Statistical analyses were performed on at 
least three different biological replicates, unless otherwise stated in the figure legend. The sample 
size was chosen to provide enough statistical power to apply parametric tests (one- or two-tailed 
homoscedastic t-test). The t-test was considered a valuable statistical test since binary 
comparisons were performed and the number of replicates was limited. Furthermore, we applied 
the homoscedastic t-test assuming that the variance between the two data sets would remain 
homogeneous due to the use of the same cell lines in culture with and without protein VII 
expression. No samples were excluded as outliers (this applies to all proteomics analyses 
described in this manuscript). Proteins with a P value smaller than 0.05 were considered to be 
significantly altered between the two tested conditions for two-tailed and one-tailed t-test. Data 
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distribution was assumed to be normal but this was not formally tested. The nano-LC-MS/MS 
analysis was performed in triplicate for each sample to determine technical variation. 
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CHAPTER 3: VIRAL-MEDIATED UBIQUITINATION IMPACTS INTERACTIONS OF 
HOST PROTEINS WITH VIRAL RNA AND PROMOTES VIRAL RNA PROCESSING 
 
This chapter has been adapted from the following manuscript being considered for publication: 
Herrmann C, Dybas JM, Liddle JC, Price AM, Charman M, Kim ET, Garcia BA, Weitzman MD. 
Viral-mediated ubiquitination impacts interactions of host proteins with viral RNA and promotes 
viral RNA processing. Nature Microbiology. In revision. 
 
3.1 Abstract 
Viruses promote infection by hijacking the host ubiquitin machinery to counteract or redirect 
cellular processes. Adenovirus encodes two early proteins, E1B55K and E4orf6, that together co-
opt a cellular ubiquitin ligase complex to overcome host defenses and promote virus production. 
Adenovirus mutants lacking E1B55K or E4orf6 display defects in viral RNA processing and 
protein production, but previously identified substrates of the ligase do not explain these 
phenotypes. Here we used a quantitative proteomics approach to identify substrates of 
E1B55K/E4orf6 that are ubiquitinated to facilitate RNA processing. While cellular proteins known 
as substrates of E1B55K/E4orf6 are degraded by the proteasome, we uncovered RNA-binding 
proteins (RBPs) as predicted substrates which are not decreased in overall abundance. We 
focused on two predominant RBPs, RALY and hnRNP-C, which we confirm are ubiquitinated 
without degradation. Knockdown of RALY and hnRNP-C rescued levels of viral RNA splicing, 
protein, and progeny production during infection with E1B55K-deleted virus. Furthermore, 
deletion of E1B55K resulted in increased interaction of hnRNP-C with viral RNA and attenuation 
of viral RNA processing. These data suggest viral-mediated ubiquitination of RALY and hnRNP-C 
relieves a restriction on viral RNA processing, revealing an unexpected role for non-degradative 
ubiquitination in the manipulation of cellular processes during virus infection. 
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3.2 Introduction 
Viruses have evolved extensive mechanisms to alter cellular pathways to their advantage and 
facilitate inactivation of host defenses. One way this can be achieved is through viral factors that 
redirect host post-translational protein modification such as ubiquitin, in order to regulate protein 
function and turnover. Viruses interface with the host ubiquitin system by encoding their own 
ubiquitin ligases, redirecting cellular ubiquitin ligases, or altering the removal of ubiquitin by 
deubiquitinating enzymes1,9,10. Ubiquitin can be employed as a signal for diverse outcomes, 
including proteasome-mediated degradation, protein localization, and regulating interactions with 
other proteins or nucleic acids159,164,295,296. This diversity of function makes hijacking the host 
ubiquitin machinery an attractive approach for viruses to manipulate multiple cellular pathways. 
The nuclear-replicating Adenovirus (Ad) encodes two early proteins (E1B55K and E4orf6) 
which integrate into an existing host ubiquitin ligase complex containing Elongin B and C, Cullin5, 
and RBX1212,213. The cellular ligase is recruited through E4orf6, and the E1B55K protein is 
involved in substrate recognition to redirect the ligase activity213. The importance of hijacking the 
host ubiquitin machinery for productive virus infection has been demonstrated using Ad deletion 
mutants or expression of dominant negative Cullin5, which all severely limit virus 
production60,216,243-246,251,252,297. A number of cellular proteins have been identified as targets for 
proteasomal degradation after expression of the Ad serotype 5 (Ad5) E1B55K/E4orf6 complex, 
including MRE11, RAD50, NBS1, DNA Ligase IV, BLM, Integrin α3, and the tumor suppressor 
p5367,212,221-224. Degradation of these proteins represses DNA damage signaling and apoptosis 
during infection219,234,298. However, the E1B55K/E4orf6 complex also stimulates export of viral late 
mRNAs and synthesis of viral late proteins60,243,244,246,251,252. Viral mutants defective for either 
E1B55K or E4orf6 show similar phenotypes but none of the known substrates have been shown 
to account for the defects in viral RNA processing and late protein synthesis60,243-246,251,252. 
In this study, we used an unbiased global proteomics approach to identify new cellular 
substrates of the ubiquitin ligase activity directed by the Ad5 E1B55K/E4orf6 complex. We used 
di-glycine remnant profiling (K-ɛ-GG)210,211 to quantify changes to the cellular ubiquitinome upon 
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expression of E1B55K and E4orf6, and predicted the impact of ubiquitination on protein 
abundance by employing whole cell proteomics (WCP). This combined approach enabled us to 
identify many potential E1B55K/E4orf6 substrates, and classify these proteins as predicted 
degraded or non-degraded substrates. Our analysis suggests that the E1B55K/E4orf6 complex 
can redirect ubiquitination onto substrates in multiple ways, and reveals that the majority of 
cellular substrates are ubiquitinated without significant changes in their protein abundance. 
Among the cellular substrates predicted to be ubiquitinated without degradation, we found an 
enrichment for cellular RNA-binding proteins (RBPs). We further validated the importance of the 
highly ubiquitinated RBPs RALY and hnRNP-C as two host proteins modified by the virus to 
overcome a restriction for late viral transcript production. We identify the first substrates to 
provide a mechanistic link between the E1B55K/E4orf6 ubiquitin ligase function and its known 
role in Ad5 viral RNA processing. Furthermore, these studies highlight a viral approach to exploit 
ubiquitination without degradation as a strategy to manipulate host pathways. 
 
3.3 Results 
3.3.1 The Ad E1B55K/E4orf6 ubiquitin ligase is required for viral late RNA splicing 
Given that cellular ubiquitination can have degradative or non-degradative outcomes, we 
hypothesized that ubiquitination mediated by E1B55K/E4orf6 redirecting the Cullin5 ligase can 
either target cellular proteins for proteasomal degradation, as seen for all currently known 
substrates such as MRE11, RAD50, and BLM67,221, or could impact function without affecting 
protein abundance (Figure 3.1a). We assessed the role of the Ad5 ubiquitin ligase on RNA 
processing and late protein accumulation by inactivating the ligase through deletion of the 
E1B55K gene or chemical inhibition of the Cullin5 ubiquitin ligase activity299. Infection with an 
E1B55K mutant virus resulted in decreased levels of viral late proteins (hexon, penton, fiber and 
protein VII) but had minimal impact on viral early protein production (DBP) when compared to 
wild-type (WT) Ad5 infection (Figure 3.1b). The Cullin5 hijacked by E1B55K/E4orf6 requires 
post-translational modification by the ubiquitin-like protein NEDD8 to form a functional ubiquitin 
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ligase complex300,301. We used a small molecule inhibitor of the neddylation activating enzyme 
(NEDDi; MLN4924299) to block Cullin-mediated ubiquitination during infection. Inhibition of Cullin 
neddylation was observed by a decrease in abundance of the slower-migrating modified Cullin5 
(Figure 3.1b). Inhibition of the viral ubiquitin ligase was confirmed by a block of MRE11 and BLM 
degradation, two previously identified substrates of viral-mediated degradation. NEDDi treatment 
during WT Ad5 infection substantially decreased levels of viral late proteins (hexon, penton, fiber 
and protein VII) but only marginally decreased production of the viral early protein DBP (Figure 
3.1b). Furthermore, NEDDi treatment did not further alter the late protein defect observed with 
E1B55K deletion (Figure 3.1b). We then assessed several steps of viral RNA processing during 
viral ligase inhibition or E1B55K deletion. We observed decreased accumulation of viral late 
mRNA for transcripts containing the major late promoter (MLP) and fiber gene during NEDDi 
treatment of WT Ad5 infection, similar to decreases detected with E1B55K deletion (Figure 3.1c). 
We used quantitative reverse transcription PCR (RT-qPCR) to determine the ratio of spliced to 
unspliced transcript as a surrogate for splicing efficiency (Figure 3.S1a). This analysis revealed 
that both NEDDi treatment and E1B55K deletion decreased splicing efficiency of viral late 
transcripts (MLP and fiber) without negatively impacting an early transcript (E1A) (Figure 3.1d; 
Figure 3.S1b, c). We also examined RNA export by fluorescence in situ hybridization (FISH) for 
fiber transcripts. This experiment demonstrated that less fiber RNA reaches the cytoplasm upon 
E1B55K deletion, which was recapitulated by NEDDi inhibition (Figure 3.1e; Figure 3.S1d). 
Failure to splice transcripts correctly causes retention in the nucleus and subsequent 
degradation302,303. Incorrect splicing could explain the observed RNA export defect and decrease 
in RNA levels observed for late viral transcripts. These data demonstrated by chemical inhibition 
of neddylation that Cullin ligase inactivation recapitulates the effects of E1B55K deletion, 
highlighting that E1B55K/E4orf6-mediated ubiquitination of substrates is important for RNA 
splicing, RNA export, and protein production from viral late transcripts during Ad5 infection. None 
of the previously identified cellular substrates of E1B55K/E4orf6-mediated ubiquitination explain 
these phenotypes. 
71 
 
3.3.2 Proteomics reveals enrichment of RNA-binding proteins among cellular substrates of 
E1B55K/E4orf6 
To identify cellular substrates of the Ad5 ubiquitin ligase we conducted global profiling of the 
ubiquitinome and associated whole cell proteome (WCP) over a time course of transduction of 
HeLa cells with viral vectors encoding E1B55K and E4orf6 of Ad5224,304 (Figure 3.2a; Figure 
3.S2). Using non-replicating viral vectors allowed us to identify substrates specific to the activity 
of the viral E1B55K/E4orf6 complex outside the context of Ad5 infection. We assayed the 
degradation kinetics of known cellular substrates of the Ad5 ligase by immunoblotting to 
determine when proteins were most likely to be modified but still detectable (Figure 3.S2a). We 
subsequently sampled for ubiquitin modification at 6, 8, and 10 hours post transduction (hpt) and 
at 10 hpt for protein abundance. We employed di-glycine remnant profiling combined with mass 
spectrometry (K-ɛ-GG)210,211 to quantify ubiquitination of host proteins upon expression of 
E1B55K/E4orf6 (Figure 3.2a). We performed three replicates for each sample and identified a 
similar number of peptides in untransduced cells (2,328 peptides) and those transduced by 
E1B55K/E4orf6 (2,254 to 2,419 peptides) (Figure 3.S2b). The identified di-glycine remnant 
peptides corresponded to ~1,100 proteins (Figure 3.S2b). Changes in peptide modification were 
then normalized to changes in protein abundance in order to assess differential ubiquitination 
over the time course. Expression of E1B55K/E4orf6 induced a significant increase in 
ubiquitination (p < 0.05 and log2 fold-change > 1) for 55 peptides (Figure 3.2b). Additionally, 51 
peptides were ubiquitinated upon expression of E1B55K/E4orf6 but were not identified as 
ubiquitinated in untransduced cells, and therefore do not have a calculated fold-change or 
associated p-value. Peptides that exhibited increased or unique ubiquitination upon 
E1B55K/E4orf6 expression included known protein substrates MRE11 (4 peptides) and RAD50 (5 
peptides). The whole cell proteome quantified a similar overall number of proteins in 
untransduced cells (6,126 proteins) and cells transduced by E1B55K/E4orf6 (6,147 proteins) 
(Figure 3.S2c). The whole cell proteome data showed that E1B55K/E4orf6 expression induced 
significant changes in abundance for several proteins, with 67 proteins decreased at least 2-fold. 
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Consistent with previous studies, we observed significant decreases for the known substrates 
MRE11, NBS1, RAD50, and LIG4 upon E1B55K/E4orf6 expression (Figure 3.2b). 
To compare K-ɛ-GG and WCP datasets, the peptide-level K-ɛ-GG data were transformed into 
protein-based K-ɛ-GG abundance changes by calculating the abundance-weighted average of 
the K-ɛ-GG peptide log2 fold-changes for all modified peptides detected for that protein. Resulting 
protein-based K-ɛ-GG log2 fold-changes were plotted against their associated WCP fold-changes 
(Figure 3.2c). We implemented a threshold for protein-based K-ɛ-GG increase of > 2 fold and 
identified 119 host proteins as putative substrates of the Ad5 ubiquitin ligase. Proteins that were 
ubiquitinated and also decreased in abundance by more than 1 standard deviation (s.d.) from the 
mean proteome change were predicted to be degraded substrates of E1B55K/E4orf6. 
Conversely, proteins that exhibited abundance changes within 1 s.d. of the mean WCP 
abundance change were predicted to be ubiquitinated by E1B55K/E4orf6 but unchanged in 
abundance (Figure 3.2c, blue shading). In total, 25 cellular proteins were classified as predicted 
to be degraded as a result of ubiquitination by E1B55K/E4orf6, including known targets MRE11 
and RAD50 (Figure 3.2c, red shading). In contrast, 90 cellular proteins were predicted to be 
ubiquitinated by E1B55K/E4orf6 without concomitant decreases in protein abundance, suggesting 
that these cellular substrates can be classified as non-degraded (Figure 3.S3a). These data 
provide the first evidence that the Ad5 ubiquitin ligase facilitates non-degradative ubiquitination 
and suggest that the majority of potential E1B55K/E4orf6 substrates fall into this category. 
We further analyzed the predicted E1B55K/E4orf6 cellular substrates for gene functions. Gene 
ontology analysis revealed significant enrichment of “poly(A) RNA binding” and “RNA-binding” 
GO annotations (Figure 3.2d). Since E1B55K deletion has been shown to induce RNA 
processing defects, we focused on the 26 proteins included within the RNA-binding GO terms 
(Figure 3.S3b). There were 7 RBPs predicted to be ubiquitinated only in the presence of 
E1B55K/E4orf6. Among these, RALY stands out as the RBP with the greatest increase in 
ubiquitination over the time-course of E1B55K/E4orf6 expression, and its homolog and interaction 
partner hnRNP-C has the largest number of sites that increase in ubiquitination among RBPs 
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(Figure 3.2e; Figure 3.S3c). We used the Reactome305 protein-protein interaction database to 
analyze interactions among all predicted E1B55K/E4orf6 substrates, and found RALY and 
hnRNP-C together in an interaction module with other RBPs (Figure 3.S4). Both RALY and 
hnRNP-C are expressed at high levels in all tissues306 and are implicated in multiple steps of 
RNA processing, including RNA splicing and export307-312. Additionally, it has been reported that 
hnRNP-C binds to Ad transcripts encoding late proteins313. We therefore chose to further validate 
RALY and hnRNP-C as cellular substrates of the ubiquitin ligase activity redirected by 
E1B55K/E4orf6 and to characterize their impact on Ad5 biology.  
3.3.3 RALY and hnRNP-C are ubiquitinated but not degraded upon E1B55K/E4orf6 expression 
RALY and hnRNP-C are ~43% homologous, with the highest homology (63%) in the coiled-
coil (CC) domain, which contains all the lysine residues that show increased ubiquitination upon 
E1B55K/E4orf6 expression (Figure 3.3a; Figure 3.S5). The lysine residue of hnRNP-C that 
shows the highest increase in ubiquitination (K204 as shown in Figure 3.2e) is homologous to the 
only detected ubiquitination site in RALY (K198). Since E1B55K is the substrate recognition 
component of the Ad ligase, we examined interaction of E1B55K with the two host RBPs during 
Ad5 virus infection (Figure 3.3b). We performed immunoprecipitation (IP) of E1B55K, RALY and 
hnRNP-C for mock, Ad5 WT and ΔE1B infection conditions followed by immunoblotting for viral 
and host proteins. Negative controls included antibodies to a viral protein (DBP) and cellular 
protein (Tubulin) which were not isolated with any condition. IP of E1B55K isolated RALY and 
hnRNP-C from cells infected with WT virus but not the ΔE1B mutant. In the reciprocal 
experiment, E1B55K was detected upon IP of RALY and hnRNP-C during WT virus infection, 
confirming interaction between the Ad ligase and the two host RBPs (Figure 3.3b). The cellular 
hnRNP-C and RALY proteins interact in reciprocal IPs, as reported previously314, and this 
association was not impacted by virus infection. To confirm ubiquitination of RALY and hnRNP-C 
by the Ad ligase, we expressed Flag-tagged proteins together with HA-tagged ubiquitin and 
E4orf6 by transfection of HEK293 cells (this cell line contains a genomic integration of Ad5 
E1B55K78). After IP for the HA epitope on ubiquitin, immunoblotting for Flag revealed an increase 
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in high molecular weight ubiquitin-complexes of RALY and hnRNP-C in the presence of E4orf6 
(Figure 3.3c). We saw similar results with hnRNP-C2, an alternative isoform of hnRNP-C (Figure 
3.S6a). To demonstrate that Cullin complexes are involved in ubiquitination of RALY and hnRNP-
C by the Ad5 ligase, we performed experiments in the presence of NEDDi. The elevated 
ubiquitination of RALY and hnRNP-C detected by expression of E4orf6 and HA-ubiquitin was 
decreased upon NEDDi treatment (Figure 3.3d). We also verified that hnRNP-C was 
ubiquitinated during Ad5 WT infection but not with the ΔE1B mutant (Figure 3.3e). The RALY 
antibody quality precluded our ability to detect the endogenous protein in this assay. Our whole 
cell proteome analysis showed that RALY and hnRNP-C are not decreased in abundance during 
infection (Figure 3.S3b). Lack of degradation was confirmed by immunoblotting of RALY and 
hnRNP-C protein levels over a time course of Ad5 WT infection or transduction with 
E1B55K/E4orf6 vectors (Figure 3.3f; Figure 3.S6b). We observed a rapid decrease for the 
known degraded targets MRE11 and RAD50, but there was no substantial change in RALY and 
hnRNP-C levels (Figure 3.3f). Similar observations were made upon transduction of A549 and 
U2OS cells with E1B55K/E4orf6 vectors, as well as transfection of HEK293 cells with an E4orf6 
expression vector (Figure 3.S6c). RALY and hnRNP-C could be degraded in the context of 
continually increasing transcript abundance and protein synthesis, which could account for the 
observed consistent total abundance during infection (Figure 3.3f). To rule out this possibility, we 
examined the effect of infection on RALY and hnRNP-C turnover by quantifying protein 
abundances over a time course of cycloheximide treatment (Figure 3.3g). While MRE11 and 
RAD50 turnover increased upon infection, RALY and hnRNP-C protein levels remained relatively 
stable during infection in the presence of cycloheximide. We also found no significant change in 
mRNA levels for RALY and hnRNP-C as measured by RT-qPCR during a time course of Ad WT 
infection (Figure 3.S6d). We therefore propose that E1B55K/E4orf6 can induce ubiquitination 
that has both degradative and non-degradative outcomes. To support this hypothesis further, we 
investigated differences in ubiquitination of MRE11, RAD50, RALY, and hnRNP-C induced by 
E1B55K/E4orf6. Proteasome inhibition by drugs such as MG132 leads to accumulation of 
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ubiquitinated proteins that would otherwise be degraded. Ubiquitination assays were performed 
by transfection of HEK293 cells with and without MG132-mediated inhibition of the proteasome 
(Figure 3.3h). Expression of E4orf6 increased ubiquitination of MRE11 and the ubiquitination was 
further increased during proteasome inhibition, consistent with MRE11 being a known degraded 
substrate of the viral ubiquitin ligase. In contrast, expression of E4orf6 increased ubiquitination of 
RALY and hnRNP-C but there was no further increase upon treatment with MG132. The fact that 
MG132 treatment did not alter ubiquitination of RALY and hnRNP-C suggests that ubiquitination 
of these substrates does not result in degradation by the proteasome, supporting a non-
degradative function of viral-mediated ubiquitination. Since the effect of proteasomal inhibition 
varies between E1B55K/E4orf6 substrates, we examined the ubiquitin chains attached to RALY 
and hnRNP-C as compared to MRE11 and RAD50. The ubiquitin linkage most commonly 
associated with proteasomal degradation is K48. Therefore, we hypothesize that the 
E1B55K/E4orf6 complex generates K48 polyubiquitin chains on MRE11 and RAD50. 
Furthermore, since our data suggest that hnRNP-C and RALY are not degraded, we hypothesize 
that these substrates are marked with non-K48 ubiquitin chains. To determine whether K48-linked 
ubiquitin is attached to the MRE11, RAD50, RALY, or hnRNP-C we performed native IPs of HA-
ubiquitin, expressed in HEK293 cells together with E4orf6, and then compared the degree of 
ubiquitination after treatment with deubiquitinating enzymes (DUBs) that cleave either all ubiquitin 
linkages (DUBPan) or only K48-linked ubiquitin chains (DUBK48)190 (Figure 3.3i). The previously 
identified degradation substrates, MRE11 and RAD50, showed a clear decrease of high 
molecular weight ubiquitin chains upon treatment with both DUBs. This indicates that K48-linked 
ubiquitin is attached to these E1B55K/E4orf6 substrates to induce proteasomal degradation. In 
contrast, ubiquitination of RALY and hnRNP-C only decreased with the DUBPan but not the more 
specific DUBK48. This suggests that RALY and hnRNP-C are substrates for non-K48 linked 
ubiquitination that is distinct from the K48-linked ubiquitin chains on degraded substrates MRE11 
and RAD50. Together, these data validate RALY and hnRNP-C as the first non-degraded cellular 
substrates identified for the E1B55K/E4orf6 Ad5 ligase. 
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3.3.4 RALY and hnRNP-C are detrimental for viral late RNA processing in the absence of a 
functional Ad ubiquitin ligase 
To determine whether RALY and hnRNP-C impact Ad infection, we used siRNA to knockdown 
these host proteins in HeLa and primary-like HBEC3-KT cells, and then infected with WT Ad5 and 
ΔE1B viruses (Figure 3.4). Although RALY and hnRNP-C are not degraded, this approach 
allowed us to determine whether these RBPs are beneficial or detrimental to virus infection. 
Knockdown of RALY and hnRNP-C did not affect viral protein levels during WT Ad5 infection, 
suggesting that in the context of infection with a fully competent virus their presence does not 
have a significant impact. Infection with ΔE1B mutant virus generated reduced viral late protein 
levels as compared to WT Ad5 (Figure 3.4a). Depletion of RALY and hnRNP-C rescued this viral 
late protein defect almost to the level observed in WT Ad5 (Figure 3.4a; Figure 3.S7a). We 
examined whether knockdown of RALY and hnRNP-C also affects progeny production of the 
mutant virus (Figure 3.4b). There was no difference between WT Ad5 and ΔE1B at 8 hours post 
infection (hpi), before production of new infectious virions, confirming comparable virus input and 
entry. By 24 hpi the E1B55K mutant virus produced > 100-fold fewer viral particles than WT Ad5. 
Knockdown of RALY and hnRNP-C had no effect on WT Ad5, but significantly increased progeny 
production for the mutant virus (Figure 3.4b). Similar rescue of the E1B55K mutant virus was 
observed with RALY and hnRNP-C knockdown prior to infection in HBEC3-KT cells (Figure 
3.4b). These data suggest that RALY and hnRNP-C are detrimental to Ad infection and that 
E1B55K/E4orf6-mediated ubiquitination relieves their restriction on virus production. Since RALY 
and hnRNP-C are involved in RNA splicing and export, we hypothesized that their depletion 
selectively increases late RNA processing without affecting DNA replication and early viral RNAs. 
We therefore examined viral DNA replication by quantitating genome accumulation using qPCR 
(Figure 3.4c). We observed a modest decrease (2-fold) in DNA replication for the ΔE1B virus as 
compared to WT Ad5, in agreement with prior reports315. Viral DNA accumulation for both WT 
Ad5 and ΔE1B was not significantly affected by depletion of RALY and hnRNP-C (Figure 3.4c), 
confirming that their effects are mediated at a step after viral genome replication. We then 
77 
 
quantified RNA levels of both early (E1A) and late (MLP and fiber) viral transcripts (Figure 3.4d). 
We observed reduced levels of late but not early transcripts upon infection with the ΔE1B virus, 
which shows qualitative correlation with the decrease in late proteins shown in in Figure 3.1b. 
Depletion of RALY and hnRNP-C rescued mRNA levels for both MLP and fiber at both 18 hpi and 
24 hpi during infection with the ΔE1B virus, to levels observed in WT Ad5 (Figure 3.4d) without 
impacting the E1A transcript (Figure 3.S7b). We observed a similar pattern when we examined 
splicing efficiency of viral transcripts. The ΔE1B mutant virus displayed a reduction in splicing 
efficiency of MLP and fiber that was rescued to WT Ad5 levels upon knockdown of RALY and 
hnRNP-C (Figure 3.4e; Figure 3.S7c). We also used FISH to examine the effect of RALY and 
hnRNP-C depletion on export of fiber mRNA into the cytoplasm. siRNA treatment increased the 
amount of cytoplasmic fiber RNA visible in ΔE1B infection, while not impacting WT Ad5 (Figure 
3.4f). We also verified that knockdown of either RALY or hnRNP-C alone rescued late RNA and 
protein defects of the ΔE1B virus. Depletion of either RBP by itself increased viral late protein, 
RNA levels, and splicing efficiency of the mutant virus, with hnRNP-C knockdown having a more 
dramatic effect than RALY knockdown (Figure 3.S7d-f). To connect the impact of RALY and 
hnRNP-C depletion on late stages of Ad infection with Cullin-dependent ubiquitination by 
E1B55K/E4orf6, we combined siRNA-mediated knockdown with NEDDi treatment during WT Ad5 
infection. The NEDDi treatment decreased viral late RNA levels, splicing efficiency, and protein 
production (Figure 3.4g-i). Knockdown of RALY and hnRNP-C completely rescued this defect 
caused by inhibition of Cullin function without impacting viral early proteins or RNA (Figure 3.4g-
i; Figure 3.S7g, h). These data suggest that RALY and hnRNP-C are detrimental to the late 
stages of Ad5 infection in the absence of a functional viral ubiquitin ligase. 
3.3.5 Ubiquitination of hnRNP-C specifically reduces interaction with viral late RNA 
Our data suggest that ubiquitination of RALY and hnRNP-C relieves a restriction on viral late 
RNA processing without the need for proteasomal degradation. Non-degradative ubiquitination 
has been reported to alter protein localization, for example by obscuring nuclear localization 
sequences and preventing nuclear import189. We examined localization of RALY and hnRNP-C by 
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immunofluorescence (IF) in untreated HeLa cells and during infection with either WT Ad5 or 
ΔE1B virus (Figure 3.S8a). Both RALY and hnRNP-C showed a diffuse nuclear pattern in 
uninfected HeLa cells, in accordance with the reported localization of both proteins306. Upon 
infection, both proteins were excluded from viral replication centers marked by DBP or USP7 in a 
pattern that matches viral RNA and other RBPs316,317. However, there was no obvious difference 
in localization between WT Ad5 and ΔE1B infection, suggesting that viral-induced ubiquitination 
does not specifically change their cellular localization. Since both RALY and hnRNP-C are 
ubiquitinated within the coiled-coil domain that is involved in multimerization and protein-RNA 
interaction (Figure 3.3a), we examined whether overall protein complex formation and RNA 
association are affected during Ad5 infection. To examine complex formation, we treated HeLa 
cells with disuccinimidyl suberate (DSS) at various concentrations during mock, WT Ad5 or ΔE1B 
infection (Figure 3.S8b). DSS is a cell-permeable crosslinker that forms stable amide bonds 
between lysine residues in close proximity (less than 11.4 Å), crosslinking protein complexes. 
DSS treatment caused a mobility shift of hnRNP-C and RALY, consistent with multimerization 
and previous reports of dimers and tetramers318. During WT Ad5 or ΔE1B infections these 
patterns did not change noticeably, suggesting that viral-induced ubiquitination does not 
significantly affect overall protein complex formation of hnRNP-C or RALY. Finally, to examine the 
effect of ubiquitination on interaction of hnRNP-C with viral RNA we performed crosslinking-
immunoprecipitation (CLIP) followed by RT-qPCR for several viral and cellular transcripts (Figure 
3.5a, Figure 3.S8c). Commercially available antibodies for RALY were not suitable for this 
technique (data not shown). The hnRNP-C transcript itself served as a positive control, while the 
GAPDH RNA was a negative control (according to ENCODE data of hnRNP-C eCLIP-Seq.). This 
approach was validated by detection of the hnRNP-C transcript upon CLIP-qPCR with hnRNP-C 
antibody in both WT Ad5 and ΔE1B infections, with very low signal for GAPDH (Figure 3.5b). All 
viral late transcripts were detected above background under WT Ad5 conditions, however, there 
was a 2 to 4-fold increase in the amount of late RNA detected during ΔE1B infection. There was 
however no significant difference in the level of early RNAs detected between WT Ad5 and 
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mutant virus. This indicates that viral-induced ubiquitination of hnRNP-C specifically decreases 
the interaction with viral late transcripts. To confirm that this difference between WT and ΔE1B 
virus was caused by ubiquitination, we repeated the hnRNP-C CLIP-qPCR with inhibition of 
Cullin-dependent ubiquitination during WT Ad5 infection (Figure 3.5c, Figure 3.S8d). Following 
the trend with ΔE1B infection, the interaction of hnRNP-C with viral late transcripts increased at 
least 2-fold upon treatment with NEDDi, while there were only minor differences for viral early and 
cellular transcripts. This experiment confirms that hnRNP-C interacts specifically with viral late 
RNAs in the absence of the functional viral ubiquitin ligase. 
 
3.4 Discussion 
Viruses commonly adapt cellular regulatory mechanisms towards efficient viral production. 
The E1B55K/E4orf6 complex is known to interact with the cellular Cullin5 ubiquitin ligase to 
redirect ubiquitination and to stimulate viral late mRNA nuclear export and late protein synthesis. 
A number of prior studies identified binding partners of the complex and a limited number of 
substrates67,212,213,221-224,238,253-255, however, these studies did not enrich for proteins specifically 
ubiquitinated by the E1B55K/E4orf6 or explicitly link potential cellular substrates to effects on viral 
RNA processing. Here we employed a systematic proteomics approach to identify cellular 
substrates of the E1B55K/E4orf6 viral ubiquitin ligase by combining quantification and analysis of 
the ubiquitinome and the associated whole cell proteome upon expression of E1B55K/E4orf6. We 
identified 119 potential substrates, with specific enrichment of RBPs that may be involved in viral 
RNA processing. In addition to RNA processing, functional analysis of the predicted substrates 
highlights other host pathways that may be manipulated by Ad5-mediated ubiquitination: ubiquitin 
machinery and de-ubiquitinating enzymes, antigen presentation, protein folding, cellular transport, 
and cell signaling (Figure 3.S4a). We focused on two of the most highly ubiquitinated RBPs, 
RALY and hnRNP-C, which we demonstrated to be the first non-degraded substrates of the Ad5 
ligase. We demonstrated differential interaction of hnRNP-C with viral late transcripts in the 
presence of E1B55K/E4orf6 ligase activity, supporting a model in which ubiquitinated RALY and 
80 
 
hnRNP-C are excluded from viral late ribonucleoprotein (RNP) complexes, to promote efficient 
processing of late RNA (Figure 3.6). Since hnRNP-C and RALY have reported roles in alternative 
splicing307,309,310, we propose that their ubiquitination by the Ad5 ligase results in exclusion from 
viral RNP complexes to promote splicing of late viral RNAs. Substrates of the E1B55K/E4orf6 
complex can vary across human Ad serotypes, although some target proteins fall within the same 
cellular pathway239,240. It will be interesting to determine whether RBPs are similarly modified 
between serotypes or whether effects on RNA processing are achieved through different 
substrates. There is a precedent for post-translational modification regulating hnRNP-C affinity for 
RNA, with conjugation of the ubiquitin-like protein SUMO decreasing the affinity of hnRNP-C for 
RNA319. Ubiquitin and related proteins have emerging roles in regulating splicing by altering the 
properties and dynamics of spliceosomal complexes through altered protein-protein 
interactions320. It is likely that RBPs such as RALY and hnRNP-C are also functionally regulated 
through ubiquitination by cellular ubiquitin ligase. Correlating changes to host splicing induced as 
a result of the impact of ubiquitination during Ad infection may provide insights into host pathways 
that are altered by ubiquitination of these RBPs.  
Manipulation of the host ubiquitin machinery during virus infection has traditionally been 
studied in the context of proteasomal degradation and there are very few known examples of 
viruses directing ubiquitin towards cellular substrates that are not subsequently degraded1,9,10. 
This has been true for the Cullin5 ligase redirected by Ad E1B55K/E4orf6 which was previously 
shown to induce degradation of proteins involved in the cellular DNA damage response and 
apoptosis67,212,221,222,224. Our observation that the majority of potential cellular substrates of the 
E1B55K/E4orf6 viral ligase appear to be ubiquitinated without significant decrease in abundance 
suggests that a major aspect of the activity of this ligase is non-degradative ubiquitination. This 
finding highlights the need to combine ubiquitinome analysis together with whole cell proteome 
quantification when identifying outcomes of ubiquitination. Future studies of other viral ligases 
should include this type of analysis of non-degradative ubiquitination in order to ensure that all 
aspects of viral manipulation by ubiquitin are identified. We propose that ubiquitination without the 
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need for proteasome-mediated degradation provides increased flexibility and more rapid 
approaches to counter host responses and redirect cellular processes. Viral ubiquitin ligases may 
present particularly good model systems to study how ubiquitin ligases in general can facilitate 
both degradative and non-degradative ubiquitination of distinct substrates. Given the increasing 
appreciation that cellular ubiquitin ligases (such as the Cullin ligase hijacked by Ad) can facilitate 
the formation of multiple different types of ubiquitin chains321-323, viral infections provide systems 
to decipher the rules that govern outcomes of ubiquitination. 
In addition to its contributions to fundamental knowledge of cellular and molecular biology, Ad 
has also been developed as a vector for gene delivery and oncolytic cancer treatment. Mutant 
viruses that lack E1B55K have been shown to replicate conditionally in cancer cells, with 
selectivity that was initially suggested to be based on p53 inactivation but is more likely due to 
preferential viral late mRNA export241,242,324. Since many cancers have altered RNA processing, 
the Ad ΔE1B used for oncolytic therapies may be complemented by defects in E1B55K/E4orf6 
substrates. Our work suggests that alterations in these substrates, such as the RBPs RALY and 
hnRNP-C, may make tumor cells more susceptible to ΔE1B-based oncolytic viruses.  
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3.5 Figures 
 
 
Figure 3.1 | E1B55K deletion or inhibition of Cullin-mediated ubiquitination decreases 
adenovirus late RNA splicing and RNA processing overall. a, The E1B55K/E4orf6 complex 
redirects substrate recognition of the host Cullin5 ubiquitin ligase to target proteins for 
proteasomal degradation or lead to alternative outcomes of ubiquitination. b-e, HeLa cells 
infected with wild-type (WT) or E1B55K-deleted (ΔE1B) Ad5 at multiplicity of infection (MOI) of 
10.  Cell were treated with either DMSO or NEDDi (neddylation inhibitor MLN2449) at 8 hours 
post-infection (hpi) and assayed at 24 hpi. b, Immunoblot analysis of viral and cellular protein 
abundance. The neddylated (●) and unmodified (○) forms of Cullin5 are indicated. Results are 
representative of three biological experiments. c, Bar graph representing spliced RNA levels of 
viral late transcripts for the major late promoter (MLP) and fiber by quantitative reverse 
transcription PCR (RT-qPCR). Shown is mean+s.d., n equals three biological experiments. d, Bar 
graph representing splicing efficiency as the ratio of spliced to unspliced transcripts of MLP and 
fiber relative to the WT DMSO control by RT-qPCR. Shown is mean+s.d., n equals three 
biological experiments. e, RNA FISH visualizing the localization of fiber transcripts (white) in 
relation to nuclear DNA stained with DAPI (blue) and quantification of observed pattern for > 50 
HeLa cells. Scale bar 10 μm. Statistical significance was calculated using an unpaired, two-tailed 
Student’s t-test, * p < 0.05, *** p < 0.005. Panel e by AM Price. 
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Figure 3.S1 | E1B55K deletion or inhibition of Cullin-mediated ubiquitination does not 
decrease viral early RNA levels or splicing. a, Schematic illustrating primer design to 
differentiate spliced and unspliced viral transcripts. b-d, HeLa cells infected with wild-type (WT) 
or E1B55K-deleted (ΔE1B) Ad5 (MOI=10) in the presence of DMSO or NEDDi (neddylation 
inhibitor MLN2449) added at 8 hours post-infection (hpi). Cells were harvested for RNA analysis 
at 24 hpi. b, Bar graph representing spliced RNA levels of viral early transcripts E1A by RT-
qPCR, shown is mean+s.d., n equals three biological experiments. c, Bar graph representing 
splicing efficiency as the ratio of spliced to unspliced transcripts of E1A relative to the WT DMSO 
control by RT-qPCR, shown is mean+s.d., n equals three biological experiments. d, RNA FISH 
visualizing the localization of fiber (green) and GAPDH (magenta) transcripts in relation to 
nuclear DNA stained with DAPI (blue). Nuclei are labeled with the classification of each cell 
according to the pattern of fiber used for Figure 1d. Scale bar 10 μm. Panels a and d by AM 
Price. 
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Figure 3.2 | Unbiased proteomics reveals RNA-binding proteins among putative non-
degraded substrates of the Ad ubiquitin ligase. a, Proteomics workflow for identification of 
E1B55K/E4orf6 substrates. HeLa cells were transduced with recombinant Ad vectors expressing 
E1B55K and E4orf6 (MOI=10), and subjected to both di-glycine remnant profiling (K-ɛ-GG) to 
identify ubiquitinated lysine residues and whole cell proteomics to determine protein abundance. 
b, Volcano plots showing log2 fold-changes between 0 h and 10 h for ubiquitination (above) and 
protein abundance (below). For ubiquitination, individual peptides containing the modified lysine 
residues are normalized to protein abundance. Peptides and proteins with a fold change > 
±s.e.m. and p-value < 0.05 are considered significantly changed and highlighted in dark grey. 
Ubiquitinated peptides and proteins corresponding to known E1B55K/E4orf6 substrates are 
highlighted in red. n equals three biological replicates. c, Scatter plot integrating changes in 
protein abundance (X-axis) and ubiquitination (Y-axis). Putative degraded substrates are shown 
in red (increased ubiquitination, decreased protein abundance), putative non-degraded 
substrates are shown in blue (increased ubiquitination, no significant change in protein 
abundance). Known degraded substrates MRE11 and RAD50 are indicated. Blue dots circled at 
the top indicate proteins that were only ubiquitinated upon expression of E1B55K/E4orf6 and 
were not detected as ubiquitinated in mock conditions. d, Bar graph representing gene ontology 
(GO) analysis of all predicted substrates by molecular functions. Categories containing RNA-
binding proteins are highlighted. e, Heat map of all ubiquitinated lysine residues within RNA-
binding proteins with a normalized log2 abundance z-score > -0.5 and maximum log2 fold-
change > 1 over the time course of E1B55K/E4orf6 transduction. The colors in the heat map 
correspond to the average z-score of the ubiquitination and are indicated in the accompanying 
scale. Highly ubiquitinated proteins RALY and hnRNP-C are highlighted. Panels b-e with help of 
JM Dybas and JC Liddle. 
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Figure 3.S2 | Quantification of number of peptides and proteins identified in di-glycine 
remnant profiling and whole cell proteome data sets. a-c, HeLa cells transduced with rAd 
E1B55K/E4orf6 at an MOI of 10. a, Immunoblot of time course of E1B55K/E4of6 expression 
showing degradation kinetics of known substrates. hpt = hours post transduction. b,  Numbers of 
peptides and corresponding proteins  identified following K-ɛ-GG antibody enrichment in di-
glycine remnant combined with mass spectrometry analysis at 0, 6, 8, and 10 hours post 
E1B55K/E4orf6 expression. c, Number of proteins identified by whole cell proteomics analysis at 
time 0 and 10 hours post E1B55K/E4orf6 expression. b,c, Dark blue, medium blue, and light blue 
bars indicate the counts for three individual biological replicates. Analysis in panels b and c by JM 
Dybas. 
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Figure 3.S3 | Di-glycine remnant profiling and whole cell proteome data for RNA-binding 
proteins enriched within the predicted E1B55K/E4orf6 substrates. a, Predicted substrates 
that either decrease (red), increase (grey) or remain unchanged (blue) in their protein abundance 
during expression of E1B55K/E4orf6. b-c, Gene ontology analysis identified RNA-binding 
proteins enriched in the set of proteins that exhibited an increase in normalized protein-based 
ubiquitin abundance of log2 fold change > 1 following 10 h transduction of E1B55K/E4orf6. b, 
Enriched RNA-binding protein, ubiquitination log2 fold changes (left) and whole cell protein 
abundance log2 fold changes (right) following 10 h transduction by E1B55K/E4orf6. c, Heat map 
showing relative ubiquitination of the respective lysine residues quantified by di-glycine remnant 
profiling analysis at 0, 6, 8, and 10 h of E1B55K/E4orf6 expression for peptides within enriched 
RNA-binding proteins. Heat map color gradient is based on low (yellow) to high (red) ubiquitin 
abundance and grey indicates “not identified” at that time point. Analysis in panels a-c by JM 
Dybas. 
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Figure 3.S4 | Network analysis of predicted E1B55K/E4orf6 substrates identifies a 
“RALY/hnRNP-C module” enriched for RNA-binding proteins. a,b, The Reactome-FI 
application in Cytoscape was utilized to generate a protein-protein interaction network in which 
nodes represent proteins and edges represent Reactome-based protein-protein interactions. 
Node size corresponds to relative protein-based ubiquitination log2 fold change and node color 
corresponds to whole cell proteome log2 fold change following 10 h transduction of 
E1B55K/E4orf6. a, Protein-protein interaction network of proteins that exhibited normalized 
protein-based ubiquitin abundance log2 fold change > 1 following 10 h transduction of 
E1B55K/E4orf6. Reactome-FI interaction module analysis was performed to generate clusters of 
highly interacting proteins. b, RALY and hnRNP-C are contained within a single module. c, Gene 
ontology analysis for molecular function identified enrichment of RNA-binding and Poly(A) RNA-
binding proteins within the RALY/hnRNP-C network module. d, Heat map showing relative 
ubiquitin abundance quantified by di-glycine remnant profiling analysis at 0, 6, 8, and 10 h post 
E1B55K/E4orf6 transduction for peptides from proteins within the RALY/hnRNP-C network 
module. Heat map color gradient is based on low (yellow) to high (red) ubiquitination and grey 
indicates “not identified” at that time point. e, RALY/hnRNP-C network module protein ubiquitin 
log2 fold changes (left) and whole cell protein abundance log2 fold changes (right) comparing 0 
and 10 h post transduction with E1B55K/E4orf6. 
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highly interacting proteins. b, RALY and hnRNP-C are contained within a single module. c, Gene 
ontology analysis for molecular function identified enrichment of RNA-binding and Poly(A) RNA-
binding proteins within the RALY/hnRNP-C network module. d, Heat map showing relative 
ubiquitin abundance quantified by di-glycine remnant profiling analysis at 0, 6, 8, and 10 h post 
E1B55K/E4orf6 transduction for peptides from proteins within the RALY/hnRNP-C network 
module. Heat map color gradient is based on low (yellow) to high (red) ubiquitination and grey 
indicates “not identified” at that time point. e, RALY/hnRNP-C network module protein ubiquitin 
log2 fold changes (left) and whole cell protein abundance log2 fold changes (right) comparing 0 
and 10 h post transduction with E1B55K/E4orf6. Analysis in Panels a-e by JM Dybas. 
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Figure 3.S5 | MS2 evidence for ubiquitination site localization in RALY (a) and hnRNP-C (b-
f) peptides. Spectra were obtained from LC-MS/MS analyses using collision-induced dissociation 
(CID) at 35%, and identified in MaxQuant 1.6.0.1. All modified residues can be confidently 
identified by confirming ions, except for hnRNP-C K198 (d), which lacks ions to distinguish 
between K197 and K198. Best evidence spectra were selected for annotation of b-ion (blue) and 
y-ion (red) series and their masses for singly- and doubly-charged fragments. Analysis in panels 
a-f by JC Liddle. 
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Figure 3.3 | RALY and hnRNP-C are non-degraded substrates of the Ad ubiquitin ligase. a, 
Domain structure of RALY and hnRNP-C. RRM = RNA recognition motif, NLS = nuclear 
localization sequence, CC = coiled-coil region, GRR = glycine rich region. CC region shown 
below contains all the lysine residues with increased ubiquitination upon E1B55K/E4orf6 
expression highlighted in red. b, Immunoblot analysis of E1B55K, RALY, and hnRNP-C 
immunoprecipitations (IP) probing for pull-down of viral and cellular proteins during mock, WT 
and ΔE1B infection of HeLa cells at MOI of 10 for 24 hpi.  denotes the signal of the antibody 
heavy chain. c, HEK293 cells transfected with the indicated constructs for 24 h followed by 
denaturing IP with HA antibody and immunoblot analysis of RALY-Flag or hnRNP-C-Flag. d, 
HEK293 cells transfected with the indicated constructs for 24 h and treated with DMSO or NEDDi 
6 h prior to harvest followed by denaturing IP with HA antibody and immunoblot analysis of 
RALY-Flag or hnRNP-C-Flag. e, Immunoblot of denaturing hnRNP-C IP probing for ubiquitin 
during mock, WT and ΔE1B infections at MOI of 10 for 24 h.  indicates non-specific signal of the 
antibody heavy chain. f, Immunoblot analysis of protein levels over a time course of Ad5 WT 
infection (MOI=10) of HeLa cells. g, Immunoblot analysis and quantification of RALY, hnRNP-C, 
MRE11, and RAD50 over a time course of cycloheximide (CHX) treatment of mock or Ad5 WT 
infected HeLa cells. Quantification showing mean+s.d. of two biological replicates. h, HEK293 
cells transfected with the indicated constructs for 24 h and treated with DMSO or proteasome 
inhibitor MG132 3 h prior to harvest followed by denaturing IP with HA antibody and immunoblot 
analysis of MRE11, RALY-Flag, and hnRNP-C-Flag. i, HEK293 cells transfected with the 
indicated constructs for 24 h followed by denaturing IP with HA antibody, treatment with the 
indicated deubiquitinating enzymes (DUBs) and immunoblot analysis of MRE11, RAD50, RALY-
Flag, and hnRNP-C-Flag. All immunoblots are representative of at least three biological 
replicates. 
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MRE11, and RAD50 over a time course of cycloheximide (CHX) treatment of mock or Ad5 WT 
infected HeLa cells. Quantification showing mean+s.d. of two biological replicates. h, HEK293 
cells transfected with the indicated constructs for 24 h and treated with DMSO or proteasome 
inhibitor MG132 3 h prior to harvest followed by denaturing IP with HA antibody and immunoblot 
analysis of MRE11, RALY-Flag, and hnRNP-C-Flag. i, HEK293 cells transfected with the 
indicated constructs for 24 h followed by denaturing IP with HA antibody, treatment with the 
indicated deubiquitinating enzymes (DUBs) and immunoblot analysis of MRE11, RAD50, RALY-
Flag, and hnRNP-C-Flag. All immunoblots are representative of at least three biological 
replicates. Panels b and e with help of ET Kim and panel d with help of JC Liddle. 
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Figure 3.S6 | RALY and hnRNP-C are not decreased upon transduction in multiple cell 
lines. a, HEK293 cells transfected with the indicated constructs for 24 h followed by denaturing IP 
with HA antibody and immunoblot analysis of hnRNP-C2-Flag. b, Immunoblot analysis of protein 
levels in HeLa cells over a time course of transduction with recombinant Ad vectors expressing 
only E1B55K and E4orf6 (MOI=10). c, Immunoblot analysis of protein levels in HeLa, U2OS, 
A549 and HEK293 cells. HeLa, U2OS and A459 cells were transduced with recombinant Ad 
vectors expressing only E1B55K and E4orf6 for 24 h. HEK293 cells, which contain an 
endogenous copy of E1B55K, were mock transfected or transfected with plasmids expressing 
E4orf6 or GFP. d, Bar graphs of RALY and hnRNP-C RNA levels over a time course of infection 
with Ad5 WT (MOI=10) relative to mock as determined by RT-qPCR, shown is mean+s.d, n 
equals three biological replicates. All immunoblots are representative of at least three biological 
replicates. 
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Figure 3.4 | Knock-down of RALY and hnRNP-C rescues the RNA processing defect 
caused by the absence of a functional viral ubiquitin ligase. a-f, HeLa cells or HBEC3-KT 
(only a,b) transfected with control (siCTRL) or RALY and hnRNP-C (siRALY/hnC) siRNA 24 h 
prior to infection with Ad5 WT or ΔE1B (MOI 10), harvested at respective time points. a, 
Immunoblot analysis of viral and cellular protein levels. b, Bar graph representing plaque assays 
for viral progeny. c, Bar graph representing qPCR of viral genomes normalized to input. d, Bar 
graph representing spliced RNA levels of viral late transcripts MLP and fiber measured by RT-
qPCR. e, Bar graph representing splicing efficiency as defined as the ratio of spliced to unspliced 
transcripts of MLP and fiber measured by RT-qPCR. f, RNA FISH visualizing the localization of 
fiber transcripts (white) in relation to nuclear DNA stained with DAPI (blue) and quantification of 
observed pattern for > 100 HeLa cells. RC - replication center. Scale bar 10 μm. g-i. HeLa cells 
transfected with control (siCTRL) or RALY and hnRNP-C (siRALY/hnC) siRNA 24 h prior to 
infection with Ad5 WT (MOI=10), treated with either DMSO or NEDDi at 8 hpi and processed at 
24 hpi. g, Bar graph representing spliced RNA levels of MLP measured by RT-qPCR. h, Bar 
graph representing splicing efficiency as defined as the ratio of spliced to unspliced transcripts of 
MLP measured by RT-qPCR. i Immunoblot analysis of viral and cellular protein levels, with 
neddylated (●) and unmodified (○) forms of Cullin5 indicated. All immunoblots are representative 
of at least three biological experiments. All graphs show the mean+s.d. with n equals three 
biological replicates. Statistical significance was calculated using an unpaired, two-tailed 
Student’s t-test, * p < 0.05, ** p < 0.01, *** p < 0.005. Panels d-f with help of AM Price. 
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Figure 3.S7 | RALY and hnRNP-C single knock-down rescue late protein, RNA and splice 
efficiency during infection with Ad ΔE1B. a-c, HeLa cells transfected with control (siCTRL) or 
RALY and hnRNP-C (siRALY/hnC) siRNA 24 h prior to infection with Ad5 WT or ΔE1B (MOI=10), 
harvested at respective time points. a, Extended immunoblot analysis of viral and cellular protein 
levels. b, Bar graph representing spliced RNA levels of viral early transcript E1A measured by 
RT-qPCR. c, Bar graph representing splicing efficiency as defined as the ratio of spliced to 
unspliced transcripts of E1A measured by RT-qPCR. d-f, HeLa cells transfected with control 
siRNA (siCTRL), siRNA for RALY (siRALY), siRNA for hnRNP-C (sihnRNP-C) or siRNA for both 
RALY and hnRNP-C (siRALY/hnC) 24 h prior to infection with Ad5 WT or ΔE1B (MOI=10) and 
harvested at 24 hpi. d, Immunoblot analysis of viral and cellular protein levels. e, Bar graph 
representing spliced RNA levels of E1A, MLP and fiber measured by RT-qPCR. f, Bar graph 
representing splicing efficiency as defined as the ratio of spliced to unspliced transcripts of E1A, 
MLP and fiber measured by RT-qPCR. g,h. HeLa cells transfected with control (siCTRL) or RALY 
and hnRNP-C (siRALY/hnC) siRNA 24 h prior to infection with Ad5 WT (MOI=10), treated with 
either DMSO or NEDDi at 8 hpi and processed at 24 hpi. g, Bar graph representing spliced RNA 
levels of E1A measured by RT-qPCR. h, Bar graph representing splicing efficiency as defined as 
the ratio of spliced to unspliced transcripts of E1A measured by RT-qPCR. All immunoblots are 
representative of at least three biological experiments. All graphs show the mean+s.d. with n 
equals three biological replicates. Panels b and c with help of AM Price. 
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Figure 3.5 | The interaction of hnRNP-C with viral late RNA increases in the absence of a 
functional viral ubiquitin ligase. a, Schematic of the Ad5 genome and viral transcription units. 
Location of amplicons for viral early (E1A, DBP, E4) and viral late (MLP, Penton, Hexon, 100K, 
Fiber) are noted. b, HeLa cells infected with either WT Ad5 or ΔE1B55K (MOI=10), UV-
crosslinked and harvested at 24 hpi, subjected to hnRNP-C CLIP and RT-qPCR for viral early 
and late transcripts. GAPDH is a cellular negative control. hnRNP-C is a cellular positive control. 
c, HeLa cells infected with WT Ad5 (MOI=10), treated with either DMSO or NEDDi at 8 hpi, UV-
crosslinked and harvested at 24 hpi, subjected to hnRNP-C CLIP and RT-qPCR for viral early 
and late transcripts. GAPDH is a cellular negative control. hnRNP-C is a cellular positive control. 
Graphs show mean+s.d, n equals three biological replicates. Statistical significance was 
calculated using an unpaired, two-tailed Student’s t-test, * p < 0.05, ** p < 0.01. Panels b and c 
with help of AM Price. 
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Figure 3.S8 | No dramatic difference in protein localization and protein-complex formation 
of RALY and hnRNP-C between Ad WT and ΔE1B infection. a, Representative images of 
immunofluorescence comparing the localization of RALY and hnRNP-C (both green) in mock, Ad 
WT and ΔE1B infection of HeLa cells (MOI=10, 24 hpi). Viral replication centers are stained by 
DBP or USP7 (both magenta) and nuclear DNA by DAPI (grey). Scale bar 10 μm. b, Imunoblot 
analysis of RALY and hnRNP-C protein complexes formed upon mock, Ad WT and ΔE1B 
infection of HeLa cells (MOI=10) and treatment with indicated concentrations of disuccinimidyl 
suberate (DSS) for 30 min at 24 hpi. Representative of three biological replicates. c, Control 
immunoblot for hnRNP-C CLIP-qPCR shown in Figure 5b. Higher molecular weight complexes 
stained with hnRNP-C antibody represent hnRNP-C crosslinked to RNA. * marks the antibody 
heavy chain detected in the IP. Representative of three biological replicates for both CLIP-qPCR 
and immunoblot analysis thereof. d, Control immunoblot for hnRNP-C CLIP-qPCR shown in 
Figure 5c. Higher molecular weight complexes stained with hnRNP-C antibody represent hnRNP-
C crosslinked to RNA. * marks the antibody heavy chain detected in the IP. Representative of 
three biological replicates for both CLIP-qPCR and immunoblot analysis thereof. Panel a by M 
Charman.
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Figure 3.6 | Non-degradative ubiquitination of RNA-binding proteins promotes efficient 
adenoviral RNA processing. During wild-type (WT) Ad5 infection the E1B55K/E4orf6 complex 
induces ubiquitination of RNA-binding proteins RALY and hnRNP-C to facilitate efficient viral late 
RNA processing. Ubiquitination regulates interaction of these host proteins with viral RNA to 
facilitate viral infection. In the absence of the E1B55K/E4orf6 ubiquitin ligase activity, the RBPs 
bind to viral late mRNAs and limit RNA processing and protein production. RNP - 
ribonucleoprotein 
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3.6 Materials and Methods 
3.6.1 Cell culture 
All cell lines were obtained from the American Type Culture Collection (ATCC) and cultured at 
37°C and 5% CO2. HeLa (Cat#: ATCC CCL-2), HEK293 (Cat#: ATCC CRL-1573), and U2OS 
cells (Cat#: ATCC HTB-96) were grown in DMEM (Corning, Cat#: 10-013-CV) supplemented with 
10% v/v fetal bovine serum (FBS) (VWR, Cat#: 89510-186) and 1% v/v Pen/Strep (100 U/ml of 
penicillin, 100 μg/ml of streptomycin, Gibco, Cat#: 15140-122). A549 cells (Cat#: ATCC CCL-185) 
were maintained in Ham’s F-12K medium (Gibco, Cat#: 21127-022) supplemented with 10% v/v 
FBS and 1% v/v Pen/Strep. Primary like HBEC3-KT (Cat#: ATCC CRL-4051) were grown in 
Airway Epithelial Cell Basal Medium (Cat#: ATCC PCS-300-030) supplemented with Bronchial 
Epithelial Cell Growth Kit (Cat#: ATCC PCS-300-040) and 1% v/v Pen/Strep. All cell lines tested 
negative for mycoplasma using the LookOut Mycoplasma PCR Detection Kit (Sigma-Aldrich).  
3.6.2 Viruses and infection 
Ad5 wild-type (WT) was purchased from ATCC. The Ad5 E1B55K-deletion mutant dl110 has 
been described previously245 and was a gift from G. Ketner. The E1 deletion mutant recombinant 
adenovirus vectors expressing E1B55K (rAd E1B55K)304 and E4orf6 (rAd E4orf6)224 were 
obtained from P. Branton. All viruses were propagated on HEK293 cells, purified using two 
sequential rounds of ultracentrifugation in CsCl gradient and stored in 40% v/v glycerol at -20°C. 
Viral titers were determined by plaque assay on HEK293 cells for all but rAd E4orf6. For this virus 
we assumed a plaque forming unit-to-particle ratio of 1:50. All infections were carried out using a 
multiplicity of infection (MOI) of 10 and harvested at indicated hours post infection (hpi). Infections 
were performed on monolayers of cells by dilution of the virus in respective low serum growth 
medium. After 2 h at 37°C additional full serum growth medium was added. For plaque assays, 
the virus infection media was removed after 2 h and cells were washed 1x in PBS before addition 
of full serum growth medium. 
3.6.3 Plasmids, siRNA and transfection 
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Full-length RALY with a carboxyl-terminal Flag-tag (cDNA obtained from Dharmacon, Cat#: 
MHS6278-202857995) and hnRNP-C isoforms 1 and 2 with a carboxyl-terminal Flag-tag (cDNA 
containing plasmids were a gift from K. Lynch) and RFP were cloned into the pcDNA3.1 vector 
using the BamHI and XbaI restriction sites. The pRK5 vector encoding Ad5 E4orf6 was generated 
by subcloning from purified Ad5 DNA as previously described325. The expression vector for HA-
tagged tetra ubiquitin as previously described326 was a gift from R. Greenberg DNA transfections 
were performed using the standard protocol for Lipofectamine2000 (Invitrogen). 
The following siRNAs were obtained from Dharmacon: non-targeting control (Cat#: D-001206-
13-05), RALY (Cat#: M-012392-00-0005) and hnRNP-C (Cat#: M-011869-01-0005; Cat#: L-
011869-03-0005 only used for hnRNP-C single knockdown in supplementary Fig. 7). siRNA 
transfections were performed using the standard protocol for Lipofectamine RNAiMAX 
(Invitrogen). 
3.6.4 Antibodies and inhibitors 
The following primary antibodies for viral proteins were obtained: Adenovirus late protein 
antibody staining Hexon, Penton and Fiber (gift from J. Wilson278, species: rabbit, WB 1:10,000), 
Protein VII (gift from H. Wodrich327, Clone: Chimera 2-14, WB 1:200), DBP (gift from A. Levine280, 
Clone: B6-8, WB 1:1000, IF 1:400), E1B55K (gift from A. Levine328, Clone: 58K2A6, WB 1:500) 
and E4orf6 (gift from D. Ornelles329, Clone: RSA#3, WB 1:500). 
The following primary antibodies were used for cellular proteins: MRE11 (Novus Biologicals, 
Catalog#: NB100-142, WB 1:1000), BLM (Abcam, Catalog#: ab476, WB 1:1000), Cullin5 (Bethyl 
Laboratories, Catalog#: A302-173A, WB 1:200), Actin (Sigma-Aldrich, Catalog#: A5441-100UL, 
WB 1:5000), RALY (Bethyl Laboratories, Catalog#: A302-070A, WB 1:1000; Bethyl Laboratories, 
Catalog#: A302-069A, IF 1:500, IP 5 μl = 5 μg), hnRNP-C (Santa Cruz Biotechnology, Catalog#: 
sc-32308, WB 1:1000, IF 1:1000, IP 25 μl=5 μg), Tubulin (Santa Cruz Biotechnology, Catalog#: 
sc-69969, WB 1:1000), Flag (Sigma-Aldrich, Catalog#: F7425-.2MG, WB 1:1000), Histone H3 
(Abcam, Catalog#: ab1791, WB 1:100,000), Ubiquitin (Santa Cruz, Catalog#: sc-9133, IP 10 μl=2 
μg; Abcam, Catalog#: ab7780, IP 5 μl), NBS1 (Novus Biologicals, Catalog#: NB100-143, WB 
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1:1000), RAD50 (GeneTex, Catalog#: GTX70228, WB 1:1000) and USP7 (Bethyl Laboratories, 
Catalog#: A300-033A, IF 1:500). 
Horseradish peroxidase-conjugated (HRP) secondary antibodies for immunoblot were 
purchased from Jackson Laboratories. Anti-mouse IgG conjugated to HRP for immunoblot of 
immunoprecipitation samples (used in Fig. 3b) was purchased from Abcam (Cat#: ab131368). 
Fluorophore-conjugated secondaries for immunofluorescence were purchased from Life 
Technologies. 
Cycloheximide (CHX) was purchased from Calbiochem (Cat#: 293764), dissolved in DMSO to 
a stock concentration of 25 mM and used at a final concentration of 25 μM. NEDDylation inhibitor 
MLN4924 was purchased from Sigma-Aldrich (Cat#: 505477), dissolved in DMSO to a stock 
concentration of 1 mM and used at a final concentration of 3 μM. Proteasome inhibitor MG132 
was purchased from Sigma-Aldrich (Cat#: 474791) at a concentration of 10 mM in DMSO and 
used at a final concentration of 20 μM. 
3.6.5 Immunoblotting 
Protein samples were prepared using lithium dodecyl sulfate (LDS) loading buffer (NuPage) 
supplemented with 25 mM dithiothreitol (DTT) and boiled at 95°C for 10 min. Equal amounts of 
protein lysate were separated by SDS-PAGE and transferred onto a nitrocellulose membrane 
(Millipore) at 30 V for at least 60 min (overnight for ubiquitination assays). Membranes were 
stained with Ponceau to confirm equal loading and blocked in 5% w/v milk in TBST supplemented 
with 0.05% w/v sodium azide. Membranes were incubated with primary antibodies overnight, 
washed for 30 min in TBST, incubated with HRP-conjugated secondary for 1 h and washed again 
for 30 min in TBST. Proteins were visualized with Pierce ECL Western Blotting Substrate 
(Thermo Scientific) and detected using a Syngene G-Box. Images were processed and 
assembled in Adobe CS6.  
3.6.6 Immunofluorescence 
HeLa cells were grown on coverslips in 24-well plates, infected with indicated viruses and 
fixed at 24 hpi in 4% w/v paraformaldehyde in PBS for 10 mins. Cells were permeabilized with 
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0.5% v/v Triton-X in PBS for 10 mins. The samples were blocked in 3% w/v BSA in PBS (+ 0.05% 
w/v sodium azide) for 30 mins, incubated with primary antibodies in 3% w/v BSA in PBS (+ 0.05% 
w/v sodium azide) for 1 h, followed by secondary antibodies and 4,6-diamidino-2-phenylindole 
(DAPI) for 2 h. Secondary antibodies used were Alexa Fluor α-rabbit 488 and α-mouse 555. 
Coverslips were mounted onto glass slides using ProLong Gold Antifade Reagent (Cell Signaling 
Technologies). Immunofluorescence was visualized using a Zeiss LSM 710 Confocal microscope 
(Cell and Developmental Microscopy Core at UPenn) and ZEN 2011 software. Images were 
processed in ImageJ and assembled in Adobe CS6. 
3.6.7 RNA Fluorescence in situ hybridization 
RNA FISH was performed following previously established protocols330, with the following 
modifications. Thirty-two singly labeled DNA oligonucleotides targeting the Fiber open reading 
frame were designed using the Stellaris smFISH probe designer and ordered with a 3’ mdC-TEG-
Amino label from LGC Biosearch. Fiber FISH probes were pooled and labeled with ATTO 647N 
NHS-Ester (ATTO-TEC, Cat#: AD 647N-31), isopropanol precipitated and purified by HPLC as 
previously described330. GAPDH probes labeled with Cy3 were used as a counterstain to 
demarcate cytoplasmic boundaries and were a kind gift from S. Schaffer331. HeLa cells were 
grown on coverslips, harvested, fixed, and permeabilized as described for conventional 
immunofluorescence above. After permeabilization, cells on coverslips were equilibrated in Wash 
Buffer (2X SSC, 10% formamide) before being inverted over 30 μl Hybridization Buffer (2X SSC, 
10% formamide, 10% dextran sulphate) containing 500 nM Fiber and GAPDH FISH probes and 
incubated at 37°C in a humidified chamber overnight. The following day coverslips were washed 
twice with Wash Buffer for 30 minutes at 37°C with DAPI added to the second wash, briefly 
washed three times at room temperature with 2X SSC, and then affixed to glass slides using 
clear nail polish. Images were acquired on a Zeiss LSM 710 microscope with ten z-stacks of 0.7 
μm each in the z-direction. Images were deconvoluted by maximum intensity projection in the z-
direction using ImageJ. Fiber RNA localization was scored as described in Figure 3.S1 over 41-
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160 individual cells. Representative images were further processed in ImageJ and assembled in 
Adobe CS6. 
3.6.8 RNA isolation and RT-qPCR 
Total RNA was isolated from infected cells at the indicated time points using the RNeasy 
Micro Kit (Qiagen). Complementary DNA (cDNA) was synthesized using 1 μg of input RNA and 
the High Capacity RNA-to-cDNA Kit (Thermo Fisher). Quantitative PCR was performed by 
standard protocol using diluted cDNA, primers for different viral and cellular transcripts (see 
Supplementary Table 4 for complete list of primers) and SYBR Green (Thermo Scientific) using 
the QuantStudio 7 Flex Real-Time PCR System (Thermo Scientific). The relative values for each 
transcript were normalized to a control RNA (actin or HPRT). 
3.6.9 Viral genome accumulation by qPCR 
Infected cells were harvested by trypsinization at 4 and 24 hpi and total DNA was isolated 
using the PureLink Genomic DNA kit (Invitrogen). qPCR was performed using primers for the Ad5 
DBP and cellular tubulin. Values for DBP were normalized internally to tubulin and to the 4 hpi 
time point to control for any variations in virus input. qPCR was performed using the standard 
protocol for SYBR Green and analyzed with the QuantStudio 7 Flex Real-Time PCR System. 
3.6.10 Plaque assay 
Infected cells seeded in 12-well plates were harvested by scraping at the indicated time points 
and lysed by three cycles of freeze-thawing. Cell debris was removed from lysates by 
centrifugation at max speed (21,130 g), 4°C, 5 min. Lysates were diluted serially in DMEM 
supplemented with 2% v/v FBS and 1% v/v Pen/Strep to infect HEK293 cells seeded in 12-well 
plates. After incubation for 2 h at 37°C, the infection media was removed, and cells were overlaid 
with DMEM containing 0.45% w/v SeaPlaque agarose (Lonza) in addition to 2% v/v FBS and 1% 
v/v Pen/Strep. Plaques were stained using 1% w/v crystal violet in 50% v/v ethanol between 6 to 
7 days post-infection.  
3.6.11 Immunoprecipitation 
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Approximately 2x107 cells were harvested, washed, pelleted and flash frozen for each 
immunoprecipitation. For IP of hnRNP-C and RALY 50 μl of Protein G Dynabeads (Thermo 
Fisher) per sample were washed 3x in IP buffer (50 mM HEPES pH7.4, 150 mM KCl, 2 mM 
EDTA, 0.5% v/v NP-40, 0.5 mM DTT, 1x cOmplete Protease Inhibitor Cocktail (Roche)) and 
incubated with 5 μg of antibody (α-hnRNP-C or α-RALY) rotating at 4°C for 2h. Cell pellets were 
resuspended in 1 ml IP buffer and incubated for 1 h on ice. Samples were sonicated with a 
Diagenode Biorupter on low setting for 30 s on and 30 s off for ten rounds at 4°C and spun at max 
speed (21,130 g) for 10 min at 4°C. 300 μl of sample were added to washed beads and incubated 
rotating at 4°C for 2h. Beads were washed 4x in IP wash (same as above but with only 0.05% v/v 
NP-40). Samples were eluted in 50 μl 1x LDS sample buffer with 25 mM DTT by boiling for 10 
min at 95°C and further processed for analysis by immunoblot. 
The following changes were made to the protocol for IP of E1B55K: IP buffer contained 50 
mM Tris-HCl pH7.4, 0.1% v/v Triton X-100, 150 mM NaCl, 50 mM NaF, 1 mM Na3VO4, 1x 
cOmplete Protease Inhibitor Cocktail. 
3.6.12 Denaturing in vivo ubiquitination assay 
Approximately 1x107 cells were washed, pelleted and stored at -80°C for each 
immunoprecipitation. For HEK293 cells, the pellets were thawed on ice and resuspended in 100 
μl of Lysis buffer (1% w/v SDS, 5 mM EDTA, 10 mM DTT, 1x cOmplete Protease Inhibitor 
Cocktail) with 1 μl Benzonase (Sigma-Aldrich) by vortexing. Samples were incubated on ice for 5 
min and then further denatured by heating to 95°C for 5 min. 900 μl of Wash buffer (10 mM Tris-
HCl pH 7.4, 1 mM EDTA, 1 mM EGTA, 150 mM NaCl, 1% v/v Triton X-100, 0.2 mM Na3VO4, 1x 
cOmplete Protease Inhibitor Cocktail), passed 10 times through a 23G syringe and spun at max 
speed (21,130 g) for 5 min at 4°C. A minimum off 800 μl of sample was added to 50 μl washed 
Pierce Anti-HA Magnetic beads (Thermo Fisher). Sample was incubated with beads rotating for 1 
h at 4°C, washed 3x in Wash buffer and eluted in 1x LDS sample buffer with 25 mM DTT for 
further processing by immunoblot. 
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The following changes were made to the protocol for HeLa cells: the Lysis buffer contained 
1% w/v SDS in PBS, Tris buffered saline with Tween-20 was used as wash buffer, Protein G 
Dynabeads incubated for 1 h with a mix of both α-ubiquitin antibodies listed above were used for 
the IP. 
3.6.13 De-ubiquitination assay 
Approximately 1x107 HEK293 cells were washed, pelleted and stored at -80°C for each 
immunoprecipitation. The pellets was resuspended in 1 ml IP buffer B (20 mM HEPES-KOH pH 
7.4, 110 mM potassium acetate, 2 mM MgCl2, 0.1% v/v Tween-20, 0.1% v/v Triton X-100, 150 
mM NaCl, 1 mM DTT, 0.1 mM PTSF) containing 1x cOmplete Protease Inhibitor Cocktail, 20 μM 
PR-619 (LifeSensors, Cat#: SI9619-5X5MG), 5 mM 1,10-phenanthroline (LifeSensors, Cat#: 
SI9649), and 1 μl/ml Benzonase (Sigma-Alrich). Samples were incubated on ice for 30 min, 
sonicated with a Diagenode Biorupter on low setting for 30 s on and 30 s off for five rounds at 4°C 
and spun at max speed (21,130 g) for 5 min at 4°C. 925 μl of sample was added to 100 μl 
washed Pierce Anti-HA Magnetic beads (Thermo Fisher). Sample was incubated with beads 
rotating for 2 h at 4°C, washed 3x in IP buffer B, resuspended in 100 μl of IP buffer B and split 
into three 30 μl aliquots. 1 μl of 20 mM PR-619 was added to sample 1 (untreated), 1 μl of USP2 
(LifeSensors, Cat#: DB501) was added to sample 2 (DUBPAN) and 2 μl of OTUB1 (LifeSensors, 
Cat#: DB201) was added to sample 3 (DUBK48). Samples were incubated at 30°C for a minimum 
of 1 h. Samples were eluted by addition of 10 μl 4x LDS sample buffer with 100 mM DTT and 
boiling at 95°C for 10 min for further processing by immunoblotting. 
3.6.14 CLIP-qPCR 
The CLIP protocol was adapted from existing protocols332. In short, approximately 2x107 cells 
were crosslinked on ice with 0.8 J/cm2 UV 254 nm in a UV Stratalinker 2400 (Stratagene), 
washed in PBS with 2 mM EDTA and 0.2 mM PMSF, flash frozen in liquid nitrogen and stored at -
80°C. 50 μl of Protein G Dynabeads per sample were washed 3x in iCLIP lysis buffer A (50 mM 
Tris-HCl pH 7.4, 10 mM NaCl, 0.2% v/v NP-40, 0.1% w/v SDS, 0.5% w/v Sodium deoxycholate, 
1x cOmplete Protease Inhibitor Cocktail), resuspended in 100 μl iCLIP lysis buffer A and 
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incubated with 5 μg of α-hnRNP-C antibody or 5 μl of Normal Mouse Serum Control (Thermo 
Fisher) rotating 1 h at 4°C. Cell pellets were resuspended in 1 ml of iCLIP lysis buffer B (same as 
buffer A but with 1% v/v NP-40 and 11 μl of Murine RNase inhibitor (NEB) per 1 ml) and 
incubated on ice for 15 min. Samples were sonicated with a Diagenode Biorupter on low setting 
for 30 s on and 30 s off for five rounds at 4°C. 2 μl of TURBO DNase (Thermo Fisher) were added 
and samples incubated at 37°C for 6 min. Lysates were cleared by centrifugation at max speed 
(21,130 g) for 15 min at 4°C and supernatants transferred to a new tube. 300 μl of lysate were 
added to washed beads and incubated rotating at 4°C for 2 h. Beads were washed 2x in High 
Salt buffer (50 mM Tris-HCl pH 7.4, 1 M NaCl, 1 mM EDTA, 0.2% v/v NP-40, 0.1% w/v SDS, 
0.5% w/v Sodium deoxycholate), 2x in Wash buffer (20 mM Tris-HCl pH 7.4, 10 mM MgCl2, 0.2% 
v/v Tween-20) and 2x in Proteinase K buffer (100mM Tris-HCl pH 7.4, 50 mM NaCl, 10 mM 
EDTA, 0.2% w/v SDS). Beads were resuspended in 50 μl Proteinase K buffer and 10 μl removed 
and processed for immunoblot analysis. 10 μl of Proteinase K (NEB) and 2 μl Murine RNase 
Inhibitor were added to the remaining beads or to 30 μl of input (10%) and incubated at 50°C for 
1 h. The RNA was extracted using a standard protocol for TRIzol (Thermo Fisher) and further 
processed for RT-qPCR. 
3.6.15 Analyzing protein complexes by crosslinking  
Cells were crosslinked using disuccinimidyl suberate (DSS, Thermo Fisher) dissolved to 100 
mM in DMSO and further diluted to 0.1 mM, 0.3 mM and 1 mM in PBS. Cells seeded as a 
monolayer in 6-well plates were washed once with PBS, overlaid with 500 μl with PBS or the 
different DSS dilutions and incubated at room temperature for 30 min. The reaction was 
quenched by addition of 500 μl of 20 mM Tris-HCl pH 7.4, washed twice with PBS and further 
processed for immunoblot analysis. 
3.6.16 Mass spectrometry 
3.6.16.1 Cell lysis and initial desalting 
Approximately 10 mg of input was generated from 5x15 cm plates of HeLa cells transduced 
with rAd E1B55K and rAd E4orf6 constructs for 0 h (mock), 6 h, 8 h, and 10 h. Each timepoint 
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was produced in biological triplicate. Cell were harvested with 0.25% Trypsin (Gibco), washed 1x 
in PBS, flash frozen in liquid nitrogen and stored at -80°C. Pellets were thawed, resuspended in 1 
ml of lysis buffer (6 M urea, 2 M thiourea, in 50 mM ammonium bicarbonate pH 8.0) with 1x Halt 
Protease Cocktail inhibitor solution, and incubated for ~5 min on ice. Samples were then diluted 
10-fold in 50 mM ammonium bicarbonate, reduced with 10 mM DTT, alkylated with 20 mM 
iodoacetamide, and digested with trypsin protease overnight. Digestion was quenched by 
acidification to pH 2 with trifluoroacetic acid (TFA) and samples were desalted over Waters tC18 
SepPak cartridges (Cat#: 036805). A 10% aliquot was set aside for global proteomic analysis and 
all samples were dried to completion. 
3.6.16.2 Di-glycine (K-ε-GG) enrichment, fractionation, and desalting 
A Cell Signaling PTMScan ubiquitin remnant motif kit (Cat#: 5562) was used to enrich for 
peptides that had been ubiquitinated. Aliquoted beads were cross-linked for 30 minutes in 100 
mM sodium borate and 20 mM dimethyl pimelimidate (Thermo Scientific), following the protocol 
outlined by Udeshi et. al.211. Tryptic peptides were resuspended in IAP buffer (50 mM MOPS, pH 
7.2, 10 mM sodium phosphate, 50 mM NaCl) and immunoprecipitated with the provided antibody 
for 2 h at 4°C. Samples were eluted in LC-MS grade water (Thermo Fisher) with 0.15% v/v TFA 
and separated into either 3 high-pH fractions (enriched ubiquitinated peptides) or 7 high-pH 
fractions (global proteome) over C18 columns (The Nest Group, MicroSpin column C18 silica, 
part#: SEM SS18V, lot#: 091317). Fractionated samples were desalted a final time over Oligo R3 
reverse-phase resin (Thermo Scientific, Cat#:1-1339-03). 
3.6.16.3 Data acquisition and search parameters 
All solvents used in analysis of MS samples were LC-MS grade. Samples were analyzed with 
an Easy-nLC system (Thermo Fisher) running 0.1% v/v formic acid (Buffer A) and 80% v/v 
acetonitrile with 0.1% v/v formic acid (Buffer B), coupled to an Orbitrap Fusion Tribrid mass 
spectrometer. Peptides were separated using a 75 µm i.d. silica capillary column packed in-
house with Repro-Sil Pur C18-AQ 3 µm resin and eluted with a gradient of 3-38% Buffer B over 
85 minutes. Full MS scans from 300-1500 m/z were analyzed in the Orbitrap at 120,000 FWHM 
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resolution and 5x105 AGC target value, for 50 ms maximum injection time. Ions were selected for 
MS2 analysis with an isolation window of 2 m/z, for a maximum injection time of 50 ms, to a 
target AGC of 5x104.  
MS raw files were analyzed by MaxQuant software version 1.6.0.16, and MS2 spectra were 
searched against a target + reverse database with the Andromeda search engine using the 
Human UniProt FASTA database [9606] (reviewed, canonical entries; downloaded November 
2017) and adenovirus serotype 5 UniProt FASTA database (reviewed, canonical entries; 
downloaded February 2018). The search included variable modifications of methionine oxidation, 
N-terminal acetylation, and GlyGly on lysine residues, with a fixed modification of 
carbamidomethyl cysteine. For global proteome samples, iBAQ quantification was performed on 
unmodified, unique peptides only. Trypsin cleavage was specified with up to 2 missed cleavages 
allowed. Match between runs was enabled with a retention time alignment window of 20 min and 
a match time window of 0.7 min. False discovery rate (FDR) was set to 0.01.  
3.6.17 Proteomics and bioinformatics analysis 
3.6.17.1 Data normalization and filtering 
MaxQuant output was filtered to remove identified contaminant and reverse proteins. 
MaxQuant “Intensity” and “iBAQ”287 label free quantification values were used to measure 
abundances for the K-ε-GG and WCP data, respectively. Abundances were transformed to log2 
values, with unidentified values assigned as “NA”. K-ε-GG and WCP data were normalized 
separately. Data were normalized by subtracting the sample medians from log2 transformed 
abundances within each sample. Both the KεGG and the WCP datasets were filtered at each 
timepoint to require identification in at least 2 of 3 replicates to be included in the analysis. 
3.6.17.2 Fold change, p-value, and z-score calculations 
The fold change across time points was calculated by averaging the log2 transformed, 
normalized peptide or protein abundances for each replicate identification within a time point and 
subtracting the averaged abundance values for compared time points. Hypothesis testing was 
performed using unpaired, two-tailed Students t-tests. The log2 transformed, normalized 
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abundance values were compared for cases in which abundances were quantified for at least two 
replicates within each time point. A p-value threshold of < 0.05 was required to reject the null 
hypothesis. Multiple testing correction was not performed. Z-scores were used to measure 
relative abundances within a time point. Z-scores were calculated by averaging the peptide or 
protein abundances for each replicate identification within a time point and comparing to the 
mean and standard deviation of averaged values within that time point.  
3.6.17.3 Protein ubiquitin abundance calculation 
The di-glycine technique quantifies peptide-based abundance of the K-ε-GG modification. In 
order to quantify protein-based K-ε-GG abundance changes, we implemented a calculation to 
combine the peptide-based fold changes for cases in which multiple K-ε-GG peptides comprise a 
modified protein. If a single K-ε-GG peptide was identified for a modified protein, that K-ε-GG 
abundance fold change is representative of the protein-based K-ε-GG fold change. For cases in 
which multiple K-ε-GG peptides are quantified for a modified protein, the fold changes of each 
peptide are weighted by the abundance of that peptide and the weighted fold changes are 
averaged to calculate the protein-based K-ε-GG fold change. In cases for which a peptide was 
reproducibly uniquely identified in the mock or 10 hour transduction time point, a log2 fold change 
of 7, representing the largest fold change identified in the dataset, was assigned to this peptide. 
The K-ε-GG abundance fold changes are normalized by the total protein abundance fold change 
of the respective protein in the corresponding whole cell proteome. The normalization of the K-ε-
GG fold change by total protein fold change was performed to identify differentially increased or 
decreased ubiquitination, beyond what would be expected if modification abundance was driven 
solely by changes in total protein abundance. 
3.6.17.4 K-ε-GG and whole cell proteome comparison 
The protein-based K-ε-GG and corresponding whole cell proteome data were compared to 
identify proteins that exhibited an increase in K-ε-GG abundance and to predict the effect of 
ubiquitination on total protein abundance. The data integration was performed for protein-based 
K-ε-GG and whole cell proteome quantifications for 10 hours post-transduction compared to 
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untransduced cells. Proteins that exhibited a protein-based, normalized K-ε-GG log2 fold change 
> 1 were classified as being increased in ubiquitination in response to E1B55K/E4orf6 
expression. Proteins that exhibited whole cell proteome log2 fold change greater than the mean 
fold change +/- 1 standard deviation were classified as increased or decreased in total protein 
abundance. Proteins for which total protein expression did not deviate more than +/- 1 standard 
deviation from the mean fold change were classified as unchanged in protein abundance in 
response to E1B55K/E4orf6 expression. Proteins that were ubiquitinated and decreased in total 
protein abundance were predicted to be potential substrates of E1B55K/E4orf6 ubiquitin-
mediated degradation. Proteins that were ubiquitinated and unchanged in total protein abundance 
were predicted to be non-degraded substrates of E1B55K/E4orf6. 
3.6.17.5 Gene ontology and protein-protein interaction network analysis 
The proteins that exhibited increased protein-based ubiquitination were analyzed using the 
ReactomeFI plug-in (6.1.0)305 within the Cytoscape network visualization software (3.4.0)333. The 
protein-protein interaction network was generated using the Gene Set analysis within the ”2016” 
ReactomeFI network version with “linker genes” included. The network was clustered using the 
in-built ReactomeFI clustering algorithm. Gene ontology “Molecular Function” analysis was 
performed within the ReactomeFI application for the entire network as well as for each clustered 
module. Network node attributes included size, which corresponded to degree of increased 
ubiquitination, and color, which corresponded to total protein increase or decrease. Network 
edges were set to non-directed, solid lines for all types of Reactome protein-protein interactions. 
3.6.18 Statistics and reproducibility 
Each experiment was carried out at least in triplicate with reproducible results. The sample 
size was chosen to provide enough statistical power apply parametric test (unpaired, two-tailed 
Student’s t-test unless otherwise noted). Details regarding statistical analysis are reported in each 
figure legend.  
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CHAPTER 4: Conclusions and future directions 
4.1 Summary 
Viruses, as obligate intracellular pathogens, rely on altering the host cell environment to create 
favorable conditions for viral replication and ultimately successful infection of the host (Figure 
4.1a). Viruses have evolved a myriad of strategies to hijack cellular pathways necessary for viral 
processes and antagonize immune responses mounted by the host to block infection. Studying 
these complex interactions between viruses and their host not only provides new insights into 
viral infection, but also reveals regulatory mechanisms for fundamental cellular processes, 
enables new strategies for antiviral therapies, and can be used to improve viral-based vectors for 
oncolytic therapy, gene therapy, and vaccine development. My thesis focuses on Ad, a nuclear-
replicating virus and important model system for basic research, and the different strategies used 
by this pathogen to exploit cellular processes. This work illustrates the complex interaction of Ad 
with its host cell by examining how this virus manipulates both immune responses and host cell 
environment in favor of viral propagation.  
In Chapter 2, we investigated the hypothesis that a viral histone-like protein such as Ad 
protein VII can interact with and manipulate host chromatin (Figure 1.9). We discovered that 
protein VII localizes to both viral and host DNA during infection and can bind to host nucleosomes 
in cells and in vitro. Furthermore, we identified PTMs on protein VII reminiscent of modifications 
found on cellular histones and demonstrated that these PTMs regulate the association of protein 
VII with host chromatin. We also determined the changes in protein composition of host 
chromatin caused by protein VII and identified several proteins of the HMGB family, including 
HMGB1, that are sequestered in chromatin through direct interaction with the Ad histone-like 
protein. HMGB proteins can function as cellular alarmins upon release from the cell by binding to 
several immune receptors and activating downstream immune responses. We showed that 
association with protein VII decreases HMGB1 levels in cell culture supernatant and mouse lungs 
upon immune stimulation. In a mouse model we also showed that protein VII expression resulted 
reduced immune cell infiltration. This work demonstrated that protein VII, as a viral histone-like 
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protein, can indeed manipulate cellular chromatin and revealed a novel association between 
chromatin composition and modulation of host responses towards viral infection (Figure 4.1b)258. 
In Chapter 3, we hypothesized that as of yet undiscovered substrates of the E1B55K/E4orf6 
complex contribute to the RNA processing phenotype observed upon inhibition of viral-mediated 
ubiquitination (Figure 1.13). We used a combined proteomics approach to identify host proteins 
ubiquitinated upon E1B55K/E4orf6 expression. We then predicted whether ubiquitination of these 
host proteins induced degradation or resulted in potential alternative outcomes by determining 
changes in protein abundance through whole cell proteome profiling. This analysis led to the 
discovery that RBPs are enriched among proteins that were ubiquitinated by the viral ligase but 
not decreased in abundance. We then focused on the closely related RBPs RALY and hnRNP-C. 
We validated that these cellular proteins are ubiquitinated but not degraded upon E1B55K/E4orf6 
expression or Ad infection. This makes these host RBPs the first confirmed non-degraded 
substrates of the Ad ubiquitin ligase. Knockdown of RALY and hnRNP-C using siRNA did not 
impact WT virus infection but rescued RNA processing, protein production, and progeny 
production of an E1B55K-deleted mutant virus. We also demonstrated that hnRNP-C associates 
less with viral late RNA in the absence of a functional viral ubiquitin ligase, when viral RNA 
processing was attenuated. These data suggest that RALY and hnRNP-C are detrimental to 
processing of Ad RNA and that ubiquitination relieves this restriction. In this project we not only 
discovered E1B55K/E4orf6 substrates that explain the RNA processing defect of the mutant 
viruses, but we also uncovered an unexpected role for non-degradative ubiquitination in Ad 
infection (Figure 4.2c). 
These two projects revealed two new aspects of the interaction of Ad and viruses in general 
with host cells. Our discoveries open up exciting new avenues for research regarding viral 
histone-like proteins and their impact on host chromatin as well as the role of viral-mediated non-
degradative ubiquitination in manipulating the host cell environment. This chapter of my thesis 
focuses on the broader implications of our work and future directions for both projects. 
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4.2 Viral histone-like proteins and the manipulation of host chromatin 
Several viruses encode proteins that have been proposed to function similar to histones for 
compaction of viral genomes. However, while it has been shown that cellular histones are very 
important in context of host chromatin and in association with viral genomes, the impact of viral 
histone-like proteins on the host genome is unknown. Our work on Ad protein VII is the first time it 
has been demonstrated that viral histone-like proteins can interact with and manipulate cellular 
chromatin258. This opens up new areas of research investigating additional viral histone-like 
proteins and other viral proteins associated with the cellular genome, focusing on how these 
proteins affect host chromatin structure and function, and the contribution of these processes to 
virus infection. Accordingly, the assays introduced in Chapter 2 and proposed below could be 
applied to infection by other viruses to answer some of the following questions: Which viral 
proteins associate with cellular chromatin? What are the changes in protein composition of 
cellular chromatin upon infection? What are the overall differences in nuclear architecture during 
infection and which viral proteins are involved? What is the association between global changes 
of the nucleus and alterations in chromatin state and gene expression? How do these changes in 
host chromatin contribute to viral infection? 
4.2.1 Potential additional functions mediated by proteins VII 
In Chapter 2, we demonstrated that protein VII is sufficient to alter host chromatin structure 
and that recruitment of HMGB1 decreases inflammation mediated by this alarmin258. Protein VII 
association with chromatin could fulfill more functions than just suppressing the host immune 
response and there remain several questions worth addressing. For instance, where in the 
chromatin does protein VII bind? What consequences does the binding of protein VII have on 
local chromatin structure and functions such as transcription? How do these changes impact Ad 
infection? 
We propose that protein VII localizes to and changes the chromatin structure of distinct 
locations in the chromatin. This would allow for directed manipulation of host chromatin functions 
such as altering transcription, and represent an additional way protein VII could alter the state of 
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the host cell. This hypothesis could be addressed using protein VII chromatin 
immunoprecipitation (ChIP) upon Ad infection and in our inducible protein VII-HA cell line as 
compared to control conditions. Analysis of these data could also identify a potential protein VII 
binding motif, or determine if this viral protein has a preference for binding near chromatin-
associated host factors. 
Another question is how protein VII binding changes the state and activity of associated 
chromatin. Other Ad encoded proteins, such as E1A, E1B55K, and E4orf6, have been 
demonstrated to alter histone PTMs and host transcription47-51,79-81,212,226-228. Protein VII-mediated 
changes in cellular gene expression may represent an additional strategy used by Ad to alter the 
host transcriptome. Dramatic changes to the overall chromatin structure are visible upon protein 
VII expression by IF. In addition, preliminary experiments measuring chromatin accessibility upon 
protein VII expression using an assay for transposase-accessible chromatin followed by 
sequencing (ATAC-Seq)334 revealed large changes in the openness of chromatin when compared 
to control conditions (data not shown). Other assays such as Hi-C chromatin conformation 
capture335,336 could be used to further examine the overall impact of protein VII and Ad infection 
on host chromatin structure. In addition, ChIP assays for specific histone modifications associated 
with active or repressed chromatin as well as RNA Polymerase II occupancy could be used to 
provide insight into protein VII-mediated changes in chromatin state. The changes to host 
chromatin structure and composition could also impact host transcription. To test this, we could 
use RNA-Seq, comparing control conditions to protein VII expression and Ad infection. All of 
these data could then be combined with the protein VII ChIP data to correlate changes in 
chromatin structure, chromatin state, and transcription with protein VII binding. Overall, these 
data provide a foundation for additional experiments that could identify further functions and 
consequences of protein VII association with host chromatin. 
Our data in Chapter 2 indicate that PTMs on protein VII are important for regulating 
association of this viral histone-like protein with host chromatin258. As protein VII in virions is not 
acetylated and the protein VII ΔPTM mutant accumulates in nucleoli, we propose that PTMs 
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regulate the distinct association of protein VII with host or viral DNA. This could allow for control 
of the separate functions that protein VII fulfills on cellular and Ad genomes. In addition, PTMs on 
cellular histones have important functions in the regulation of chromatin87-90 and modifications of 
protein VII could fulfill a similar purpose. To study the importance of these PTMs for Ad infection, 
different PTM mutations that either mimic or ablate the ability to modify specific residues within 
protein VII could be introduced into the sequence of the WT Ad genome. We could then define 
the impact of these PTM mutations on localization of protein VII during infection. We propose that 
preventing addition of PTMs on protein VII will lead to predominant association of protein VII with 
Ad DNA and Ad replication compartments. Conversely, we hypothesize that protein VII mutants 
containing PTM mimics will interact more with cellular chromatin. We could then examine the 
effect of these protein VII mutants on different stages of Ad infection, quantifying the impact on 
viral DNA replication by qPCR, viral protein expression by WB and RT-qPCR, and virus 
production by plaque assay. By examining the effect of these mutations on the Ad life cycle, we 
could determine the contribution of PTMs to regulation of different functions of protein VII, 
including protection of incoming genomes, regulation of initial Ad transcription, manipulation of 
host chromatin, and packaging of new Ad genomes into viral particles. Ultimately this would allow 
us to assess the contribution of these protein VII functions to Ad infection in general. 
In summary, manipulation of host chromatin by protein VII could further alter chromatin 
function and ultimately contribute to Ad infection in additional ways. The experiments proposed 
above would begin to address this hypothesis. 
4.2.2 Investigating further functions for protein VII-mediated recruitment of HMGB1 to chromatin 
Our data in Chapter 2 demonstrate that sequestration of HMGB1 in chromatin reduces 
extracellular release of this host alarmin and downstream inflammation258. In addition to its 
extracellular roles, HMGB1 also functions within cells to regulate nucleosome mobility and 
transcription factor binding to target DNA sequences260. We proposed that by recruiting HMGB1 
to chromatin, protein VII also manipulates these intracellular functions of HMGB1, ultimately 
supporting Ad infection.  
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To test this hypothesis, we created an HMGB1 KO cell line using CRISPR/Cas9 and 
examined whether deletion of HMGB1 impacts any stages of Ad infection. Surprisingly, when we 
examined Ad WT RNA levels, genome replication, protein levels, and progeny production in 
HMGB1 WT and KO cells, there were no significant differences (see Appendix II, Figure A2.5). 
Therefore, we conclude that HMGB1 is dispensable for the intracellular steps of Ad infection. 
Considering HMGB1’s role in nucleosome mobility, we proposed that this host protein could be 
recruited to chromatin to facilitate the large structural changes to the host nucleus observed upon 
protein VII expression and Ad infection. To test this, we transduced HMGB1 WT and KO cells 
with vectors for GFP and protein VII-GFP and assessed differences in overall chromatin structure 
by IF. This revealed that protein VII expression was still able to alter host chromatin in the 
absence of HMGB1151. In addition, we also tested whether HMGB1 was involved in protein VII-
mediated suppression of the DDR. However, upon deletion of HMGB1, protein VII was still able to 
suppress the DDR151. While dispensable for the overall alteration of the nuclear architecture 
facilitated by protein VII, HMGB1 may still be important for manipulating chromatin structure at a 
level that cannot be appreciated by confocal microscopy. To explore this theory, we could repeat 
the assays introduced in Chapter 4.2.1 that examine the impact of protein VII on chromatin 
structure and state in the HMGB1 KO cells. These experiments would enable us to determine the 
contribution of HMGB1 to protein VII-mediated local changes in host chromatin function. 
Considering HMGB1’s function in facilitating transcription factor binding, sequestration of 
HMGB1 may also contribute to altering the transcriptional landscape of protein VII expressing 
cells and we have some evidence to support this hypothesis (see Appendix 2 Figure A2.6). We 
tested this hypothesis by examining the impact of protein VII on induction of the interferon 
response. We found that expression of protein VII reduces IFNβ expression upon stimulation with 
poly(dA:dT), a repetitive double-stranded DNA sequence that can be recognized by cytosolic 
DNA sensors and triggers an interferon response (Figure A2.6a). This demonstrated that protein 
VII can alter the expression of at least one host gene. Whether this is achieved through 
manipulation of transcription or other steps involved in IFNβ induction, still needs to be 
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addressed. We furhter determined that protein VII localization to chromatin is important for this 
phenotype, as the nucleolar protein VII ΔPTM mutant (introduced in Chapter 2) is unable to 
decrease IFNβ mRNA levels. This suggests that protein VII suppresses IFNβ expression through 
a chromatin-associated mechanism or that other functions of the PTMs are involved in this 
phenotype (Figure A2.6a). We found that protein VII does not impact signaling downstream of 
IFN, as expression of ISGs upon IFNβ treatment is not decreased in the presence of protein VII 
(Figure A2.6b). We next examined whether HMGB1 is important for protein VII-mediated 
suppression of IFNβ. In HMGB1 KO cells transduced with protein VII-GFP, protein VII expression 
was unable to suppress IFNβ. This indicates that HMGB1 is necessary for suppression of IFNβ 
transcription by protein VII (Figure A2.6c). Future experiments could focus on determining which 
of the cytosolic DNA sensors such as cGAS, IFI16, or AIM2 is antagonized by protein VII in a 
manner dependent on HMGB1. Through HMGB1-mediated manipulation of cellular transcription, 
protein VII may also regulate expression of other host genes, potentially altering the immune 
signals produced by infected cells. This would not have impacted single-cycle infection as 
discussed previously (see Appendix 2 Figure A2.5). Instead, this would be important during in 
vivo infection where Ad needs to counteract antiviral signals produced by infected cells to 
facilitate efficient spread. The RNA-Seq proposed in Chapter 4.2.1 would reveal protein VII-
dependent changes in transcription. Repeating these experiments in HMGB1 KO cells followed 
by RT-qPCR for transcripts of interest would indicate which of these changes in host gene 
expression are mediated through the protein VII-HMGB1 interaction. Another option is to analyze 
the supernatant produced by cells upon infection with Ad by mass spectrometry, comparing 
control conditions to those with deletion of HMGB1 or protein VII (using the Cre-Lox system 
introduced in Chapter 2). Host factors released by infected cells only in the absence of protein VII 
and HMGB1 would represent potential targets of protein VII-mediated transcriptional repression. 
Overall, while we have shown that HMGB1 is dispensable for intracellular steps of Ad infection 
and overall manipulation of host chromatin by protein VII, we have some preliminary data 
supporting a role for the protein VII-HMGB1 interaction in downregulating host transcription, 
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including the IFNβ gene involved antiviral immune responses. The proposed experiments could 
form the foundation for identifying additional functions of the protein VII-HMGB1 interaction for Ad 
infection. 
 
4.3 Non-degradative ubiquitination during viral infection and RNA processing  
Our study in Chapter 3 revealed an unexpected function for viral-mediated non-degradative 
ubiquitination in regulating viral RNA processing. While our work has given some indications into 
how ubiquitin may alter the interaction of RBPs with RNAs and regulate the processing of these 
transcripts, many aspects of this phenomenon remain to be elucidated. As many of the RBPs 
identified in our proteomics analysis were also ubiquitinated in mock conditions, studying viral-
mediated regulation of RNA processing may also reveal general regulatory roles for ubiquitination 
of RBPs in processing of associated target RNAs. In addition, our findings represent one of the 
first examples of how non-degradative ubiquitination mediated by a viral ubiquitin ligase can alter 
the host cell environment and support viral infection. This observation opens up opportunities to 
study the role of non-degradative ubiquitination for different viruses.  
4.3.1 Elucidating the difference between processing of early and late Ad RNA 
It has been known for a long time that deletion of E1B55K specifically affects processing of Ad 
late, but not early, RNAs60,243-246,251,252. In Chapter 3 we demonstrated that the E1B55K/E4orf6 
complex ubiquitinates RBPs RALY and hnRNP-C without inducing degradation, overcoming a 
detrimental effect these host proteins have on splicing of viral late transcripts. We also showed 
that these host RBPs bind more abundantly to viral late, but not early RNA, in the absence of a 
functional viral ubiquitin ligase. This suggests that viral-mediated ubiquitination could directly alter 
the specificity of host RBPs for RNA. These data also raise questions of how specificity for 
binding of viral late transcripts is achieved, what differences exist in processing of individual Ad 
RNAs, and what role ubiquitination plays in this. Studying how E1B55K/E4orf6-mediated 
ubiquitination can impact viral late RNAs may also provide insights into regulation of RNA 
processing in general. As introduced in Chapter 1, one of the major differences between Ad early 
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and late RNAs is that late transcripts are expressed from one common major late promoter and 
are then heavily alternatively spliced to at least 14 different ORFs in 5 distinct transcription units 
with separate poly(A) sites (Figure 1.4)12. We propose that E1B55K/E4orf6-mediated 
ubiquitination is involved in regulating this complex pattern of alternative splicing. Another 
difference between Ad transcripts is that late RNAs are only produced after onset of viral genome 
replication, when E1B55K and E4orf6 levels are high. Early RNAs start to be produced before 
high levels of the Ad ubiquitin ligase are present and thus hnRNP-C and RALY ubiquitination is 
low. Therefore, these early RNAs may have evolved to be processed efficiently independent of 
the ubiquitination status of E1B55K/E4orf6 substrates. In both cases we would expect a 
differential binding pattern of RALY and hnRNP-C to viral early and late transcripts. In addition, 
this binding pattern should specifically be altered for viral late RNAs when comparing WT and 
ΔE1B infection, while early RNAs would remain unchanged. 
To test these hypotheses, we plan to define the binding sites of hnRNP-C and RALY in Ad 
RNAs during WT and ΔE1B infection using eCLIP-Seq332. These data would allow us to 
differentiate between various scenarios for the effect of RALY and hnRNP-C binding on RNA 
processing and what changes are facilitated by ubiquitination of these RBPs. We expect that 
RALY and hnRNP-C interact with distinct regions of late RNAs when comparing WT and ΔE1B 
infection. One possibility is that ubiquitination regulates the interaction of RALY and hnRNP-C 
with specific sites within introns and exons of Ad RNA. There are known roles for hnRNP-C in 
regulating alternative splicing307. For example, binding sites in exons overlapped with splice 
acceptor sites and correlated with exon exclusion. Binding to introns was correlated with exon 
inclusion, potentially by positioning splice acceptor sites in a more favorable conformation307. 
Considering the many alternative splice forms of the viral late RNAs, regulating the interaction of 
hnRNP-C with these transcripts may be exceedingly important to prevent this RBP from 
interfering with generation of the different RNA species. In addition, it has been demonstrated that 
hnRNP-C can act as a nuclear export inhibitor for bound RNAs337. Therefore, hnRNP-C may also 
regulate export in addition to splicing. For example, if hnRNP-C binds within an intron, this 
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interaction is lost upon splicing and the mRNA could be exported. If the binding site is instead 
within an exon, the interaction would be retained upon intron removal. Accordingly, the host RBP 
would need to be removed to facilitate export of the RNA. Both of these scenarios, interfering with 
splicing and blocking RNA export, are supported by the presence of poly-U stretches, the known 
binding motif for both hnRNP-C and RALY311,338,339, within exons of several late transcripts. 
However, these potential binding sites need to be validated using the proposed eCLIP-Seq. In 
addition, it needs to be determined whether these poly-U stretches are absent in early transcripts 
or located in introns instead. To further demonstrate the functionality of the different binding sites 
in Ad early and late RNA, we could mutate or swap the specific regions and test their effect on 
RNA processing. For example, if we remove hnRNP-C binding sites in viral late RNAs, would 
their processing become independent of E1B55K/E4orf6 mediated ubiquitination?  
To gain more mechanistic insight into the impact of ubiquitination on the ability of RALY and 
hnRNP-C to bind RNA, we could perform in vitro ubiquitination experiments. This assay coupled 
with RNA electrophoretic mobility shift assay (EMSA) or isothermal titration calorimetry (ITC) 
could be used to determine changes in affinity for RNA upon ubiquitination. Repeating these 
experiments with different RALY and hnRNP-C mutants with specific domains have been deleted 
or the ubiquitination sites abolished would show their contribution to regulation of RNA binding. 
We could also visualize the extent of binding of hnRNP-C and RALY to viral early and late 
RNA by immunofluorescence combined with proximity ligation assay (PLA), and then determine 
differences between WT and ΔE1B infection. This would also reveal the sites in the nucleus 
where interaction occurs. Immunofluorescence co-staining for other proteins could show the 
location of hnRNP-C/RALY-RNA complexes in relation to viral replication centers and other RNA 
processing factors. We could also determine the localization of ubiquitinated hnRNP-C and RALY 
by PLA for the RBPs and ubiquitin. This approach would reveal whether this event occurs at a 
specific site in the nucleus, for example at locations of viral late RNA processing. This could 
provide further insight into the impact of hnRNP-C and RALY on viral RNA processing and how 
ubiquitination alters this interaction.  
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Another hypothesis for the distinct regulation of early and late RNAs is that E1B55K/E4orf6 
functions as an RNA-dependent ubiquitin ligase. E1B55K contains predicted RNA-binding 
domains that have been shown to interact with RNA in vitro340. However, this function of E1B55K 
remains controversial. One study showed a lack of RNA binding for E1B55K during infection and 
demonstrated that mutations in the RNA-binding domains do not affect infection341. Another 
study, however, found some evidence for interaction of E1B55K with RNA342. We propose that 
E1B55K interacts specifically with viral late RNAs and facilitates localized ubiquitination of RBPs 
such as hnRNP-C and RALY, specifically altering their function for processing of Ad late RNAs. 
This would explain why inhibition of Ad-mediated ubiquitination specifically alters the interaction 
of hnRNP-C with viral late RNA. This hypothesis could be tested by performing E1B55K CLIP-
qPCR or eCLIP-Seq to define the interaction of E1B55K with RNA. These techniques could 
demonstrate whether E1B55K is able to interact with RNAs and if there is a specificity for binding 
Ad late RNAs. Another option is to perform PLA for viral RNA and E1B55K. This assay could be 
used to determine whether E1B55K is recruited to sites of late RNA processing. In addition, this 
technique would also demonstrate association of E1B55K with RNA even if the interaction is not 
direct but rather facilitated through additional factors.   
An alternative scenario is that the protein composition of complexes associated with viral early 
and late RNA differs, and that ubiquitination plays a role in regulating which RBPs associate with 
viral RNAs. To test this hypothesis, we could use a modified version of ChIRP (Chromatin 
isolation by RNA purification)343 coupled with mass spectrometry that will allow us to identify 
proteins specifically associated with Ad early and late RNA species during WT and ΔE1B 
infection. This would enable us to determine whether E1B55K/E4orf6 substrates differentially 
interact with early or late RNAs, and how this association changes in the absence of a functional 
viral ubiquitin ligase. We could then knock down individual components of early and late RNP 
complexes using siRNA to determine their role in viral RNA processing. Another open question is 
how Ad achieves selective export of its late RNA over host and early RNAs. By identifying the 
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proteins associated with different RNA species we may identify the RNA export factors 
responsible for the phenotype. 
The techniques and approaches highlighted in this section would allow us to determine the 
difference in Ad early and late RNA processing and may give insight into regulation of host RNA 
processing in general. 
4.3.2 Investigating the potential manipulation of host RNA processing by Ad 
In Chapter 3, we analyzed the interaction of hnRNP-C with one of its known cellular target 
RNAs during infection and found a trend towards increased interaction in the absence of a 
functional Ad ubiquitin ligase. Other viruses have been shown to alter host RNA processing by 
hijacking host RBPs, such as influenza protein NS1 interacting with NS1-BP and hnRNP family 
member hnRNP-K344. In addition, ubiquitin and other ubiquitin-like proteins have been implicated 
in the regulation of host RNA processing. Many cellular RBPs have ubiquitin-binding domains or 
have been found to be ubiquitinated320. However, the specific roles ubiquitination of different 
RBPs plays in facilitating proper RNA processing remains to be elucidated. This raises the 
question whether Ad infection in general and ubiquitination of RBPs by the E1B55K/E4orf6 
complex specifically impact host RNA processing. And if so, could this manipulation of host 
transcripts be beneficial for viral infection? 
We already know of several strategies employed by Ad to manipulate host gene expression. 
Ad early protein E1A has been demonstrated to alter the host cell transcriptome, modulating the 
cellular environment in a proviral manner47-51. In addition, E1B55K and E4orf6 were shown to 
block p53-dependent transcription, either through their ubiquitin ligase activity or independent of 
each other79-81,212,226-228. Therefore, manipulation of host transcripts through Ad-mediated 
ubiquitination could represent another layer of host gene expression control. To determine the 
impact of Ad on the host transcriptome, we performed an initial RNA-Seq experiment comparing 
mock and Ad WT infection. Our preliminary analysis revealed large changes in both general RNA 
abundances and specific splicing events between the conditions (data not shown). To determine 
which of these differences are dependent on E1B55K/E4orf6-mediated ubiquitination, we could 
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perform RNA-Seq focusing on host RNAs under mock, Ad WT, and Ad ΔE1B infection conditions, 
ideally over a time course. By cross-referencing Ad ubiquitin ligase substrates with potential 
motifs identified through bioinformatics analysis in altered RNA, we could reveal links between 
RNA processing and ubiquitination of RBPs by E1B55K/E4orf6. To test the importance of the 
identified RBPs for Ad, we could perform an siRNA knockdown screen and monitor the impact of 
the specific host factors on Ad WT and Ad ΔE1B infection by Western blot or IF. To test the 
importance of specific splice events, we could use Morpholino antisense oligos to block specific 
splice isoforms and assay the effect on Ad infection. 
In the case of hnRNP-C and RALY specifically, the eCLIP-Seq experiment proposed in 
Chapter 4.3.1 above could reveal changes in interaction of these RBPs with cellular RNAs under 
mock, Ad WT, and Ad ΔE1B conditions. The analysis of these data could reveal whether Ad 
infection changes the interaction of these RBPs with host RNAs and the potential role for 
ubiquitination in this process. This technique could also be used to investigate the alterations in 
RNA-binding patterns of any additional RBPs discovered in the RNA-Seq experiment. An 
alternative approach to identify host RBPs involved in regulating host RNA splicing during 
infection could be ChIRP-MS comparing the RNA-associated proteome for those transcripts most 
significantly altered and those unaffected upon Ad infection. This may reveal specific host RBPs 
that differentially associate with the altered but not the unaltered host RNAs when comparing 
mock, Ad WT, and Ad ΔE1B infection. The manipulation of host RNA processing goes beyond 
the manipulation of RNA splicing and should also include investigation of the block in host RNA 
export that occurs during the late stage of infection. The ChIRP-MS data could reveal export-
related proteins that associate with all host RNA species specifically during infection with Ad WT 
but not the other conditions. 
The approaches described above could help to determine whether and how Ad infection alters 
host RNA levels and processing. These experiments could also reveal a potential role for 
E1B55K/E4orf6-mediated ubiquitination in this process. In addition, Ad could function as a tool to 
understand how ubiquitination of RBPs could affect RNA processing in general. 
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4.3.3 Exploitation of additional host pathways by Ad-mediated ubiquitination 
Our approach to identify novel substrates of E1B55K/E4orf6 introduced in Chapter 3 allows for 
identification of both degradative and non-degradative ubiquitination. This allowed us to perform a 
comprehensive analysis of Ad-mediated manipulation of the host cell environment through 
ubiquitination. In addition to identifying RBPs as a major target of Ad-mediated ubiquitination, our 
data also highlight other pathways that may be redirected using this strategy. These novel Ad 
ubiquitin ligase substrates include transmembrane proteins (such as EGFR, CAR), protein 
chaperones (several heat shock proteins), other components of the host ubiquitin machinery 
(DUBs such as USP5, USP16, and USP25), proteins directing intracellular transport (several 
members of the RAB family), proteins involved in metabolism (such as citrate synthase as a 
component of the TCA cycle), and host factors important for antigen presentation (TAP1, TAP2).  
Manipulation of all these different cellular components could be beneficial for Ad infection. We 
could use a secondary screen to determine which of these ubiquitinated host proteins are of 
functional importance for Ad infection. Proteins that decrease in protein abundance upon 
ubiquitination likely represent antiviral host factors that are downregulated by the virus to 
overcome a host response. For these proteins, a suitable strategy is siRNA mediated knockdown 
or CRISPR/Cas9 mediated knockout followed by infection with WT Ad and different mutants. 
Western blot analysis could then be used to identify any impact on viral protein levels. For those 
host factors that are substrates for non-degradative ubiquitination the situation is more complex. 
While we saw a rescue for ΔE1B virus infection upon knockdown of RALY and hnRNP-C, this 
may not be the case for other proteins in this category. A better strategy would be to conduct 
several screens that include overexpression of the respective protein, expression of a version 
with K-to-R mutation of the ubiquitin sites, or even CRISPR mutation of the respective 
endogenous genes in addition to an siRNA screen. Combining the data of these screens could 
allow us to determine the importance of these proteins for Ad infection and inform which of these 
candidates merit further investigation. 
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Another approach to determine which pathways are manipulated by Ad is to identify 
substrates that are ubiquitinated by different Ad serotypes. Overlap in ubiquitinated proteins or 
targeted networks would highlight those important for viral infection. We could use a similar mass 
spectrometry strategy as introduced in Chapter 3 to compare the ubiquitinome and whole cell 
proteome during infection with human serotypes Ad5 WT, Ad5 ΔE1B, Ad4, and Ad35 in primary-
like human bronchial epithelial cells (HBEC3-KT). Furthermore, we could also analyze 
ubiquitination of host proteins facilitated by the distantly related mouse Ad serotype MAV-1 in 
mouse embryonic fibroblasts (MEF). We could use the results of these experiments to verify the 
E1B55K/E4orf6-dependent ubiquitination events during Ad5 infection that we have identified in 
Chapter 3. In addition, there are other Ad5 proteins that can induce ubiquitination. For example, 
E4orf3 recruits host proteins to PML nuclear bodies and functions as a SUMO-ligase58,63,64,235,345-
347. This can induce ubiquitination of E4orf3 interaction partners through PML resident STUBLs 
(SUMO-targeted ubiquitin ligases)348. These substrates of Ad-mediated ubiquitination would not 
have been identified by our initial mass spectrometry experiment in Chapter 3 as we only 
examined changes in ubiquitination upon E1B55K and E4orf6 expression. The additional 
serotypes in this proposed experiment have been shown to possess different substrate 
specificities for ubiquitin-mediated degradation239,240,349. Subsequently, it is likely that these 
serotypes will also show additional differences in viral-mediated ubiquitination. Comparing the 
ubiquitinome of these different serotypes will highlight common pathways manipulated by Ad 
serotypes. In particular, the comparison with the distantly related MAV-1 could highlight these 
conserved targets. In addition, this approach could also reveal any serotype-specific manipulation 
of the host environment. Depending on the outcome, this analysis may be expanded to other Ad 
serotypes with different tissue tropism that would allow us to probe tissue specific use of 
ubiquitination during Ad infection. 
Overall, the experiments highlighted in this section would support a more comprehensive 
understanding of the role of Ad-mediated ubiquitination in shaping the host cell environment. 
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4.3.4 The role of non-degradative ubiquitination for viral infection 
Our research revealed that Ad can use the same viral protein complex to facilitate both 
degradative and non-degradative ubiquitination in order to manipulate the host cell environment. 
We have used a similar proteomics approach to identify substrates ubiquitinated by the HSV-1 E3 
ubiquitin ligase ICP0. Preliminary data analysis indicates that ICP0 can also generate both 
degradative and non-degradative ubiquitination (53 predicted degraded and 142 predicted non-
degraded substrates). In both cases, non-degradative ubiquitination appears to be the 
predominant form of ubiquitination facilitated by these viral ubiquitin ligases. This highlights the 
possibility that non-degradative ubiquitination is abundantly used by viruses, especially since 
ICP0 and the E1B55K/E4orf6 complex belong to different types of viral E3 ubiquitin ligases (Type 
I for ICP0, Type II for E1B55K/E4orf6; see Chapter 1.4.2)1. Most other studies that examined viral 
mediated ubiquitination were not designed in such a way that would have allowed for 
identification of non-degradative ubiquitination. Consequently, we are likely missing insights into 
many ubiquitin-mediated functions during virus infection. This is particularly interesting as non-
degradative ubiquitin chains have very diverse functions and would allow for more targeted 
manipulation of the host cell environment than proteasomal degradation alone. Using our 
approach of combining the di-glycine remnant profiling to define the ubiquitinome combined with 
whole cell proteome analysis (or similar strategies) would allow identification of non-degraded 
substrates of viral ubiquitin ligases and should be considered in future studies to allow more 
thorough study of viral-mediated ubiquitination. These studies could also provide new insights 
into the function of ubiquitin by identifying different pathways that are regulated by ubiquitination, 
or reveal new roles of ubiquitin in those instances. There is a particularly large potential for 
defining new functions of the less commonly used ubiquitin-chain types, which have remained 
understudied so far.  
Viral E3 ubiquitin ligases also represent a useful tool to understand the determinants for 
degradative and non-degradative ubiquitination facilitated by the same ubiquitin ligase. There is 
increasing evidence that many cellular ubiquitin ligases, such as Cullin complexes, can facilitate 
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different types of ubiquitination321-323. The Ad E1B55K/E4orf6 complex or other viral ubiquitin 
ligases could be used to define how this is regulated. For example, our lab has previously used a 
large array of E1B55K mutants to determine different residues important for MRN and p53 
ubiquitination and subsequent degradation219. This resource could allow us to determine whether 
degraded and non-degraded substrates interact with different residues and domains of E1B55K 
and potentially reveal patterns that are involved in regulating the different ubiquitination 
outcomes. Cullin complexes, such as the one hijacked by E1B55K/E4orf6, commonly associate 
with E2 proteins that facilitate degradative K48 ubiquitination196. However, we have shown that 
non-K48 ubiquitin is associated with RALY and hnRNP-C during Ad infection. Therefore, 
additional E2 proteins must exist that can function with Cullin complexes to facilitate 
ubiquitination. These E2 proteins could be identified using the Ad ubiquitin ligase, either through 
siRNA mediated knockdown of different E2 proteins and probing for loss of RALY and hnRNP-C 
ubiquitination, or by IP of the viral proteins and identification of interacting proteins by mass 
spectrometry. The latter approach would also reveal if other proteins are involved in regulating 
ubiquitination of different substrates. For example, a study published earlier this year showed that 
HIV protein Vif, which hijacks a host Cullin complex, can also recruit a second E3 ubiquitin ligase 
to ubiquitinate substrates using a E1-E2-E3/E3-substrate ubiquitination mechanism350. 
The experiments discussed in this section highlight the potential of studying viral-mediated 
non-degradative ubiquitination for increasing our understanding of virus-host interaction and 
revealing new roles for ubiquitination in regulating cellular processes. These studies could also 
provide new targets for antiviral therapies as preventing non-degradative ubiquitination or 
inhibiting host proteins manipulated by viruses through this strategy may be less disruptive than 
the inhibition of the proteasome. 
 
4.4 Implications for oncolytic virus design 
Oncolytic viruses, such as Ad-based vectors, are commonly designed with two aims in mind. 
The first is specific replication of the viral vector in cancer cells followed by cell lysis. The second 
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is production of an immune signal that can overcome the anti-inflammatory environment created 
by the cancer cells and induce the immune system to attack the cancer cells. Both projects 
described in Chapter 2 and 3 of this thesis can inform better design of oncolytic Ad vectors, 
addressing both of these aims. 
While protein VII is dispensable for virion assembly and genome packaging, it is essential for 
uncoating in the endosome of the next cells153. Because of this important function in propagation 
of infection, protein VII is present in Ad-based vectors. Sequestration of HMGB1 in host 
chromatin by protein VII reduces inflammation in response to the virus. While this is beneficial for 
WT Ad infection, it is unfavorable for the purpose of an oncolytic virus. Therefore, it would be 
ideal to separate the role of protein VII in packaging viral genomes from the anti-inflammatory 
sequestration of HMGB1 in chromatin. We discovered that while protein VII from human Ad 
serotypes interacts with HMGB1, protein VII from murine serotype MAV-1 does not (See 
Appendix 2 Figure A2.1). MAV-1 protein VII still fulfills its role in packaging of Ad genomes, and 
as such separates the function in virion assembly from HMGB1 sequestration. Therefore, one 
strategy to increase the immunogenicity of Ad oncolytic vectors could be to replace the human Ad 
protein VII with its murine counterpart. This would enable HMGB1 release during infection without 
compromising virion propagation. An alternative approach could be to mutate human Ad protein 
VII to ablate HMGB1-binding. We have used the difference in HMGB1 binding between human 
and murine protein VII to map the region of human Ad protein VII that interacts with this host 
factor (See Appendix 2 Figure A2.2). These data could be used as a starting point to create more 
refined human Ad protein VII mutants that function normally in virion assembly but do not interact 
with HMGB1. 
The initial theory of using Ad as an oncolytic vector was based on ΔE1B viruses and the idea 
that these Ad mutants could replicate more efficiently in cells with defective p53. It has now been 
demonstrated that the oncolytic potential of these viruses is independent of the p53 status but 
rather relies on altered RNA processing241,242. Many cancer cells exhibit altered processing of 
RNA and exhibit changes in expression in many of the RBPs identified in our study in Chapter 
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3351,352. The insight into interaction of E1B55K/E4orf6-mediated ubiquitination and viral RNA 
processing will allow us to better define biomarkers that could predict which cells support 
replication of an Ad vector lacking E1B55K and therefore better target the use of these oncolytic 
viruses. In addition, we could further define which residues in E1B55K facilitate the interaction 
with RALY and hnRNP-C (or additional RBPs). This would enable the creation of mutant viruses 
that encode a E1B55K mutant protein that still facilitates the degradation of DDR proteins and 
p53 but does not ubiquitinate RBPs and therefore would still be dependent on altered RNA 
processing in cancer cells. 
Overall, a better understanding of how Ad interacts with its host cell will enable the design of 
better Ad-based vectors for treating disease. 
 
4.5 Concluding remarks 
Ad has long been recognized as an excellent tool for studying virus-host interactions as well 
as elucidating fundamental cellular processes. The work presented in this thesis reveals 
previously unknown strategies used by Ad to manipulate the host chromatin and RNA processing 
in favor of viral infection. Our findings and experimental approaches could serve as the basis for 
further research into the role of viral histone-like proteins and their impact on host chromatin 
structure as well as function, and the study of viral-mediated ubiquitination, especially non-
degradative ubiquitination. In addition, our work could be expanded to further improve Ad-based 
vectors used in oncolytic therapy and to investigate the regulation of host processes such as 
splicing and chromatin structure. 
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4.6 Figures 
 
Figure 4.1 | Thesis summary. a, Viruses employ many different strategies to manipulate their 
host and the focus of this thesis are two different tactics used by Ad to overcome antiviral host 
responses (chapter 2) or alter a cellular process to enable efficient infection (chapter 3). b, The 
first project of this thesis covered in chapter 2 examines the impact of Ad histone-like protein VII 
on host chromatin. We discovered that protein VII alters chromatin structure and composition, 
sequestering host alarmin HMGB1 to prevent its release from cells and downstream immune 
activation. c, Chapter 3 highlights how Ad uses E1B55K/E4orf6-mediated ubiquitination to alter 
the interaction of host proteins RALY and hnRNP-C with viral RNA. We show that non-
degradative ubiquitination of these host RBPs counteracts the detrimental effect RALY and 
hnRNP-C have on viral RNA processing. 
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APPENDIX  
Appendix 1: Differential Salt Fractionation of Nuclei to Analyze Chromatin-
associated Proteins from Cultured Mammalian Cells 
 
This chapter has been published as: 
Herrmann C, Avgousti DC, Weitzman MD. Differential Salt Fractionation of Nuclei to Analyze 
Chromatin-associated Proteins from Cultured Mammalian Cells. Bio Protoc 7 (2017). PMID: 
28845440.353 
 
A1.1 Abstract 
Nucleosomes are the core units of cellular chromatin and are comprised of 147 base pairs 
(bp) of DNA wrapped around an octamer of histone proteins. Proteins such as chromatin 
remodelers, transcription factors, and DNA repair proteins interact dynamically with chromatin to 
regulate access to DNA, control gene transcription, and maintain genome integrity. The extent of 
association with chromatin changes rapidly in response to stresses, such as immune activation, 
oxidative stress, or viral infection, resulting in downstream effects on chromatin conformation and 
transcription of target genes. To elucidate changes in the composition of proteins associated with 
chromatin under different conditions, we adapted existing protocols to isolate nuclei and 
fractionate cellular chromatin using a gradient of salt concentrations. The presence of specific 
proteins in different salt fractions can be assessed by Western blotting or mass spectrometry, 
providing insight into the degree to which they are associated with chromatin. 
 
A1.2 Background 
Many chromatin-associated proteins are insoluble under low salt conditions because of their 
charged-based interaction with DNA or histones. Since salt disrupts charged-based protein-DNA 
and protein-protein interactions, chromatin-associated proteins become more soluble with 
increasing concentration of NaCl267. Proteins strongly bound to DNA are expected to elute with 
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high salt whereas loosely bound proteins, such as transcription factors, will elute with low salt. We 
are specifically interested in how virus infection alters the composition of factors associated with 
the cellular chromatin. Nuclear replicating viruses, such as adenovirus, herpes simplex virus, and 
Epstein-Barr virus, dramatically alter the appearance of the host chromatin during 
infection155,156,158,258. We hypothesized that these changes in appearance are partly due to 
differences in protein composition of host chromatin. Changes in host chromatin could reflect 
antiviral defenses mounted by the cell or active manipulation by the virus. To compare 
association of proteins with chromatin in uninfected and infected cells we developed this protocol 
to fractionate nuclei using a salt gradient (Figure A1.1). In this protocol we isolate nuclei, digest 
the DNA down to mono-nucleosome length, and then wash the nuclei with increasing 
concentrations of salt, collecting each fraction for analysis by Western blotting. We recently used 
this protocol to elucidate changes to cellular chromatin during infection with adenovirus258. We 
now present this protocol as a general approach to monitor association of proteins with chromatin 
under a wide range of perturbing conditions. 
 
A1.3 Materials and Reagents 
Note: Comparable reagents from different suppliers may be used for the protocol. 
1. 150 mm tissue culture dishes (Corning, Falcon®, catalog number: 353025) 
2. 15 ml centrifuge tube (Corning, catalog number: 430790) 
3. 5 ml pipettes (VWR, catalog number: 89130-908) 
4. Transfer pipette (Denville Scientific, catalog number: P7222) 
5. 30 ml glass tube (Corning, Corex®, catalog number: 1-8445-30) 
Note: This product has been discontinued. 
6. 1.7 ml microcentrifuge tubes (VWR, catalog number: 87003-294) 
7. Pipette tips 
o 0.1-10 μl (Corning, catalog number: 4153) 
o 1-200 μl (Corning, catalog number: 4126) 
o 100-1,000 μl (Corning, catalog number: 4129) 
8. 250 ml sterile disposable filter units with 0.2 μm PES membrane (Thermo Fisher Scientific, 
Thermo Scientific ™, catalog number: 568-0020) (used for Buffer I and Buffer II) 
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9. 60 ml syringe (BD, catalog number: 309653) (used for Buffer IV.80, IV.150, IV.300 and 
IV.600) 
10. 25 mm syringe filter (Pall, catalog number: 4612) (used for Buffer IV.80, IV.150, IV.300 and 
IV.600) 
11. A549 cells (ATCC, catalog number: CCL-185) 
12. Ham's F-12K cell culture media (Thermo Fisher Scientific, Gibco™, catalog number: 21127-
022) 
13. Fetal bovine serum (FBS) (VWR, catalog number: 89510-182) 
14. Penicillin-streptomycin (Pen/Strep) (Thermo Fisher Scientific, Gibco™, catalog number: 
15140-122) 
15. Trypsin-EDTA (0.25%) (Thermo Fisher Scientific, Gibco™, catalog number: 25200-056) 
16. Phosphate buffered saline (PBS) (Mediatech, catalog number: 21-030-CM) 
17. Liquid nitrogen 
18. NP-40/IGEPAL® CA-630 (Sigma-Aldrich, catalog number: I8896) (10% stock solution in H2O) 
19. Phenylmethanesulfonyl fluoride (PMSF) (Sigma-Aldrich, catalog number: P7626) (0.1 M 
stock solution in isopropanol) 
20. 1,4-dithiothreitol (DTT) (Sigma-Aldrich, catalog number: 10197777001) (1 M stock solution in 
HEPES buffer, pH 7.75) 
21. Protease inhibitor cocktail (Roche Diagnostics, catalog number: 11697498001) (prepared as 
50×stock solution in H2O according to manufacturer instructions) 
22. Micrococcal nuclease (MNase) (Sigma-Aldrich, catalog number: N3755) (0.2 U/μl stock 
solution in H2O) 
23. Ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid (EGTA) (Sigma-Aldrich, 
catalog number: E3889) (0.1 mM stock solution in H2O, pH = 10) 
24. PCR purification kit (QIAGEN, catalog number: 28104) 
25. Orange G (Sigma-Aldrich, catalog number: O3756) (0.35% [w/v] orange G with 30% [w/v] 
sucrose in H2O for 6× stock solution) 
26. 100 bp DNA ladder (New England Biolabs, catalog number: N3231) 
27. Broad range protein ladder (Thermo Fisher Scientific, Thermo Scientific TM, catalog number: 
26623) 
28. GelRed nucleic acid gel stain (Biotum, catalog number: 41003) 
29. LDS sample buffer (4×) (Thermo Fisher Scientific, Novex™, catalog number: NP0007) 
30. Sucrose (Fisher Scientific, catalog number: BP220-1) 
31. Potassium chloride (KCl) (Sigma-Aldrich, catalog number: P9541) (1 M stock solution in H2O) 
32. Sodium chloride (NaCl) (Sigma-Aldrich, catalog number: S9625) (5 M stock solution in H2O) 
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33. Magnesium chloride hexahydrate (MgCl2·6H2O) (Sigma-Aldrich, catalog number: M2670) (1 
M stock solution in H2O) 
34. Trizma base (Sigma-Aldrich, catalog number: T1503) (1 M stock solution in H2O adjusted to 
pH 7.4 with HCl) 
35. UltraPure agarose (Thermo Fisher Scientific, Invitrogen™, catalog number: 16500500) 
36. Hydrochloric acid 6.0 N solution (HCl) (Fisher Scientific, catalog number: MK-H168-4) 
37. Calcium chloride dihydrate (CaCl2·2H2O) (Sigma-Aldrich, catalog number: C5080) (0.5 M 
stock solution in H2O) 
38. Triton X-100 (Sigma-Aldrich, catalog number: T8787) 
39. HEPES (Sigma-Aldrich, catalog number: H3375) (1 M stock solution in H2O adjusted to pH 
7.9 with NaOH) 
40. Sodium hydroxide (NaOH) (AMRESCO, catalog number: M137) 
41. Buffer I.A and I.B (see Recipes) 
42. Buffer II (see Recipes) 
43. Buffer III.A and III.B (see Recipes) 
44. Buffer IV.80, IV.150, IV.300 and IV.600 (see Recipes) 
45. Hypotonic buffer (see Recipes) 
 
A1.4 Equipment 
Note: Equipment with similar properties may be used for the protocol, however, we recommend 
using a specific kind of reusable centrifuge tubes (listed in 5) to ensure high quality isolation of 
nuclei. 
1. CO2 incubator for cell culture (BINDER, catalog number: 9040-0082) 
2. Benchtop centrifuge (Beckman Coulter, model: Allegra X-14R) 
3. Rotors for benchtop centrifuge (Beckman Coulter, models: SX4750 for tissue culture and 
FX6100 for 10,000 ×; g spins, or seminal rotors suitable for high speeds) 
4. Adapters for FX6100 rotor (Beckman Coulter, catalog number: 392830) 
5. 30 ml reusable centrifuge tubes (Sigma-Aldrich, catalog number: T2793) 
6. Tabletop centrifuge 5424 R (Eppendorf, model: 5424 R) 
7. 1 ml tissue grinder (Dounce homogenizer) with tight fitting pestle (Ace Glass Incorporated, 
catalog number: 8343-01) 
8. Water bath (Fisher Scientific, model: Isotemp™ Digital-Control Water Baths Model 215, 
catalog number: 15-462-15Q) 
9. Tube rotator (VWR, catalog number: 10136-084) 
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10. Pipettes 
o 1-10 μl (Gilson, catalog number: F144055P) 
o 2-20 μl (Gilson, catalog number: F144056M) 
o 20-200 μl (Gilson, catalog number: F144058M) 
o 100-1,000 μl (Gilson, catalog number: F144059M) 
11. Agarose gel electrophoresis systems (Thermo Fisher Scientific, Thermo Scientific™, model: 
Owl EasyCast B1A system) 
12. Fluorescence and chemiluminescence gel imaging system (Syngene, model: G:BOX Chemi 
XT4) 
13. Heat block (Fisher Scientific, model: Isotemp™ Digital Dry Baths/Block Heaters, catalog 
number: 88-860-022) 
14. Protein electrophoresis apparatus (Bio-Rad Laboratories, model: Mini-PROTEAN® Tetra 
Vertical Electrophoresis Cell for Mini Precast Gels, catalog number: 1658005) 
15. Western blot apparatus (Thermo Fisher Scientific, model: SureLock™ Mini-Cell 
Electrophoresis System) 
 
 
A1.5 Software 
1. ImageJ (freely available from National Institutes of Health, https://imagej-nih-
gov.proxy.library.upenn.edu/ij/) 
 
A1.6 Procedure 
A1.6.A Cell culture 
Note: This protocol was optimized for nuclear isolation and chromatin fractionation of roughly 4 × 
107 A549 cells (for A549 cells that is approximately two 100% confluent 150 mm cell culture 
dishes). This number of cells was chosen for efficient nuclear isolation as described in Procedure 
B. This protocol can be used for other cell types but should be optimized accordingly. 
1. For each condition, grow roughly 4 × 107 A549 cells in F-12K media with 10% FBS and 1% 
Pen/Strep. 
Note: Time treatments such that the required cell number is reached at time of harvest. 
2. Harvest cells using trypsin and combine into one 15 ml tube per condition. 
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3. Centrifuge for 2 min, 500 × g, room temperature using benchtop centrifuge (Allegra X-14R 
with rotor SX4750). 
4. Wash cells once with 10 ml of PBS and centrifuge again for 2 min, 500 × g, room 
temperature. 
5. Aspirate as much of the supernatant as possible without disturbing the cell pellet. 
6. Flash freeze samples in liquid nitrogen. 
7. Store samples at −80 °C until ready to process. 
A1.6.B Nuclear isolation 
Note: This section describes two alternative methods for nuclear isolation. The procedure 
detailed in B1 yields a clean nuclear fraction but B2 is recommended for highly mobile nuclear 
proteins that are lost from the nuclear fraction when mild detergents are used as described in B1 
(see example in Figure A1.2).  
1. Nuclear isolation using mild detergent and sucrose cushion. 
Note: This section describes permeabilizing the cell membrane using a mild detergent (NP-40), 
followed by separation of the nuclei from cytoplasmic debris by sucrose cushion. The sucrose 
cushion consists of a layer with 1.2 M sucrose at the bottom (Buffer II) and a layer with 0.32 M 
sucrose on top (Buffer I, Figure A1.3A). The nuclei are more dense than the 1.2 M sucrose buffer 
and will pellet at the bottom of the tube while the less dense cytoplasmic debris will remain in the 
upper sucrose layer (Figure A1.3B). 
 
a. Thaw cells on ice (about 10 min until pellet is loose). 
b. In the meantime, prepare one aliquot each of Buffer I.A and I.B by addition of PMSF, 
DTT, and protease inhibitor cocktail immediately before use (see Recipes for final 
concentrations). Add NP-40 to Buffer I.B. 
c. Gently resuspend cells in 2 ml of Buffer I.A using a 5 ml pipette. Avoid the formation 
of bubbles. 
d. Set aside 50 μl of the cell suspension in a new tube labeled ‘cells fraction’. 
e. Add 2 ml of Buffer I.B containing NP-40 to the 2 ml of cell suspension and mix gently 
by inverting the tube 2-3 times. 
f. Incubate samples on ice for 10 min. Mix gently by inverting after 5 min. 
g. Pipette 8 ml of ice-cold Buffer II into 30 ml reusable centrifuge tubes (one per 
sample). 
h. Carefully layer cell suspension onto Buffer II (Figure A1.3A). 
137 
 
i. If the number of tubes is even, balance the tubes with Buffer I.A before 
centrifugation. If the number of tubes is uneven, use an additional tube containing 
water as balance. 
j. Centrifuge for 20 min, 10,000 × g, 4 °C using benchtop centrifuge (Allegra X-14R with 
rotor FX6100) with low brakes (deceleration setting 1 for this centrifuge model, 5-10 
min of deceleration for other centrifuge models) to avoid disruption of pellet. 
Note: Use the adapters listed in the Equipment section under 4 to fit the 30 ml 
reusable centrifuge tubes into the FX6100 rotor. The nuclei form a dense pellet at the 
bottom of the tube while the cytoplasmic debris remains in the upper sucrose layer, 
Figure A1.3C. 
k. Carefully remove the supernatant using a transfer pipette. Keep pellet containing the 
nuclei and proceed to Procedure C. 
2. Nuclear isolation by manual disruption 
Note: Using mild detergents such as NP-40 for nuclear isolation is important to ensure that 
the nuclear membrane remains largely intact. In some cases, highly mobile nuclear proteins 
such as HMGB1273 may diffuse out of the nucleus upon isolation with this method. To prevent 
loss of these proteins from the nuclear fraction, we adapted an alternative method that relies 
on a hypotonic buffer and subsequent manual disruption of the cell membrane using a 
Dounce homogenizer. The short centrifugation times in this step minimize diffusion of these 
proteins out of the nuclei (Figure A1.2). 
a. Thaw cells on ice (about 10 min until pellet is loose). 
b. Gently resuspend cells in 1 ml of hypotonic buffer and transfer into a 1.7 ml tube 
using a P1000 pipette with the tip cut (or wide orifice pipette tips) to avoid disrupting 
the cellular membranes. 
c. Set aside 25 μl of the cell suspension in a new tube as ‘cells fraction’. 
Note: This is proportional to the 50 μl aliquot taken from 2 ml of cell suspension in 
step B1. 
d. Incubate on ice for 30 min. 
e. Pre-cool the Dounce homogenizer and the pestle on ice for at least 5 min. 
f. Transfer the cell suspension to cold Dounce homogenizer using a transfer pipette. 
g. Disrupt the cell membrane using 40 strokes of the tight-fitting pestle. Minimize the 
formation of bubbles. 
h. Transfer sample to 1.7 ml tube using a transfer pipette. 
i. Centrifuge for 5 min, 1,500 × g, 4 °C using a tabletop centrifuge. 
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j. Carefully remove the supernatant using a P1000 pipette. Transfer supernatant and 
label as ‘cytosol fraction’ if desired. Keep pellet containing the nuclei and proceed to 
Procedure C. 
Note: The nuclei form a loose pellet at the bottom of the tube that can be easily disturbed. The 
cytoplasmic fraction in step B1 is too dilute to isolate as a result of the sucrose cushion. 
A1.6.C Micrococcal nuclease digestion 
Note: In this step the DNA is digested to the length of mono-nucleosomes (roughly 150 bp) using 
MNase. While partial MNase digest in combination with nuclear fractionation by salt gradient can 
be used to separate euchromatin from heterochromatin267, our protocol aims to identify global 
association of proteins with chromatin and does not distinguish between different types of 
chromatin. Subsequently, it is important that the DNA is completely digested into mono-
nucleosomes to break up chromatin and allow for elution of all soluble proteins in Procedure D 
(Figure A1.4). EGTA is used instead of EDTA to stop the MNase digestion as EGTA 
preferentially chelates Ca2+ ions that are necessary for MNase enzymatic activity but does not 
impact Mg2+ ions important for protein-protein interactions. Proteins loosely bound to chromatin 
elute during MNase digest and can be detected in the supernatant collected in this section of the 
protocol. 
1. Prepare and cool Buffer III.A and III.B. 
2. Add 400 μl Buffer III.A to the nuclei. 
3. Gently resuspend the nuclei using a P1000 pipette with the tip cut (or wide orifice pipette tips) 
to avoid disrupting the nuclear membranes. 
4. Add 5 μl of MNase (1 U) and incubate at 37 °C (in a water bath) for 30 min. 
5. Mix every 10 min by gently inverting the tube 2-3 times. 
6. After 30 min add 25 μl of ice-cold 0.1 M EGTA to stop the digest. 
7. Set aside a 60 μl aliquot of the nuclear suspension as ‘nuclei fraction’ and for DNA isolation 
to confirm the sufficient digest of DNA (described in Procedure E). 
8. Centrifuge for 10 min, 400 ×; g, 4 °C. 
9. Transfer supernatant to fresh tube and label ‘MNase fraction’. 
10. Wash the nuclei once by resuspending them in 400 μl Buffer III.B. 
11. Centrifuge again for 10 min, 400 ×; g, 4 °C. Discard the supernatant. 
A1.6.D Chromatin fractionation 
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Note: In this step the nuclei are further fractionated using buffers with increasing amounts of 
NaCl. Proteins only weakly bound to DNA are expected to be soluble under low salt conditions 
and will elute from nuclei in the buffers with low NaCl concentration. Proteins tightly bound to 
chromatin only become soluble under high salt conditions and only elute from nuclei in the buffers 
with high NaCl concentration. 
1. Gently resuspend the nuclei in 400 μl Buffer IV.80 using a P1000 pipette with the tip cut (or 
wide orifice pipette tips). 
2. Rotate at 4 °C for 30 min. 
3. Centrifuge for 10 min, 400 ×; g, 4 °C. 
4. Transfer supernatant to fresh tube and label ‘80 mM fraction’. 
5. Repeat steps D1-D4 with Buffer IV.150, IV.300 and IV.600 in that order. Keep the 
supernatants as fractions ‘150 mM’, ‘300 mM’ and ‘600 mM’, respectively. 
6. Prepare samples for Western blot immediately (see Table A.1) or store at −20 °C. 
 
A1.6.E DNA isolation and DNA gel 
Note: In this step DNA is isolated from the samples after MNase digestion to test the length of 
DNA fragments. The goal is to digest the DNA down to mono-nucleosome level of around 150 bp 
to ensure optimal chromatin fractionation (Figure A1.4). It is important that orange G or another 
small molecular weight dye is used for loading the DNA. Commonly used DNA loading dyes such 
as bromophenol blue run around the same size as 150 bp of DNA and may obscure the results. 
 
1. Dilute 10 μl of the ‘nuclei’ fraction in 90 μl H2O for better DNA purification. 
2. Use a PCR purification kit to isolate the DNA from this sample following the kit instructions. 
Elute the DNA in 30 μl of H2O. 
3. Take out 5 μl (about 5 μg) of DNA and add 1 μl of 6× Orange G. Keep the rest of the DNA on 
ice until results are finalized or freeze at −20 °C. 
4. Run samples and a 100 bp ladder on a 2% agarose gel containing 1×GelRed at 100 V for 1 
h. 
5. Visualize the DNA using gel imager and check for prominent DNA band of around 150 bp 
with minimal DNA laddering (Figure 4). 
A1.6.F Verifying the quality of nuclear fractionation by Western blot 
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Note: The quality of the nuclear fractionation can be analyzed using SDS-PAGE combined with 
Western blotting (Figure 1G). Efficient nuclear isolation can be tested by probing for proteins such 
as tubulin that are only found in the cytoplasm. The quality of chromatin fractionation can be 
tested by probing for histone proteins such as histone H3 or proteins expected to bind histone 
tails such as bromodomain containing protein Brd1354. The interaction of the histone H3 and Brd1 
with chromatin should only be disrupted under high salt conditions. In addition, proteomics can be 
performed to identify changes to global chromatin composition under different conditions. Further 
details concerning mass spectrometry of salt fractions can be found in (Avgousti et al., 2016258). 
1. Prepare samples for analysis by Western blotting according to Table 1. 
2. Denature samples at 95 °C (in a heat block) for 10 min. 
3. Analyze 15 μl of each sample via SDS-PAGE and Western blot. Probe for tubulin and histone 
H3 as controls. 
 
A1.7 Data analysis 
To compare the association of a protein of interest with chromatin under different conditions, 
the samples should be run on the same SDS-PAGE gel and Western blot as different exposures 
may confound the interpretation. Expected results for various proteins are described here to aid in 
data analysis, though each protein of interest tested should be considered separately. The ‘cells’ 
fraction represents the total amount of protein in a sample for relative comparison with other 
fractions. A cytoplasmic protein such as tubulin should only be present in the ‘cells’ fraction 
(Figure 1G). Nuclear proteins should also be present in the ‘nuclei’ fraction as seen for H3 and 
Brd1 (Figure 1G). The band intensity for the remaining fractions represents the solubility of 
nuclear proteins under these conditions. H3 and Brd1 have the highest band intensity in the ‘600 
mM’ fraction, signifying greater solubility under high salt conditions typical for chromatin-
associated proteins. For HMGB1 the highest band intensity can be observed for the ‘MNase’ and 
‘80 mM’ fraction, indicating solubility under low salt conditions, suggesting weak association with 
chromatin. Differences in band intensity for different fractions can be quantified using ImageJ 
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(freely available from National Institutes of Health, https://imagej-nih-
gov.proxy.library.upenn.edu/ij/). 
Details concerning data analysis for mass spectrometry of salt fractions can be found in 
(Avgousti et al., 2016258). 
 
A1.8 Notes 
This protocol is suitable to compare changes in the chromatin-associated proteome under 
different conditions. We have used this method to show changes to cellular chromatin during 
infection with adenovirus258. 
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A1.9 Figures 
Figure A1.1 | Schematic of nuclear fractionation and example Western blot. A. Roughly 4 × 
107 cells are prepared per condition. B. Plasma membranes are permeabilized and nuclei are 
isolated either by sucrose cushion (step B1) or using a Dounce homogenizer (step B2). C. DNA is 
digested to mono-nucleosome length using MNase. Proteins loosely bound to chromatin elute 
during this step. D. The chromatin is further fractionated by washing the nuclei in buffers with 
increasing salt concentration. E. The DNA is isolated from nuclei to confirm digestion of the 
cellular genome to 150 bp fragments. F. The quality of fractionation is tested using SDS-PAGE 
and Western blot (WB) for control proteins (e.g., tubulin, histone H3). The grey colored 
supernatants (and the pellet in case of the nuclei) represent the samples used for Western blot 
analysis. G. Example Western blot analysis of chromatin fractionation. Tubulin is found only in the 
cytoplasmic fraction and is a suitable control to test the quality of nuclear isolation. Histone H3 is 
a component of cellular chromatin and only elutes from nuclei in buffers with high salt. HMGB1 is 
a highly mobile nuclear protein and thus elutes during MNase digest and under lower salt 
conditions. Brd1 directly binds to histone tails and elutes under high salt conditions. 
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Figure A1.2 | Fractionation of nuclear protein HMGB1 can differ depending on the method 
of nuclear isolation. Western blot of chromatin fractionation of A549 cells using different 
methods of nuclear isolation. HMGB1 is lost from nuclei during nuclear isolation B1 using NP-40 
and a sucrose cushion. HMGB1 is retained in the nuclear fraction during isolation of nuclei with 
the alternative method described in step B2. 
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Figure A1.3 | Intermediate steps of nuclear isolation. A, Layers of the sucrose cushion. 1 = 
cells resuspended in Buffer I containing 0.32 M sucrose. 2 = Buffer II containing 1.2 M sucrose. 
Clear glass tube was used for better visibility of the two layers. B, Layers of sucrose cushion as 
seen before the centrifugation step in the 30 ml reusable tube. Layer 1 = Buffer I. Layer 2 = Buffer 
II. C, Layers of sucrose cushion as seen after the centrifugation step in the 30 ml reusable tube. 
Layer 1 = Buffer I. Layer 2 = Buffer II. D and E, Pellet of nuclei after spin at 10,000 × g indicated 
by red arrow. The buffers were removed before these pictures were taken. 
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Fraction Sample H2O 4× LDS sample buffer with 10% DTT 
cells (from B1) 10 μl 20 μl 10 μl 
cells (from B2) 5 μl 25 μl 10 μl 
nuclei 10 μl 20 μl 10 μl 
MNase 30 μl - 10 μl 
80 mM 30 μl - 10 μl 
150 mM 30 μl - 10 μl 
300 mM 30 μl - 10 μl 
600 mM 30 μl - 10 μl 
Table A1.1 | Preparation of different fractions for Western blot. 
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Figure A1.4 | Digestion of cellular DNA using MNase. Agarose gel analysis of DNA extracted 
from nuclei during a time course of MNase treatment. The position of DNA bands corresponding 
to mono-, di- and tri-nucleosomes are indicated on the left while the DNA size in base pairs (bp) 
is indicated on the right. Without MNase digestion (0 min), cellular DNA barely enters the agarose 
gel because of the large size of the DNA molecules. After 1 min of MNase digestion, DNA 
fragments show the characteristic banding pattern of multiples of 150 bp. After 5 min the DNA 
fragments correspond to one to three nucleosomes in length. After 30 min most DNA fragments 
are close to 150 bp, indicating the desired digestion of cellular DNA necessary for optimal 
chromatin fractionation. The high concentration of DNA causes the slightly lower shift of the 
mono-nucleosome band. The nuclei used for this time course were isolated using method B.1. No 
differences in MNase digestion efficiency have been observed with nuclei isolated using method 
B.2. 
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A1.10 Recipes 
1. Buffer I.A and I.B 
• 0.32 M sucrose 
• 60 mM KCl 
• 15 mM NaCl 
• 5 mM MgCl2 
• 0.1 mM EGTA 
• 15 mM Tris pH 7.4 
• Filtered and stored at 4 °C 
• Add fresh: 
• 0.5 mM DTT 
• 0.1 mM PMSF 
• 1× protease inhibitor cocktail 
• Add only to Buffer I.B: 
• 0.1% NP-40 
2. Buffer II 
• 1.2 M sucrose 
• 60 mM KCl 
• 15 mM NaCl 
• 5 mM MgCl2 
• 0.1 mM EGTA 
• 15 mM Tris pH 7.4 
• Filtered and stored at 4 °C 
• Add fresh: 
• 0.5 mM DTT 
• 0.1 mM PMSF 
• 1× protease inhibitor cocktail 
3. Buffer III.A and III.B 
• 10 mM Tris pH 7.4 
• 2 mM MgCl2 
• 0.1 mM PMSF 
• Add only to Buffer III.A: 
• 5 mM CaCl2 
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4. Buffer IV.80, IV.150, IV.300 and IV.600 
• 10 mM Tris pH 7.4 
• 2 mM MgCl2 
• 2 mM EGTA 
• 0.1% Triton X-100 
• Add the following concentrations of NaCl to the individual buffers: 
• 70 mM Buffer IV.80 
• 140 mM Buffer IV.150 
• 290 mM Buffer IV.300 
• 590 mM Buffer IV.600 
• Filtered and stored at 4 °C 
• Add fresh: 0.1 mM PMSF 
5. Hypotonic buffer 
• 10 mM HEPES pH 7.9 
• 1.5 mM MgCl2 
• 10 mM KCl 
• 0.1 mM PMSF 
• 0.5 mM DTT 
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Appendix 2: Mapping the protein VII-HMGB1 interaction and determining the role 
of HMGB1 for intracellular steps of Ad infection 
 
A2.1 Introduction 
We have demonstrated that histone-like protein VII from human Adenovirus 5 (Ad5) localizes 
to and alters cellular chromatin258. Furthermore, this viral protein sequesters members of the 
HMGB family of proteins in chromatin, preventing their release upon immune stimulation, and 
downstream inflammatory response mediated through these host alarmins. In addition to the role 
in the immune response, HMGB1 also fulfills several functions within the host cell260. HMGB1 can 
bind to and bend DNA, facilitating both nucleosome mobility and the binding of transcription 
factors to their target genes. As such, HMGB1 is involved in regulating chromatin structure, DDR, 
and transcription260. We hypothesized that by immobilizing HMGB1 in chromatin, protein VII 
manipulates these intracellular functions of HMGB1. This could contribute to the changes in host 
chromatin structure, DDR, and, potentially, transcription facilitated by protein VII151,258. Ultimately, 
manipulation of the cell intrinsic functions of HMGB1 could represent another strategy employed 
by protein VII to support Ad infection. To test this, we further characterized the interaction of 
protein VII with HMGB1 and defined the domains in both proteins that facilitate binding. We also 
created HMGB1 KO cell lines using CRISPR/Cas9 and determined the consequence of HMGB1 
deletion on different stages of Ad infection. We further used these HMGB1 KO cell lines to 
determine the contribution of HMGB1 to protein VII mediated changes in nuclear structure and 
DDR inhibition (these experiments have been published as part of Avgousti et al., JVI, 2017151 
and will not part of this chapter). We also investigated the impact of protein VII on expression of 
IFNβ and ISGs upon immune activation, and examined the role of HMGB1 in this process. 
 
A2.2 Results 
A2.2.1 Protein VII from human but not mouse adenovirus immobilizes HMGB1 in chromatin 
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In our initial study of protein VII functions in host chromatin, we tested how conserved the 
interaction between protein VII and HMGB1 is among different Ad serotypes. Infections by all 
human serotypes examined resulted in chromatin retention of HMGB1. However, when we 
infected mouse embryonic fibroblasts (MEFs) with mouse adenovirus serotype MAV-1 we 
discovered that HMGB1 does not become immobilized in chromatin during infection with this Ad 
serotype (Figure A2.1a). To verify that this phenotype is not caused by differences in cell type or 
infection between the mouse and human adenovirus, we created an A549 cell line encoding 
inducible of MAV-1 protein VII. We then compared HMGB1 retention by chromatin fractionation 
followed by Western blot for control, Ad5 protein VII-HA, and MAV-1 protein VII-HA. This analysis 
revealed that only the expression of Ad5 protein VII-HA leads to the retention of HMGB1 in high-
salt chromatin fractions, consistent with the results observed during infection (Figure A2.1b). We 
also compared the impact of the different protein VII versions on chromatin structure and changes 
in HMGB1 localization. Under control conditions, HMGB1 has a pan-nuclear localization with 
enrichment in nucleoli. Expression of Ad5 protein VII-HA altered the nuclear architecture, as 
shown previously258, and caused changes in HMGB1 localization to distinct structures in the 
nucleus that overlap with protein VII staining. MAV-1 protein VII-HA was also able to alter nuclear 
morphology, even though this pattern was distinct from the one induced by the Ad5 version. 
HMGB1 does not co-localize with the mouse protein VII-HA. Instead the host protein seems to be 
excluded from the areas with the highest levels of MAV-1 protein VII-HA (Figure A2.1c). These 
experiments demonstrated that protein VII from human and mouse adenovirus serotypes differ in 
their ability to bind and sequester HMGB1 in chromatin. 
A2.2.2 The N-terminus of Ad5 protein VII binds to HMGB1 
After confirming that protein VII from Ad5 but not MAV-1 immobilized HMGB1 in chromatin, we 
wanted to use this difference between the two viral proteins to map the interaction of Ad5 protein 
VII with HMGB1. We first determined the homology between the human and mouse version of 
protein VII and revealed only limited sequence identity between them, with the highest overlap in 
the N-terminal region (Figure A2.2a). We then made four different chimeras between Ad5 and 
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MAV-1 protein VII to test which domain of human protein VII can interact with HMGB1 (Figure 
A2.2b). When we introduced these chimeras into our inducible A549 system, we discovered that 
all of the chimeras induce changes in nuclear architecture, indicating that these chimeric viral 
histone-like proteins retain their ability to alter host chromatin (Figure A2.2c). Interestingly, the 
localization of the chimeras inside the nucleus was not the same. Chimeras 1 and 2 localized to 
distinct areas within the nucleus, reminiscent of WT MAV-1 protein, while chimeras 3 and 4 were 
more nucleoplasmic, similar to WT Ad5 protein VII (Figure A2.1c). Regarding HMGB1, only the 
first two chimeras were able to induce relocalization of HMGB1 while for the last two HMGB1 
appeared to be excluded from areas of protein VII accumulation (visualized in Figure A2.2c, 
summarized in Figure A2.2b). We concluded that the Ad5 protein VII N-terminus interact with 
HMGB1 as this domain is shared between chimeras 1 and 2. To confirm this, we generated a 
construct for Ad5 protein VII amino acids 1-66 tagged with GFP. We then expressed this 
truncated version of protein VII in A549 cells, performed a GFP-IP, and probed for HMGB1 co-
immunoprecipitation by Western blot. This showed that amino acids 1-66 of Ad5 protein VII can 
pull-down HMGB1, similar to or better than full-length human protein VII (Figure A2.2d). 
A2.2.3 Ad5 protein VII interacts with the HMGB1 A-box in cells 
After determining that the Ad5 protein VII N-terminus is responsible for binding to HMGB1, we 
wanted to determine which domain of HMGB1 is involved in this interaction. HMGB1 has three 
distinct domains: the A-box, the B-box, and the acidic tail260. We created GFP tagged versions of 
these different domains and combinations thereof (Figure A2.3a). All of these HMGB1 constructs 
showed a pan-nuclear pattern when transfected into control A549 cells. Upon induction of Ad5 
protein VII expression, only HMGB1 constructs containing the A-box were relocalized to the 
protein VII pattern (visualized in Figure A2.3b, summarized in Figure A2.3a). Next, we wanted to 
confirm that protein VII can immobilize the HMGB1 A-box in chromatin. We expressed the A-box-
GFP construct in control or protein VII expressing cells and performed FRAP. In control cells, the 
fluorescence of the bleached spot is rapidly recovered, indicating that the HMGB1 A-box is highly 
mobile in these cells. Upon expression of protein VII the signal upon bleaching recovered much 
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slower, demonstrating that under these conditions the HMGB1 A-box is immobilized (Figure 
A2.3c). These experiments indicate that in cells interaction between protein VII and the HMGB1 
A-box is sufficient to retain the host protein in chromatin. 
A2.2.4 Protein VII binds to the HMGB1 acidic tail in vitro 
To confirm the interaction between protein VII and the HMGB1 A-box in vitro, we created 
several HMGB1 constructs for the separate domains tagged with GST and purified them from 
bacteria (Figure A2.4a). We then incubated these GST-HMGB1 constructs with purified protein 
VII-His, performed a GST pull-down and probed for interaction by both Coomassie staining and 
Western blot. Surprisingly, only the full-length HMGB1 and the acidic C-terminus were able to 
pull-down protein VII-His, but not the HMGB1 A-box (Figure A2.4b). These results demonstrate 
that while the HMGB1 A-box is sufficient for protein VII interaction in cells, in vitro it is the acidic 
HMGB1 C-terminus that directly binds to protein VII.  
A2.2.5 HMGB1 knockout does not impact any stage of Ad infection 
To determine the contribution of intracellular functions of HMGB1 to adenovirus infection, we 
used CRISPR/Cas9 to create several HMGB1 knockout (KO) cells lines. We confirmed HMGB1 
deletion by both Western blot for the protein and RT-qPCR for RNA (Figure A2.5a). We then 
compared expression of Ad proteins over a time course of infection with Ad WT in the HMGB1 
WT and several KO cell lines. While KO1 showed a decrease in production of late proteins 
(Hexon, Penton, Fiber, and protein VII), we did not observe this reduction in the other two KO cell 
lines (Figure A2.5b). As these cell lines were generated from single cells, we concluded that 
HMGB1 KO1 possessed additional background mutations that caused the decrease in viral late 
protein production, and used KO2 and KO3 for all other assays. We then tested the effect of 
HMGB1 KO on viral RNA production by RT-qPCR, genome replication by qPCR, and progeny 
production by plaque assays (Figure A2.5c-e). All these experiments were carried out over a 
time course for both HMGB1 KO2 and KO3 as compared to the parental cell line. None of these 
experiments displayed any significant difference for the examined stages of Ad infection upon 
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HMGB1 deletion. We therefore concluded that protein VII-mediated recruitment of HMGB1 does 
not directly contribute to Ad infection during a single infectious cycle. 
A2.2.6 Protein VII expression suppresses INFβ expression in an HMGB1-dependent manner 
Even though HMGB1 was dispensable for Ad replication, we hypothesized that it may 
contribute to infection by supporting a protein VII function in the genome that would not be 
apparent through assays that only look at a single infectious cycle. To test this hypothesis, we 
first wanted to define any additional functions of the Ad viral histone-like protein. We found that in 
addition to altering nuclear architecture, protein VII on host chromatin can suppress induction of 
the DDR, reminiscent to its function on viral genomes144,151. When we repeated these assays in 
HMGB1 KO cell lines we observed that protein VII was still able to suppress the DDR. In addition, 
we also noticed that even upon deletion of HMGB1, protein VII still able to alter nuclear 
morphology. This indicates that both of these protein VII functions, the suppression of the DDR 
and changing host chromatin, are HMGB1-independent151. 
As protein VII directly binds to and alters cellular chromatin, we proposed that this could 
impact the cellular transcription, including expression of antiviral proteins. We therefore tested 
whether protein VII could alter the expression of cellular genes involved in the immune response. 
We transfected control and protein VII expressing cells with the dsDNA analog poly(dA:dT) and 
measured induction of INFβ at baseline and 8 hours post-treatment. We discovered that protein 
VII expression dramatically reduced INFβ RNA levels at both time points, indicating that protein 
VII interferes with the immune response towards dsDNA, the same molecular danger signal that 
is introduced into cells during Ad infection (Figure A2.6a). To determine whether chromatin 
association was necessary for this effect of protein VII, we repeated the experiment in the protein 
VII ΔPTM cell line. This protein VII mutant protein localizes to nucleoli and does not alter nuclear 
morphology. Expression of protein VII ΔPTM did not cause a no significant reductions in INFβ 
expression compared to control cells (Figure A2.6a). This suggests that protein VII needs to be 
associated with host chromatin to suppress the immune response, even though other functions of 
the PTMs may also contribute to the phenotype. 
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We proposed that protein VII may also interfere with expression of other immune genes 
downstream of IFNβ. Therefore, we treated control and protein VII cells with type I IFN and 
measured the level of induction for several ISGs. None of the examined ISGs showed significant 
differences in RNA levels upon protein VII expression (Figure A2.6b). We therefore concluded 
that protein VII specifically blocks IFNβ expression.  
Next, we wanted to determine whether HMGB1 contributes to the suppression of IFNβ 
production. We transduced WT and HMGB1 KO cells with control or protein VII-GFP encoding 
vectors and transfected them with poly(dA:dT) to induce an immune response. While protein VII-
GFP was able to decrease IFNβ RNA levels in the parental cells, there was no significant 
difference in HMGB1 KO cells. 
In conclusion, our data revealed that while HMGB1 is dispensable for virus replication, 
suppression of the DDR, and large-scale changes in nuclear morphology, this host protein may 
contribute to protein VII-mediated suppression of IFNβ upon dsDNA-mediated stimulation of host 
immune responses. 
 
A2.3 Discussion 
In this project, we further characterized the interaction between Ad5 protein VII and HMGB1. 
In addition, we also examined the importance of HMGB1 for Ad infection and the contribution to 
protein VII functions. We determined that the protein VII N-terminus is sufficient for binding to 
HMGB1. However, our experiments to define which part of HMGB1 is bound by protein VII were 
contradictory. In cells, the HMGB1 A-box is sufficient for relocalization by protein VII. Yet this 
HMGB1 domain does bind to protein VII in vitro. Instead the HMGB1 acidic tail can pull down 
protein VII in vitro, but not in cells. This indicates that likely both domains contribute to protein VII-
HMGB1 binding, but additional factors determine their specific contribution for the interaction.  
Both the HMGB1 A-box and protein VII have DNA binding capability. Therefore, DNA may 
facilitate the interaction observed in cells. To test this, we can add DNA to the in vitro binding 
assay and determine whether the HMGB1 A-box can pull down protein VII under those 
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conditions. In addition, other host proteins may contribute to the interaction. We can assess this 
hypothesis by determining the HMGB1 and protein VII interactome by IP-MS and identify proteins 
that bind to both. These proteins would be likely candidates for regulating the protein VII-HMGB1 
interaction in cells. As for investigating the impact of HMGB1 on protein VII functions, we have 
preliminary evidence that protein suppresses expression of IFNβ upon detection of dsDNA by the 
host cell and that HMGB1 is required for this response. The contribution of HMGB1 to 
suppression of IFNβ expression is discussed in detail in Chapter 4.2.2 of this thesis. In summary, 
in this chapter we further characterized the protein VII-HMGB1 interaction and started to explore 
additional functions for this association. 
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A2.4 Figures 
Figure A2.1 | The Ad5 but not MAV-1 protein VII interacts with HMGB1. a, Nuclear 
fractionation of A549 or MEF cells under mock conditions or infected with human Ad5 and mouse 
MAV-1 showing differential retention of HMGB1 in high-salt chromatin fractions during infection 
with different viruses. Fractionation was performed using increasing molarity of salt followed by 
Western blot for different cellular and viral proteins. 24 hpi, Ad5 MOI = 20, MAV-1 MOI = 5. b, 
Expression of Ad5 but not MAV-1 protein VII leads to retention of HMGB1 in chromatin. Nuclear 
fractionation of A549 cells under control conditions or treated with doxycycline for 4 days to 
induce expression of different protein VII-HA variants followed by Western blot analysis of 
indicated proteins. c, IF experiment corresponding to b showing colocalization of HMGB1 (green) 
with Ad5 but not MAV-1 protein VII-HA (red). Scale bar = 10 μm, DAPI in blue. 
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Figure A2.2 | The N-terminus of Ad5 protein VII interacts with HMGB1. a, Sequence 
alignment of Ad5 and MAV-1 protein VII showing the limited sequence homology between them. 
b, Schematic for the protein VII Ad5-MAV-1 chimeras, and summary of their phenotype regarding 
localization and redistribution of HMGB1. c, IF of different protein VII-HA chimeras (red) and the 
localization of HMGB1 (green) in relation to the viral protein. A549 cells were treated with 
doxycycline for 4 days to induce expression of the protein VII variants. Scale bar = 10 μm, DAPI 
in grey. d, Western blot for GFP IP of different Ad5 protein VII variants or GFP control. A549 cells 
were transfected with different constructs for 24 hours followed by GFP IP and probing for 
interaction with HMGB1 and tubulin. 
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Figure A2.3 | Protein VII interacts with the HMGB1 A-box in cells. a, Schematic for the 
different HMGB1-mEGFP constructs and their behavior in regards to redistribution by protein VII. 
b, IF of different HMGB1-mEGFP in A549 cells containing an inducible copy of Ad5 protein VII-
HA (red). Cells were treated with doxycycline for 4 days to induce expression of the viral protein 
and transfected with the different GFP constructs 24 hours prior to fixation. Scale bar = 10 μm, 
DAPI in blue. c, FRAP recovery for A box-mEGFP in the presence and absence of protein VII. 
A549 cells were treated with doxycycline for 4 days to induce protein VII expression and 
transfected with A box-mEGFP 24 hours before experiment. Circle denotes area of interest that 
was bleached by the laser. 
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Figure A2.4 | HMGB1 C-terminus interacts with protein VII in vitro. a, Schematic of different 
GST-HMGB1 constructs and summary of interaction with protein VII in vitro. b, Western blot 
analysis of GST IP of different HMGB1 constructs shows pull down of protein VII by full-length 
HMGB1 and the HMGB1 C-terminus. 
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Figure A2.5 | Deletion of HMGB1 does not impact Ad5 infection. a, Verification of HMGB1 
deletion by CRISPR/Cas9 in A549 cells by Western blot (left) for HMGB1 protein levels and RT-
qPCR (right) for HMGB1 mRNA comparing the parental cell line to the KO cell lines. b-e, Infection 
of HMGB1 WT or HMGB1 KO cell lines with Ad5 WT virus at MOI of 10 for indicated times. b, 
Western blot showing that levels of different viral proteins are similar in HMGB1 WT and two out 
of three HMGB1 KO cells. c, RT-qPCR for different viral RNAs over a time course with 
comparable levels between HMGB1 WT and KO cell lines. d, qPCR for viral genomes in HMGB1 
WT and KO cells with no significant differences over a time course of infection. e, plaque assay 
for infection viral particles produced from HMGB1 WT and KO cells over a time course with no 
significant differences between cell lines. 
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Figure A2.6 | Protein VII suppresses IFNβ expression through HMGB1. a, RT-qPCR showing 
decreased IFNβ mRNA levels upon expression of protein VII WT but not ΔPTM mutant. A549 
cells were treated with doxycycline for 4 days to induce expression of either protein VII WT or 
protein VII ΔPTM, transfected with poly(dA:dT) for 8 h, and RNA extracted for RT-qPCR. b, RT-
qPCR results for different interferon stimulated genes (ISGs) upon treatment with type I IFN for 
24 h showing no decrease upon expression of protein VII induced by doxycycline treatment of 
A549 cells for 4 days. NFκB serves as a negative control since it is upstream of IFN expression, 
and VII verifies the expression of protein VII. Values are normalized to untreated parental. c, RT-
qPCR results showing that deletion of HMGB1 counteracts protein VII-mediated suppression of 
IFNβ mRNA upon poly(dA:dT) treatment of A549 cells for 8 h. For all experiments shown is 
mean+s.d., n = 3 biological replicates. * p < 0.05, ** p < 0.01, ns = not significant. Data courtesy 
of NJ Pancholi. 
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A2.5 Methods 
The work of this Appendix is based on results from Chapter 2 and only methods not used in 
that chapter will be described here. Please refer to Chapter 2 for all other methods. 
A2.5.1 Cells and viruses 
The HMGB1 KO cell line was made using the CRISPR/Cas9 system and has been described 
previously (PMID: 28794020). MEF were purchased from ATCC and cultured in DMEM with 10% 
FBS and 1% Penn/Strep. MAV-1 was a kind gift of K Spindler and infections were performed 
using the same standard methods used for Ad5. 
A2.5.2 Cloning of protein VII and HMGB1 constructs 
MAV-1 protein VII was cloned from genomic DNA isolated from MEFs infected with MAV-1. 
For generation of the different protein VII inducible cell lines, the respective coding sequences 
were introduced into the inducible plasmid cassette with a C-terminal HA tag using restriction 
enzymes BsrGI and AgeI. Protein VII-GFP, protein VII 1-66-GFP, and the different GFP tagged 
versions of HMGB1 were cloned into a pmEGFP-N1 vector using XmaI and AgeI. The GST-
tagged version of HMGB1 were cloned into a pGEX 6p3 vector using XhoI and EcoRI. For all, 
positive clones were selected in DH5α cells and sequenced. All primer sequences are available 
upon request. 
A2.5.3 Purification of HMGB1 constructs 
The HMGB1 constructs were transformed into BL21 (DE3) cells (NEB C2527I). BL21 cells 
were inoculated from overnight cultures and grown to an optical density of 0.5-0.6 OD260 nm, 
induced with 0.1 mM isopropyl-β-d-thiogalactoside (IPTG; Sigma) and harvested after 4 h at 
37 °C. Cells were in 28 ml of chilled lysis buffer (50 mM Tris-HCl pH 8, 10 mM NaCl, 2 mM MgCl2, 
1 mM PMSF, 2.5 µg/ml aprotinin, 2.5 µg/ml leupeptin and pepstatin, 0.05% NP-40) and incubated 
on ice for 10-20 minutes. Cells incubated with 0.5 mg/ml Lysozyme and 25 U/ml benzonase 
(Sigma E1014) for 30 min at RT and 30 min on ice. Then 7 ml of 5 M NaCl was added to a final 
concentration of 1 M. Cells were disrupted by sonication using a Thermon Fischer Sonic 
Dismembrator at output of low for 10 s (1 s sonication with 1 s break, 18% output) which was 
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repeated twice. Samples were spun at 27,000 g for 20 min at 4 °C. 3x200 µl glutathione agarose 
beads were prepared per sample by washing with 5 ml of cold lysis buffers three times. 10-12 ml 
of supernantant from the lysed bacteria was transferred into each tube (1 vol. bed of 100 vol. 
lysate) and rotated for at 4°C for at least 3 h. Beads were spun at 700 g for 2 min at 4 °C, washed 
twice with 5-10 ml of Wash Buffer (50 mM Tris-HCl pH 8, 500 mM NaCl, 2 mM MgCl2, 1 mM 
PMSF, 2.5 µg/ml aprotinin, 0.05% NP-40) and spun again. Beads were washed once with 5 ml of 
elution buffer (50 mM Tris-HCl pH 8, 150 mM NaCl without glutathione), spun again, and 
transferred to a 1.5 ml microfuge tube. 300 μl of elution buffer with 3.07 mg reduced glutathione 
per 1 ml was added to the beads, followed by rotation at 4°C for 10 minutes and spun at 4000 
rpm at 4°C for 1 minute in tabletop microcentrifuge. Supernatant was removed and spun at 13000 
rpm at 4°C for 10 min. The elution was repeated twice. 
For purification of the GST-HMGB1-His construct only a His-tag purification was performed 
before the GST-tag purification. For this 3x200 µl of Cobalt-beads were washed three times with 
5 ml cold lysis buffer. For protein binding 5 mM imidazole was added to the bacteria supernatant. 
10 ml supernatant each were added to the beads, rotated at 4°C for at least 1 h, and spun at 
4000 g for 3 min at 4 °C. The beads were washed four times with 5-10 ml wash buffer 2 (50 mM 
Tris-HCl pH 8, 0.5 M NaCl, 2 mM MgCl2, 1 mM PMSF, 0.05% NP-40, 10 mM imidazole) and 
combined in one tube. 1 ml of elution buffer 2 (50 mM Tris-HCl pH 8, 500 mM NaCl, 300 mM 
imidazole) and spun at 4000 g at 4°C for 3 minutes. The elution was repeated three times and 
then further processed by GST purification. 
A2.5.4 In vitro binding assay for HMGB1 and protein VII interaction 
The different GST-HMGB1 constructs were combined with recombinant protein-VII-His at 
equimolar ratios and incubated at 4 °C for 1 h. Complexes were then mixed with glutathione 
agarose beads (Thermo Scientific Product # 16100) to bind the GST-HMGB1 constructs and any 
associated protein, and washed three times in the binding buffer (50 mM Tris pH 8, 300 mM NaCl, 
0.1% IGEPAL). The beads were then boiled in sample buffer, separated on an SDS-PAGE and 
visualized by Coomassie staining or further processed for Western blot. 
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A2.5.5 Interferon stimulation 
For stimulation with DNA the cells were transfected with with 1 ug/mL poly(dA:dT)/LyoVec 
(Invivogen tlrl-patc) by addition to regular media. The cells were collected 8 h post stimulation and 
processed for RT-qPCR. For ectopic treatment with interferon the cells with 1000 units/mL 
universal type I IFN (PBL Assay Science), collected 24 h post treatment and processed for RT-
qPCR. 
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